Passive Polyclonal Antibodies Therapy {#s0010}
=====================================

Passive Polyclonal Antibody Treatment Overview {#s0015}
----------------------------------------------

Polyclonal immunoglobulins have been in use since the 19th century to protect against infectious agents, toxins, and disease conditions such as those with an autoimmune etiology. These immunoglobulin preparations are made from pools of selected human donors or animals with high titers of antibodies against viruses and toxins. These antibody treatments provide passive transfer of high titer antibodies that either reduces risk or reduces severity of infection. They are used to prevent hemolytic disease of the newborn and modify inflammatory reactions. Earlier drugs were very nonselective and patients frequently succumbed to infection due to suppression of both antibody-mediated (humoral) and cell-mediated arms of the immune system. Today, the principal approach is to alter lymphocyte function using drugs or antibodies against immune proteins. However, with the advent of human organ and tissue transplantation (e.g., kidney, heart, bone marrow, and/or peripheral blood stem cells) as treatment options, these polyclonal antibody therapies in combination with other treatment regimens are being used to lower the ability of the body\'s immune system to reject these transplants. However, their use is not without risk, as complications include development of immune complexes and severe allergic reactions. A summary of these polyclonal antibody therapies may be found in [Table 16.2.](#t0015){ref-type="table"}

Immunosuppressive Agents: Disease Modifying {#s0020}
-------------------------------------------

### Antithymocyte globulin (rabbit)/thymoglobulin; antithymocyte globulin (equine)/Atgam {#s0025}

#### Description {#s0030}

Rabbit antithymocyte globulin (rATG) and equine antithymocyte globulin (eATG) are purified, pasteurized preparation of lymphocyte depleting polyclonal gamma immunoglobulin (IgG) raised against human thymus lymphocytes in rabbits and horses, respectively. They are used in prevention and/or treatment of renal transplant rejection worldwide.[@bib1], [@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7]

#### History of antibody use {#s0035}

rATG induction in combination with immunosuppressive therapy is more effective in preventing episodes of acute renal graft rejection in adult renal transplant recipients, in recurrent episodes of acute rejection,[@bib8], [@bib9] and those acute rejections that are not responsive to high-dose corticosteroid therapy than other monoclonal antibody preparations.[@bib10], [@bib11] rATG recipients had a lower incidence of biopsy-confirmed acute rejection episodes,[@bib12] greater event-free survival up to 10 years posttransplantation, and greater graft survival up to 5 years posttransplantation.[@bib13]

#### Mechanisms of action {#s0040}

The exact mechanism of these polyclonal antibodies has not been fully understood.[@bib3], [@bib4], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20] However, being polyclonal, they display specificity toward a wide variety of surface antigens (Ags) expressed on T and B-lymphocytes, dendritic cells, natural killer (NK) cells, and endothelial cells. However, T-cell depletion is considered to play a key role by modulating the expression of lymphocyte surface antigens involved in a wide variety of functions such as T-cell activation to endothelial adherence, activation of certain transcription factors, and interference with numerous immune cell processes, such as cytokine production, chemotaxis, endocytosis, cell stimulation, and proliferation.[@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20]

In vitro studies indicate that binding of eATG to cells is generally nonspecific; the drug binds to visceral tissues, including thymus and testis cell membranes and nuclear and cytoplasmic components of tissues such as tonsil, kidney, and liver,[@bib21] and is extensively bound to bone marrow cells,[@bib22] and to other peripheral blood cells besides lymphocytes.[@bib21]

#### Diseases treated {#s0045}

As mentioned earlier, both antithymocyte globulins are used for treatment and prevention of acute renal allograft rejection.[@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8] More rATG recipients have been reported to achieve the endpoint of successful response (return of serum creatinine levels to baseline by end of treatment or within 14 days of treatment initiation). However, among those who achieved a successful response, fewer episodes of recurrent rejection occurred with rATG within 90 days of treatment cessation.[@bib2] eATG is also used for treating moderate-to-severe aplastic anemia in patients who are unsuitable for bone marrow transplantation.[@bib3], [@bib23], [@bib24]

#### Adverse effects {#s0050}

The most common adverse effects are fever, thrombocytopenia, leukopenia, gastrointestinal disorders, and/or concurrent infection.[@bib1], [@bib2] Cytomegalovirus (CMV) infection was generally higher with rATG except in high-risk patients.[@bib1], [@bib25] eATG therapy may result in reactivation of or infection with CMV, herpes simplex virus,[@bib25] or Epstein--Barr virus.[@bib26] The incidence of malignancies is generally lower with rATG therapy.[@bib27] This product is made of equine and human blood components, so it may carry a risk of transmitting infectious agents such as viruses, and theoretically, the Creutzfeldt--Jakob disease (CJD) agent.

#### Update {#s0055}

There has been recent evidence that the addition of human anti-T-lymphocyte globulin (ATLG) plus cyclosporine and methotrexate to standard graft-versus-host disease (GVHD) prophylaxis is preferred over standard GVHD prophylaxis alone because it improves the probability of survival without relapse and of chronic GVHD after myeloablative peripheral blood stem-cell transplantation from a human leukocyte antigen (HLA)-identical sibling donor for patients with acute leukemia in remission. Additionally, this therapy provides better quality of life and shorter immunosuppressive treatment compared to standard GVHD prophylaxis without ATLG.[@bib22]

Antitoxin and Immune Globulins: Disease Modifying {#s0060}
-------------------------------------------------

### Tetanus immune globulin/Baytet/Hypertet {#s0065}

#### Description {#s0070}

Tetanus immune globulin (TIG) is a specific solvent-detergent-treated plasma-derived product obtained from donors immunized with tetanus toxoid. TIG contains tetanus antitoxin that provides temporary passive immunity to individuals who have low or no immunity to the toxin produced by *Clostridium tetani*.[@bib28], [@bib29]

#### Mechanisms of action {#s0075}

TIG contains tetanus antitoxin antibodies, which neutralize the free form of the powerful exotoxin produced by *Clostridium tetani*.[@bib28], [@bib30] TIG can only neutralize unbound exotoxin; it does not affect toxin already bound to nerve endings.[@bib31]

#### Diseases treated {#s0080}

TIG is used to provide passive immunity to tetanus as part of a postexposure prophylaxis regimen following an injury in patients whose immunization is incomplete or uncertain or if it has been more than 10 years since last dose of tetanus toxoid.[@bib1], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9]

#### Adverse reaction {#s0085}

Slight soreness at injection site, mild fever, and rarely sensitization to repeated injections of human immune globulin has been reported.[@bib28]

Antitoxin and Immune Globulins: Disease Modifying {#s0090}
-------------------------------------------------

### Cytomegalovirus immune Globulin/Cytogam {#s0095}

#### Description {#s0100}

Cytomegalovirus immune globulin IV (CMV-IG) is a purified immune globulin (hyperimmune globulin) that contains immunoglobulin G (IgG) derived from pooled adult human plasma selected for high titers of anti-CMV antibodies.[@bib32]

#### Mechanisms of action {#s0105}

CMV-IG provides relatively high concentration of antibodies directed against CMV. It provides prophylaxis against CMV infection or disease in immunocompromised individuals.[@bib32], [@bib33], [@bib34], [@bib35], [@bib36], [@bib37], [@bib38], [@bib39], [@bib40], [@bib41], [@bib42], [@bib43] Results from in vitro studies and mice indicate that anti-CMV antibodies can neutralize the pathogenic properties of CMV.[@bib42], [@bib43], [@bib44] As CMV usually targets a population of bone marrow-derived myeloid lineage progenitor cells, antibody-neutralization of the virus alone may not be enough to prevent or make active disease less severe in already CMV-infected individuals.[@bib42], [@bib44], [@bib45], [@bib46], [@bib47]

#### Disease treated {#s0110}

CMV-IG provides passive immunity to individuals who are at risk for primary CMV infection/disease, or secondary CMV disease (reactivation of CMV).[@bib41], [@bib42], [@bib44], [@bib45], [@bib46], [@bib48], [@bib49], [@bib50], [@bib51] It is also prescribed for the prophylaxis of CMV disease associated with transplantation of kidney, lung, liver, pancreas, and heart. With the exception of CMV-seronegative recipients of kidneys from CMV-seropositive donors, CMV-IG prophylaxis should be considered in conjunction with ganciclovir.

#### Adverse reactions {#s0115}

Most frequent adverse reactions reported are flushing, chills, muscle cramps, back pain, fever, nausea, vomiting, arthralgia, and wheezing.[@bib32], [@bib34], [@bib35], [@bib36] There is a slight risk of hemolysis, as intravenous immunoglobulin (IVIG) products can contain blood group antibodies, which may act as a hemolysin and induce in vivo coating of red blood cells with immunoglobulin, causing a positive direct antiglobulin reaction. Transfusion-related acute lung injury (noncardiogenic pulmonary edema) and thrombotic events have been reported in patients receiving IVIG preparations.[@bib32]

Similar to all other products made from human plasma, this CMV-IG also carries the possibility for transmission of blood-borne viral agents and the CJD agent. However, this IVIG is treated with a solvent detergent viral inactivation procedure to inactivate a wide spectrum of lipid-enveloped viruses, including HIV-1, HIV-2, Hepatitis B, and Hepatitis C.

### Antivenin \[*latrodectus mactans*\]/black widow spider antivenin---antivenin *Micrurus fulvius*/eastern and Texas coral snake antivenin---crotalidae polyvalent immune Fab/Crofab {#s0120}

#### Description {#s0125}

These antivenins are sterile, nonpyrogenic, purified, and lyophilized preparation of specific venom-neutralizing serum globulins obtained from the blood serum of healthy horses exposed to the venom of black widow spiders and eastern coral snake (*Micrurus fulvius*) venom, respectively.[@bib52], [@bib53], [@bib54], [@bib55] In contrast, crofab is an antivenin made up of ovine Fab (monovalent) immunoglobulin fragments obtained from blood of healthy sheep immunized with North American Crotalinae subfamily of venomous snakes that includes rattlesnakes, copperheads, cottonmouth, or water moccasins.[@bib56]

#### Mechanisms of action {#s0130}

Mode of action of these antivenins is unknown.[@bib52] However, they probably act by neutralizing venom of black widow spiders and coral snakes.[@bib54] Crofab is a venom-specific Fab fragment of IgG that works by binding and neutralizing venom toxins, facilitating their redistribution away from target tissues and their elimination from the body.[@bib56]

#### Disease treated {#s0135}

These antivenins are indicated for patients with symptoms due to bites by black widow spider (*Latrodectus mactans*)[@bib52] and bites of two genera of coral snakes, that is, Micrurus (including the eastern and Texas varieties) and Micruroides (the Sonoran or Arizona variety), found in southeastern Arizona and southwestern New Mexico.[@bib52], [@bib57], [@bib58], [@bib59] Antivenin *Micrurus fulvius* (equine origin) is indicated only for treatment and management of adult and pediatric patients exposed to North American crotalid envenomation.[@bib54]

#### Adverse effects {#s0140}

Immediate systemic reactions (allergic reactions or anaphylaxis) and death can occur in patients sensitive to antivenin from horse serum.[@bib52], [@bib60] Most common adverse reactions to crofab are urticaria, rash, nausea, pruritus, and back pain.[@bib61], [@bib62]

### High antibody titer influenza fresh frozen plasma {#s0145}

#### Description {#s0150}

Use of convalescent (persons who have recovered from a particular infection) donor plasma with high hemagglutination inhibition titer against certain influenza strains has been recommended as a primary therapy for severe respiratory infectious diseases including influenza, severe acute respiratory syndrome, and Middle East respiratory syndrome.[@bib63]

#### History of antibody use {#s0155}

A meta-analysis of previous cohort studies during the 1918 influenza pandemic showed a case-fatality rate of 16% among subjects treated with plasma, serum, or whole blood compared to 37% among controls. Similarly, in 2009, a cohort study using convalescent plasma for the treatment of pandemic H1N1 influenza resulted in a mortality of 20% in the treatment group versus 54% in the control group.[@bib64]

#### Mechanisms of action {#s0160}

Antiinfluenza convalescent plasma decreases the rate of viral shedding measured by neutralizing antibody titer and hemagglutination inhibition.[@bib65] Both preexisting immunity (previous infections and vaccinations) as well as any immune response occurring after illness onset makes this mechanism of action more complex.

#### Disease classifications treated {#s0165}

Influenza, severe acute respiratory syndrome, and Middle East respiratory syndrome.[@bib63]

#### Adverse effects {#s0170}

Convalescent plasma seems safe. The serious adverse events reported are related to the underlying influenza, its complications, preexisting comorbidities, and not due to the convalescent plasma usage.

### High antibody titer ebola fresh frozen plasma {#s0175}

#### Description {#s0180}

Antibodies to the Ebola virus (EV) in whole blood or plasma from convalescent donors may be effective in the treatment of EV infection.

#### History of antibody use {#s0185}

The World Health Organization (WHO) has stated that convalescent blood or plasma is an option in the treatment of Ebola.[@bib66] In 1999, transfusion of locally collected convalescent blood helped to decrease Ebola mortality.[@bib67] Therefore, WHO has recommended the collection of convalescent plasma to treat patients with Ebola virus infection.

#### Mechanisms of action {#s0190}

This fresh frozen plasma (FFP) has high titers of antibodies directed against Ebola virus.[@bib68]

#### Adverse effects {#s0195}

Convalescent plasma seems safe with few adverse effects.[@bib69], [@bib70]

### Digoxin immune Fab/DigiFab; Digibind {#s0200}

#### Description {#s0205}

Digoxin immune Fab is a sterile, purified, lyophilized monovalent preparation of bovine immunoglobulin Fab fragments that binds to digoxin. These Fab fragments are obtained from the blood of healthy sheep immunized with a digoxin derivative, digoxindicarboxymethoxylamine, a digoxin analogue that contains the functionally essential cyclopentaperhydrophenanthrene: lactone ring moiety coupled to keyhole limpet hemocyanin. The final product is prepared by taking the immunoglobulin fraction of the ovine serum, digesting it with papain, and isolating the digoxin-specific Fab fragments by affinity chromatography.[@bib71], [@bib72], [@bib73], [@bib74], [@bib75], [@bib76], [@bib77], [@bib78], [@bib79]

#### Mechanisms of action {#s0210}

DigiFab or Digibind have antigen-binding fragments that bind to free digoxin molecules that results in an equilibrium shift away from binding to receptors, thereby reversing the cardiotoxic effects of the glycoside.[@bib71], [@bib72], [@bib75], [@bib76], [@bib78], [@bib80], [@bib81], [@bib82], [@bib83], [@bib84], [@bib85], [@bib86], [@bib87] Subsequently, Fab-digoxin complexes are cleared by the kidney and reticuloendothelial system. Due to papain treatment, the Fab fragments lack the antigenic determinants of the Fc fragment resulting in reduced immunogenicity to patients as opposed to intact immunoglobulin products.[@bib71], [@bib72], [@bib75], [@bib76], [@bib78], [@bib79], [@bib84], [@bib88], [@bib89]

#### Diseases treated {#s0215}

Digoxin immune Fab is indicated for patients with either life-threatening or potentially life-threatening digoxin toxicity or overdose.[@bib71], [@bib79], [@bib90], [@bib91], [@bib92], [@bib93], [@bib94], [@bib95] Data from clinical trials have showed that both DigiFab and Digibind reduce levels of free digoxin in the serum to below the limit of assay quantitation for several hours after Fab administration.

#### Adverse reactions {#s0220}

Digoxin immune Fab (ovine) generally is well tolerated following intravenous (IV) administration.[@bib71], [@bib72], [@bib73], [@bib76], [@bib78] Hypokalemia may occur, sometimes developing rapidly in patients receiving digoxin immune Fab (ovine).[@bib71], [@bib72], [@bib79], [@bib96], [@bib97] DigiFab should not be administered to patients with a known history of hypersensitivity to papaya or papain unless the benefits outweigh the risks.

Immune Globulins: Antiinfectious {#s0225}
--------------------------------

### Hepatitis B immune globulin/HepaGam B/nabi-HB/BayHepB/HyperHEP B S/D {#s0230}

#### Description {#s0235}

Hepatitis B immune globulin (HBIG) is a specific immune globulin (hyperimmune globulin) that contains antibody to hepatitis B surface antigen (anti-HBs) prepared from plasma of healthy donors with high titer (\>1:100,000) of anti-HBs antibody. It provides temporary passive immunity against hepatitis B virus (HBV).[@bib98], [@bib99], [@bib100], [@bib101], [@bib102], [@bib103], [@bib104]

HepaGam-B is a solvent/detergent-treated sterile solution of purified gamma globulin containing antibody to HBs antigen that contains high titers of anti-HBs from plasma donated by healthy screened donors. Both HBIG and HepaGam-B are manufactured by a solvent/detergent (S/D) treatment procedure that is effective in inactivating lipid-enveloped viruses such as hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1 and type 2. However, S/D is less effective against nonlipid-enveloped viruses such as hepatitis A virus and parvovirus B-19.[@bib100], [@bib101], [@bib104]

#### Mechanisms of action {#s0240}

It provides passive immunization for individuals exposed to the hepatitis B virus by binding to the surface antigen and reducing rate of hepatitis B infection.

#### Diseases treated {#s0245}

HBIG provides passive prophylactic immunity to HBV infection for prevention of perinatal HBV infection in neonates born to HBs antigen-positive (HBsAg-positive) mothers,[@bib100], [@bib101], [@bib102], [@bib103], [@bib104], [@bib105], [@bib106] for postexposure prophylaxis in susceptible individuals exposed to HBV or HBsAg-positive materials (e.g., blood, plasma, serum),[@bib100], [@bib101], [@bib102], [@bib103], [@bib104], [@bib107], [@bib108], [@bib109] sexual exposure to HBsAg-positive persons, for household exposure to persons with acute HBV infection, and for prevention of HBV recurrence in liver transplant recipients who are HBsAg-positive (HepaGam-B only).[@bib104], [@bib110], [@bib111], [@bib112], [@bib113], [@bib114], [@bib115], [@bib116], [@bib117] HBIG is not indicated for treatment of active hepatitis B infection and is ineffective in the treatment of chronic active hepatitis B infection.[@bib105]

#### Adverse reactions {#s0250}

The local adverse reactions that may occur at the site of injection after intramuscular (IM) administration are pain, tenderness, swelling, and erythema.[@bib100], [@bib101], [@bib109] The systemic effects that may occur after IM administration are urticaria, angioedema, nausea, vomiting, myalgia, headache, flu- or cold-like symptoms, lightheadedness, and malaise have been reported.[@bib100], [@bib101], [@bib104]

### Varicella zoster immune globulin/VariZIG {#s0255}

#### Summary {#s0260}

Varicella zoster immune globulin (VZIG) is a specific immune globulin (hyperimmune globulin). VZIG is prepared from plasma of donors selected for high titers of antibodies to varicella zoster virus (anti-VZV) and used to provide temporary passive immunity against VZV.[@bib118], [@bib119], [@bib120]

#### Mechanisms of action {#s0265}

VZIG acts by neutralizing varicella zoster virus via high titers of IgG antibodies present in the plasma used.

#### Diseases treated {#s0270}

VZIG is used for postexposure prophylaxis of varicella (chickenpox) in individuals who do not have evidence of varicella immunity and are at high risk for severe varicella infection and its complications. These high risk individuals include immunocompromised patients such as neonates whose mothers have signs and symptoms of varicella around the time of delivery (i.e., 5 days before to 2 days after), premature infants born at ≥28 weeks of gestation who are exposed during the neonatal period and whose mothers do not have evidence of immunity, premature infants born at \<28 weeks of gestation or who weigh ≤1000 g at birth and were exposed during the neonatal period regardless of their mothers\' evidence of immunity status, and finally pregnant women.[@bib118], [@bib119], [@bib121], [@bib122]

VZIG is now recommended for outbreak control and postexposure treatment, and the vaccine is available to children with humoral immunodeficiencies and selected children with HIV infection.[@bib122] Use of VZIG for postexposure prophylaxis in pregnant women exposed to VZV may prevent or reduce severity of varicella in the woman but does not prevent fetal infection.[@bib119], [@bib121]

VZIG is not indicated for individuals who previously received age-appropriate varicella vaccination and subsequently became immunocompromised because of disease or immunosuppressive therapy later in life. Bone marrow transplant recipients should be considered susceptible to varicella regardless of previous history of varicella or varicella vaccination in themselves or their donors. However, those who develop varicella or herpes zoster after transplantation should be considered immune to varicella.[@bib119]

#### Adverse reactions {#s0275}

The most common adverse effects reported with VZIG in clinical trials in pregnant women, infants, and immunocompromised adults and children were injection site pain, headache, chills, fatigue, rash, and nausea. Severe hypersensitivity reactions may occur following administration of VZIG.[@bib118]

### Rimabotulinumtoxin B/Myobloc {#s0280}

#### Summary {#s0285}

Rimabotulinumtoxin B, a type B botulinum toxin produced by fermentation of the bacterium *Clostridium botulinum* type B (Bean strain), is a neuromuscular blocking agent (neurotoxin) and inhibitor of acetylcholine release at motor nerve terminals.[@bib123], [@bib124], [@bib125], [@bib126]

#### Mechanisms of action {#s0290}

Rimabotulinumtoxin B and other botulinum toxin serotypes act by inhibiting acetylcholine release at the neuromuscular junction via a three-step process, that is, toxin binding, toxin internalization, and inhibition of acetylcholine release into the neuromuscular junction leading to chemical denervation and flaccid paralysis.[@bib123], [@bib124], [@bib126], [@bib127]

#### Diseases treated {#s0295}

Rimabotulinumtoxin B is used for management of adults with cervical dystonia (also called as spasmodic torticollis) to reduce severity of abnormal head positioning and neck pain through reduction of undesired or excessive contraction of striated or smooth (involuntary) muscle.[@bib128], [@bib129], [@bib130], [@bib131]

#### Adverse reactions {#s0300}

The most common adverse effects reported with Botulinum toxin are dry mouth, dysphagia, dyspepsia, and injection site pain.[@bib123], [@bib132], [@bib133], [@bib134] Serious hypersensitivity reactions have been rarely reported with onabotulinumtoxin A.[@bib127]

### Botulism immune globulin/BabyBIG {#s0305}

#### Summary {#s0310}

Botulism immune globulin IV (BIG-IV) is a specific immune globulin (hyperimmune globulin) that is prepared from plasma of adult volunteer donors immunized with pentavalent botulinum toxoid, which neutralizes free botulinum toxin types A and B. It is one of the most poisonous substances known and exists in seven antigenic variants (types A to G).[@bib120], [@bib121], [@bib135]

#### Mechanisms of action {#s0315}

BIG-IV is a human-derived antitoxin that neutralizes botulinum toxin. BIG-IV has a half-life of approximately 28 days in vivo and large capacity to neutralize the toxin.[@bib135]

#### Disease treated {#s0320}

Infant botulism occurs when young infants ingest spores of *Clostridium botulinum* that then germinate, colonize the GI tract, and produce botulinum toxin. This neurotoxin causes generalized weakness and loss of muscle tone. A single infusion will neutralize the toxin for at least 6 months and toxins type A or B that may be absorbed from the colon of an infant younger than 1 year old.[@bib121], [@bib135], [@bib136], [@bib137], [@bib138], [@bib139]

#### Adverse effect {#s0325}

Mild, transient, blush-like erythematous rash on the face or trunk occurred in 9%--14% of infants receiving BIG-IV in clinical studies.[@bib135], [@bib140]

### Rabies immune globulin/bayrab/HyperRAB, imogam Rabies, KedRAB {#s0330}

#### Description {#s0335}

Rabies immune globulin (RIG) is a sterile solution of specific IgG that contains antibody to rabies antigen. It is used to provide temporary passive immunity to rabies infection as part of a postexposure prophylaxis regimen in unvaccinated individuals exposed to the disease or virus.[@bib141], [@bib142], [@bib143], [@bib144]

#### Mechanisms of action {#s0340}

RIG is a human-derived antitoxin that neutralizes rabies virus so that virus spread is reduced and its infective or pathogenic properties are inhibited. Specific rabies antibodies present in RIG neutralizes rabies. It should be used in conjunction with rabies vaccine and can be administered through the seventh day after the first dose of vaccine is given. RIG provides immediate, temporary rabies virus-neutralizing antibodies until the patient responds to active immunization and produces virus-neutralizing antibodies.[@bib121], [@bib141], [@bib142], [@bib143], [@bib144]

#### Diseases treated {#s0345}

Given to all persons suspected of exposure to rabies with one exception, those who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine.

#### Adverse reactions {#s0350}

Most common local adverse effects include tenderness, pain, muscle soreness, or stiffness that may occur at the site of injection. Low-grade fever, headache, and malaise may also occur.[@bib141], [@bib142], [@bib143]

Immune Globulins: Immunomodulation {#s0355}
----------------------------------

### Rho(D) immune globulin/WinRho; RhoGam; Rhophylac, MicRhoGAM, BatRhoD, HyperRho {#s0360}

#### Summary {#s0365}

Rho(D) immune globulin (RhIG) consists of anti-Rho(D) IgG antibodies to the red blood cell Rho(D) antigen. RhIG is prepared from human pools of plasma of Rho(D)-negative donors immunized with Rho(D)-positive red blood cells after cold alcohol fractionation, and subsequent purification and infectious disease reduction technologies.[@bib145], [@bib146], [@bib147], [@bib148], [@bib149], [@bib150]

#### Mechanisms of action {#s0370}

The exact mechanism of action of Rho(D) immune globulin in the suppression of formation of anti-Rho(D) is not fully known.

In the treatment of preventing D alloimmunization, RhIG binds to Rho(D) antigen that entered the maternal circulation during fetal--maternal hemorrhage (FMH) involving an Rho(D)-positive fetus or transfusion with Rho(D)-positive blood, preventing stimulation of the mother\'s primary immune response to Rho(D) antigen. Therefore, by preventing the active production of anti-Rho (D) by the mother, the risk of hemolytic disease of the fetus and newborn in future pregnancies is decreased.[@bib145], [@bib146], [@bib147], [@bib148], [@bib149]

In the treatment of idiopathic thrombocytopenic purpura (ITP), administration of Rho(D) immune globulin to Rho(D)-positive individuals is believed to cause transient mononuclear macrophage Fc receptor (FcR) blockade by complexes within the reticuloendothelial system, particularly the spleen, which spares the patient\'s IgG-coated platelets. This FcR blockade and decreased Fc-mediated phagocytosis of antibody-coated platelets result in increases of platelet counts in ITP patients.[@bib145], [@bib149], [@bib151], [@bib152], [@bib153], [@bib154], [@bib155], [@bib156]

#### Diseases treated {#s0375}

Prevent D alloimmunization in D-negative women of childbearing potential if the neonate is D^+^, weak-D positive, or D untested, and following perinatal events associated with FMH such as abortion, ectopic pregnancy, amniocentesis, chorionic villus sampling, external cephalic version, abdominal trauma, and antepartum hemorrhage. It is also used to prevent D alloimmunization in D-negative individuals who receive D^+^ blood components such as whole blood-derived platelets, apheresis platelets, and/or granulocytes. Similarly, it is used for the treatment of ITP in D^+^ patients who had not undergone splenectomy.[@bib145], [@bib146], [@bib147], [@bib149], [@bib151], [@bib152], [@bib153], [@bib157], [@bib158], [@bib159], [@bib160], [@bib161], [@bib162], [@bib163], [@bib164] Some preparations of Rho(D) immune globulin may be administered IM or IV (Rhophylac, WinRho SDF), whereas others are labeled for IM use only (MICRhoGAM, RhoGAM, HyperRHO S/D Full Dose, HyperRHO S/D Mini-Dose).[@bib145], [@bib146], [@bib147], [@bib149], [@bib165] When used for ITP treatment, RhIG must be administered IV.[@bib145], [@bib149]

#### Adverse reactions {#s0380}

Generally, mild with the most common being headache, fever, chills, pain at the injection site and, rarely, hypersensitivity reactions. Some degree of hemolysis is inevitable, but this is predictable and transient.[@bib146], [@bib147]

### Immunoglobulin (generic)/bbrands: Bivigam, Carimune, Cuvitru, Flebogamma, Gammagard, GamaSTAN, Gammaked, Gammaplex, Gamunex-C, Hizentra, Hyqvia, Octagam Privigen {#s0385}

#### Summary {#s0390}

Immune globulin IM (IMIG), immune globulin IV (IVIG), and immune globulin subcutaneous are sterile, nonpyrogenic preparations of globulins containing many antibodies normally present in adult human blood. Immune globulins (IG) are collected either by whole blood donations as recovered plasma (20%), or by apheresis as source plasma (80%). IVIG is a highly purified product consisting mostly of IgG with a half-life of 21--28 days.

Hyperimmune globulin (Hyper-Ig) products are manufactured from donors with high Ig titers with specificity to antigenic determinant(s) of interest. High titers of these donors can be achieved by natural immunity, prophylactic immunizations, or through targeted immunizations. Hyper-Ig products should contain at least fivefold-increased titers compared to standard preparations of IVIG.

IVIG production is regulated by the IUIS/WHO (International Union of Immunological Societies/World Health Organization), which require the following:•Source material must be plasma obtained from a minimum pool of 10,000 donors;•Product must be free of prekallikrein activator, kinins, plasmin, preservatives, or other potentially harmful contaminants;•IgA content and IgG aggregate levels need to be as low as possible;•Product must contain at least 90% intact IgG;•IgG should maintain opsonin activity, complement binding, and other biological activities;•IgG subclasses should be present in similar proportions to those in normal pooled plasma;•Antibody levels against at least two species of bacteria (or toxins) and two viruses should be determined;•Product must demonstrate at least 0.1 international units of hepatitis B antibody per mL, and hepatitis A radioimmunoassay titer of at least 1:1000;•Manufacturer should specify the contents of the final product, including the diluent and other additives, and any chemical modification of IgG.[@bib166], [@bib167], [@bib168], [@bib169], [@bib170], [@bib171], [@bib172]

#### Mechanisms of action {#s0395}

The mechanisms of Ig-induced immunomodulation are incompletely understood but include macrophage Fc receptor blockage by immune complexes formed between IVIG and native antibodies, modulation of complement, suppression of antibody production, suppression of inflammatory cytokines and chemokines, and/or antiidiotypic regulation of autoreactive B-lymphocytes or antibodies.

As IVIG contains a diverse group of antibody specificities, which protects recipients against multiple infections by eliminating opsonized infectious organisms via antibody-dependent cell-mediated cytotoxicity or by complement activation. This is followed by lysis and/or neutralization of soluble infectious proteins by immune complex formation and elimination through the RES.[@bib166], [@bib170], [@bib173], [@bib174], [@bib175]

#### Diseases treated {#s0400}

IVIG is indicated for the treatment of primary immune deficiency, secondary immune deficiency, ITP, Kawasaki disease, and congenital hypogammaglobulinemia. Currently, there is an extensive list of diseases for which IVIG could be used. It also has immunomodulatory properties resulting in an increasing list of both FDA-approved and nonapproved indications.

IMIG is used to provide passive immunity to hepatitis A virus infection for preexposure or postexposure prophylaxis in susceptible individuals who are at risk of or have been exposed to the virus. IMIG and IVIG are used to prevent or modify symptoms of measles (rubeola) in susceptible individuals exposed to the disease \<6 days. IVIG is used for replacement therapy to promote passive immunity in patients with primary humoral immunodeficiency who are unable to produce sufficient amounts of IgG antibodies and in the management of ITP to increase platelet counts, to prevent and/or control bleeding, or to allow these patients to undergo surgery.

IVIG is used for prevention of bacterial infections in patients with hypogammaglobulinemia and/or recurrent bacterial infections associated with B-cell Chronic Lymphocytic Leukemia. IVIG is used in conjunction with aspirin therapy for initial treatment of the acute phase of Kawasaki disease. IVIG is also used to treat chronic inflammatory demyelinating polyneuropathy to improve neuromuscular disability and impairment, and for maintenance therapy to prevent relapse. Furthermore, IVIG is used for maintenance treatment to improve muscle strength and disability in adults with multifocal motor neuropathy.[@bib166], [@bib167], [@bib168], [@bib169], [@bib170], [@bib171], [@bib172], [@bib173], [@bib174], [@bib175], [@bib176], [@bib177], [@bib178], [@bib179], [@bib180], [@bib181], [@bib182], [@bib183], [@bib184], [@bib185], [@bib186], [@bib187], [@bib188], [@bib189], [@bib190], [@bib191], [@bib192], [@bib193], [@bib194], [@bib195], [@bib196], [@bib197], [@bib198], [@bib199], [@bib200], [@bib201]

#### Adverse reactions {#s0405}

Approximately 2%--10% of infusions are associated with adverse reactions that include those at the infusion site (erythema, pain, swelling, pruritus, heat), phlebitis, eczema, fever, chills, myalgias, malaise, flushing, rash, diaphoresis, pruritus, bronchospasm, chest pain, back pain, extremity pain, dizziness, blood pressure changes, nausea, vomiting, and headache.[@bib167], [@bib170], [@bib172], [@bib177], [@bib178], [@bib179], [@bib181], [@bib182], [@bib183]

Passive Monoclonal Antibody Treatment {#s0410}
=====================================

In the late 20th century (∼1986), monoclonal antibodies were developed. The first monoclonal antibodies (Mabs) were of xenographic source and were wrought with problems of immunogenicity. These early Mabs did not gain favor until chimerization took pace in the mid-1990s, and in 1998 two Mabs were approved to treat one respiratory syncytial virus and the other certain breast cancers. Further development to humanize and then generate fully human Mab led to an evolution of therapies utilizing these agents. Mabs are being researched or approved to treat a multitude of diseases that include oncologic, inflammatory, autoimmune, cardiovascular, respiratory, neurologic, allergic, benign hematologic, infectious, orthopedic, coagulopathic, and metabolic indications and to decrease disease morbidity (diminution of pain), modify disease progression (i.e., macular degeneration, diabetes), and potentially alter anatomic development. In this section of the chapter, we will review the history of use of these passive monospecific antibody therapies, their mechanism of action, pharmacologic-therapeutic classification, particular medical indication, adverse reactions, and potential future use of these medications.[@bib201]

 {#s9000}

### Mechanism of action {#s0415}

Depending on the antigenic target of these antibodies multiple events are set into action. Immunologic changes occur as the specific antigens are presented more efficiently to effector cells. Some of these actions create decreased inflammatory and allergic responses, while other effects generate antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Other actions can block receptor interaction with ligands by either binding with ligands or their cognate receptors (i.e., allow activation of NK cells). Interactions may also directly cause initiation of programmed cell death (apoptosis), cessation of growth/replication/proliferation, or lead to changes in metabolism. Moreover, there are also antibodies against infectious agents to prevent cell adhesion for entry, spread, replication, and contagion. Antibodies may also be directed against toxins leading to various methods of inactivation.[@bib201]

### Adverse reactions {#s0420}

Depending on their mode of action, Mabs are associated with a myriad of side effects. They can be associated with immunogenicity that can cause a decrease in their effectiveness. Antineoplastic antibodies can be associated with tumor lysis syndrome. Similarly, reactivation of underlying infections can occur leading to progressive multifocal leukoencephalopathy, HBV, fungal, parasitic, or tuberculosis infections. Other adverse reactions include but are not limited to initiation of autoimmune disorders, increased risk for malignancy, cardiac arrhythmia, angina/ischemia, cytopenias, hemorrhage, and allergic reactions including anaphylaxis, embryo--fetal toxicity (if can cross placental barrier), and even death.

Types of Illness Treated {#s0425}
========================

Oncology {#s0430}
--------

Malignancies can be caused by infectious agents, toxins, or genetic mutations with changes in control of growth, proliferation, or programmed cell death. Historically these have been treated with a variety of radiation therapies to eradicate malignant cells or with chemotherapeutic agents to enhance maturity, decrease proliferation, or cause destruction of cancer cells. In some cases intense high-dose chemotherapy is used to cause cancer remission with stem cell transplants for subsequent rescue. Passive antibody therapy may replace or be additive to other pharmacology therapies and increase chances for complete remission, prolong disease-free survival, and overall survival.

### B-cell chronic lymphocytic leukemia {#s0435}

Rituximab (Rituxan) is a chimeric murine/human Mab (IgG1κ) that binds to CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35 {controlling differentiation and possible calcium ion channel}). Its mechanism of action is not entirely clear and may involve CDC and ADCC. Many studies have shown this antibody to have an additive benefit to standard chemotherapy alone. This antibody has been approved by the FDA to treat chronic lymphocytic leukemia (CLL) since 1997. Nowadays, this medication is often combined with ibritumomab in treating CLL (to be discussed with non-Hodgkin\'s lymphoma).[@bib202], [@bib203]

Alemtuzumab (Campath) binds to CD52 and is a humanized rat Mab (IgG1κ) binding to receptors on both T and B cells as well as macrophages, NK cells, and neutrophils, leading to CDC and ADCC. The resultant cytopenias lead to a severe immunocompromised state. Alemtuzumab was FDA approved as a single agent in the treatment of B-cell CLL in 2001.[@bib204]

Ofatumumab (Ocrevus) is a human Mab (IgG1κ) with CDC that binds to CD20 near the cellular membrane. In phase II studies, this agent had 86% objective response rate (ORR) when used alone and with CHOP therapy had 100% ORR and 62% complete remission (CR); whereas, in phase III trials, this Mab showed ORR of 10% after rituximab relapse. This medication was approved by the FDA to treat CLL in 2009.[@bib205]

Monalizumab is a humanized Mab (IgG4κ) that binds to CD94/NKG2A (an inhibitory signal receptor transmitter) on NK cells. Monalizumab demonstrated blockade of NKG2A/HLA-E and restores the ability of NK cells to lyse B cells in vitro. In addition, this Mab was shown to be of benefit in murine models. Ongoing phase I/II studies will be completed in 2019.[@bib206]

Otlertuzumab is a humanized Mab fragment (IgG Fab') with specificity to CD37 that induces both ADCC and caspase-independent apoptosis. In a phase II study both better progression-free survival (PFS) and ORR were observed when used with bendamustine compared to bendamustine used alone.[@bib207]

Urelumab is a human Mab (IgG4κ) with specificity to CD134 (an immune checkpoint inhibitor). This antibody has completed safety phase I dosing trials. Higher doses lead to significant hepatotoxicity. Safe dosing is now established in clinical phase II studies to be completed in 2020.[@bib208], [@bib209]

Ulocuplumab is a human Mab with specificity to CD184 (CXCR4). *In vitro* studies showed apoptotic effects via production of oxygen species that was not associated with better caspase activation than AMD3100. Phase I studies were completed in 2014, no manuscripts were found for review. This medication is presently in phase II trials against acute myelocytic leukemia (AML) to be completed in 2021.[@bib210], [@bib211]

Other monoclonal antibodies not demonstrating benefit in clinical trials for CLL include apolizumab, dacetuzumab, and gomiliximab (aka lumiliximab)[@bib212], [@bib213], [@bib214], [@bib215]

### Acute myelocytic leukemia {#s0440}

AML is the leading cause of leukemic mortality in the United States (US). Over the last 10 years therapy has not changed significantly for this disease. Novel therapies have been developed in the last decade, some showing temporal success and some showing a brighter tomorrow.[@bib216]

AMG330 is a bispecific T-cell engager (BiTE) antibody with specificity for CD3 and CD33. This Mab is currently in clinical trials to be completed in 2020 for treatment of AML. A BiTE antibody stimulates ADCC (via T cells) in the presence of antigenic targets on cells of interest. In vitro studies have shown effective lysis of AML cells, while in animal studies it has demonstrated significant decrease in tumor burden.[@bib217]

IMGN632 is an anti-CD123 antibody complexed to a DNA mono-alkylating agent. In vitro studies showed it had more potency against AML cells than to normal myeloid progenitor cells. In animal models there was an excellent response rate against tumor cells. Ongoing clinical trials will be completed in 2021.[@bib216]

Talacotuzumab is a humanized monoclonal antibody (IgG1-2κ) with specificity to interleukin (IL)-3 receptor subunit-α (CD123, a growth and differentiating receptor). This antibody induces ADCC both in vitro and in animal models. Phase III clinical trials were reportedly completed in 2018; published results are forthcoming.[@bib218]

Samalizumab is a humanized Mab (IgG2/IgG4κ) with specificity to CD200 (OX-2membrane glycoprotein) is in phase II trials to be completed in 2021.[@bib219]

Ficlatuzumab is a humanized Mab (IgG1κ) in a phase I trial to treat refractory/relapsing AML to be completed in 2020.[@bib220]

Other Mab not demonstrating benefit in clinical trials or withdrawn following postmarketing for AML include gemtuzumab ozogamicin (FDA approved 2000 withdrawn 2010 secondary to venoocclusive disease) and lintuzumab (*no* added benefit over standard chemotherapy).[@bib221], [@bib222], [@bib223]

*Multiple Myeloma* {#s0445}
------------------

Daratumumab (Darzalex) is a human Mab (IgG1κ) with specificity to CD38 (functions reportedly include receptor-mediated adhesion and signaling events, as well as important bifunctional ectoenzymatic activities that contribute to intracellular calcium mobilization. This Mab mechanism of action is thought to induce CDC, ADCC, antibody-dependent cellular phagocytosis, and apoptosis. This medication is used to treat refractory and recurrent multiple myeloma.[@bib224], [@bib225]

Silutuximab (Sylvant) is a chimeric Mab (IgG1κ) with specificity to IL-6. This medication was FDA approved in 2014 for multicentric Castleman\'s disease (MCD) with HIV negative and HHV-8 negative. There are ongoing studies in phase II clinical trials to be completed in 2019.[@bib226], [@bib227]

### B-cell acute lymphoblastic leukemia (B-cell ALL) {#s0450}

Blinatumomab (Blincyto) is a mouse double heavy-chain fragment (Murine {scFv - kappa -- heavy} -- {scFv - heavy -- kappa}) with specificity for CD19 and CD3 known as a BiTE. This Mab\'s mode of action is by directing CD3^+^ effector memory T cells to CD19^+^ target cells leading to T-cell activation and B-cell apoptosis. This biologic is used to treat relapsed/refractory cell ALL. In phase III trials event-free survival almost tripled and duration of remission almost doubled.[@bib228], [@bib229], [@bib230]

### Hodgkin\'s lymphoma {#s0455}

Hodgkin\'s lymphoma is a rare malignancy affecting young adults with a peak incidence in patients \>55 years old. Up to 40% of these patients can develop relapsing disease. Brentuximab vedotin (Adcentrix) is a chimeric humanized Mab drug conjugate (Mab + linker + payload {IgG1κ +protease cleavage linker + monomethyl auristatin E \[MMAE\]}) with specificity to CD30 (a cell membrane protein of the tumor necrosis factor receptor superfamily member 8. MMAE is a microtubule-disrupting agent. The combination of this a Mab and drug conjugate disrupts the intracellular microtubule network causing cell cycle arrest at G2/M stage and apoptosis. This medication has a 43% PFS at 30 months.[@bib231]

Mab to look out for in the future include Camidanlumab tesirine (ADCT-301) a human Mab (IgG1κ). This Mab has specificity to CD25 (a IL-2 receptor alpha subunit) with a drug conjugate. The drug is released intracellularly and causes DNA interstrand crosslinks. This Mab is in phase I studies to be completed in 2019 for Hodgkin\'s and non-Hodgkin\'s T- and B-cell lymphomas. In addition, there are clinical phase I studies against multiple solid tumors to be completed in 2021.[@bib232], [@bib233]

Agents abandoned or not found to be beneficial include apolizumab, denintuzumab mafodotin (HBU-12), iratumumab (MDX060), and lucatumumab (HCD122).[@bib212], [@bib234], [@bib235]

### Anaplastic large cell lymphoma {#s0460}

Brentuximab vedotin (Adcentrix) is an FDA-approved medication for patients with refractory or relapsed anaplastic large cell lymphoma who achieved CR. This Mab had 79% OS and 57% PFS at 5 years, with median response duration not reached at time of publication.[@bib236]

*Breast Cancer* {#s0465}
---------------

Atezolizumab (Tecentriq) is an FcγR binding--deficient, fully humanized Mab (IgG1κ). This Mab binds to programmed death ligand I (PD-L1) to prevent interaction with receptors PD-1 and B7.1 (a costimulatory cell-surface protein), reversing T-cell suppression. Activation of B7.1 can potentially stimulate long-term responses through development of new immunity via priming and activation of T cells in lymph nodes. A lack of FcγR binding decreases ADCC of the T cells enabling more tumor-specific T cell to remain active. This medication was approved by the FDA in 2019 to treat triple negative (estrogen receptor, progesterone receptor, human epidermal growth factor receptor-2) unresectable or metastatic breast cancers.[@bib237], [@bib238]

*Colorectal Cancer* {#s0470}
-------------------

Bevacizumab (Avastin) is a humanized Mab (IgG1κ) with specificity to vascular endothelial growth factor-a (VEGF-A) that acts as an inhibitor of angiogenesis. It was FDA approved for treatment of colorectal cancer and has recently been approved for multiple other cancers including ovarian, fallopian cancers, renal cell carcinoma, and recurrent glioblastoma multiforme (GBM).[@bib239], [@bib240]

*Urothelial Carcinoma* {#s0475}
----------------------

Atezolizumab (Tecentriq) is FDA approved as a single agent in urothelial carcinoma and for patients with disease progression despite other chemotherapy treatment.[@bib241], [@bib242]

### Nonsmall cell lung cancer {#s0480}

Atezolizumab (Tecentriq) is FDA approved as a single agent for nonsmall cell lung cancer (NSCLC).

Bevacizumab (Avastin) is FDA approved for treatment of locally advanced, recurrent or metastatic, nonsquamous NSCLC.

Nivolumab (Opdivo) is an FDA-approved human Mab (IgG4κ) immunoglobulin and blocks PD-1 preventing interaction PD-1 and its ligands PD-L1 and PD-L2. It is used to treat RCC, NSCLC, Hodgkin\'s lymphoma, melanoma, small cell lung cancer, colorectal cancer, and squamous cell carcinoma of the head and neck. In phase III clinical trials, nivolumab performed better than docetaxel in the treatment of NSCLC.[@bib243], [@bib244], [@bib245]

### Ovarian/cervical fallopian cancer {#s0485}

Bevacizumab (Avastin) is FDA approved for treatment of locally advanced, recurrent or metastatic, ovarian, cervical, and fallopian cancers after treatment with chemotherapy regimens and surgery.[@bib246]

*Merkel Cell Carcinoma* {#s0490}
-----------------------

Merkel cell carcinoma is a rare aggressive cutaneous malignancy caused by infection with polyoma virus and exposure to ultraviolet radiation. This cancer was classically treated with chemotherapeutic agents leading to rare durable responses. Avelumab (Bavencio) is a fully human Mab (IgG1λ) with specificity to PD-L1. This Mab was approved by the FDA for treatment of Merkel cell carcinoma in 2017. Treatment with this Mab increases response rates to about 50% and extended durable response times approximately five times.[@bib247], [@bib248] This Mab is in clinical trial to treat other solid tumors including but not limited to hepatocellular, ovarian, esophagogastric, colorectal NSCLC, testicular, urothelial, and adrenocortical carcinomas.[@bib249]

*Neuroblastoma* {#s0495}
---------------

Neuroblastoma is an aggressive tumor of children with a 5-year survival of about 50%. Treatment classically is high-dose intensive chemotherapy, myeloablative chemotherapy with stem cell rescue, and/or irradiation therapy. Dinutuximab (Unituxin) is a chimeric Mab (IgG1κ) with specificity to GD2 ganglioside that has mechanisms of action via CDC and ADCC. This Mab is used in patients who have had at least a partial response to classic therapy.[@bib250], [@bib251]

*Glioblastoma Multiforme* {#s0500}
-------------------------

GBM is the most common malignant primary brain tumor in adults. This disease remains incurable.

Bevacizumab (Avastin) is FDA approved for treatment of recurrent GBM as salvage therapy. This medication with chemotherapy increases overall survival by 4 months but as a single agent is not effective.[@bib252]

Relatlimab (BMS-986,016) is a human Mab (IgG4κ) with specificity to lymphocyte activation gene 3 (LAG3, CD223) and is in phase I clinical trials to be completed in 2020 for treatment of GBM.[@bib253]

Tanibirumab (aka Olinvacimab, TTAC-0001) is a human Mab (IgG1) with specificity to vascular endothelial growth factor receptor-2 (VEFR-2) and is in phase II studies to treat GBM to be completed in 2020.[@bib254], [@bib255], [@bib256]

*Malignant Ascites* {#s0505}
-------------------

Catumaxomab (Removab) is a trifunctional rat/murine hybrid antibody (IgG2a/IgG2b). Catumaxomab consists of one "half" (one heavy chain and one light chain) of an antiepithelial cell adhesion molecule (anti-EpCAM) antibody and one-half of an anti-CD3 antibody, so that each molecule of catumaxomab can bind both EpCAM and CD3. In addition, the Fc-region can bind to an Fc receptor on accessory cells such as other antibodies, which has led to calling the drug a trifunctional antibody. This antibody\'s mechanism of action is through ADCC. It is approved for use in Europe for malignant ascites from ovarian, gastric, colon, pancreatic, breast, and endometrial carcinoma and is a pending review for approval by the FDA.[@bib257], [@bib258], [@bib259], [@bib260]

### Cutaneous squamous cell carcinoma {#s0510}

Cemiplimab (Libtayo) is a human Mab (IgG4) for treatment of cutaneous squamous cell carcinoma (CSCC) that is metastatic or locally advanced and not amenable to surgery. CSCC is second only to basal cell carcinoma as the most common skin cancer. Surgical intervention is not possible in 5% of patients. This Mab offers a treatment with less morbidity than palliative radiation or surgery, and gives an ORR in 50% of these otherwise untreatable patients. There are many additional phase II studies involving this Mab to be completed from 2020 to 23.[@bib261], [@bib262]

Autoimmune/Inflammatory Diseases {#s0515}
================================

Inflammatory Bowel Disease {#s0520}
--------------------------

Inflammatory bowel disease (IBD) pathophysiology remains unknown but may have genetic, infectious, autoimmune origins including cell-mediated immunity. These diseases may be classified as ulcerative colitis (UC), isolated to the colon, or Crohn\'s disease primarily found in the colon but may involve the entire gastrointestinal tract. With long-standing active disease, malignancy is much more frequent in UC than in Crohn\'s disease. Mild UC is treated with antiinflammatory agents such as sulfasalazine and glucocorticosteroids. For more severe disease, high-dose steroids may be used to maintain disease quiescent and low-dose steroids to keep disease in remission. Low-dose chemotherapeutic agent or immunosuppressive agent may also be added if dose of corticosteroids is too high to maintain remission. Surgery may be necessary to control disease. For Crohn\'s disease, medical therapy is usually less successful in managing the disease and surgery may be necessary but is not curative as in UC. For both of these disease processes, passive antibody therapy may offer not only control of disease but possible complete remission from mucosal damage.[@bib263], [@bib264]

Adalimumab (two formulations: Humira and Amjevita) is a recombinant human Mab (IgG1) with specificity to tumor necrosis factor alpha (TNF-α). Both forms are FDA approved to treat Crohn\'s disease as well as multiple types of rheumatoid arthritis. In Crohn\'s disease, this medication decreases signs and symptoms of disease and is able to induce clinical remissions.[@bib265], [@bib266]

Certolizumab (Cimzia) is a recombinant humanized m fragment with TNF-α as target. It is FDA approved for both Crohn\'s disease and Rheumatoid arthritis.[@bib267], [@bib268], [@bib269]

Vedolizumab (Entyvio) is a humanized Mab (IgG1κ) that has selectivity for integrin α4β7 and is FDA approved for treatment of Crohn\'s disease. This Mab mode of action is to selectively block trafficking of memory T cells into inflamed gut tissue by inhibiting α4β7-mucosal addressin cell adhesion molecule-1 (MAd-CAM-1) interaction with intestinal vasculature. This medication has shown a good safety profile with no cases of promyelocytic leukemia (PML), no increased risk of infections, malignancies compared with classically treated IBD, and low incidence of infusion-related reactions. This medication is also FDA approved for UC.[@bib270], [@bib271]

Infliximab (Remicade, Inflectra, Remsira) is a chimeric Mab (IgG1κ) with specificity to TNF-α and is FDA approved for IBD and multiple inflammatory arthritic diseases. This medication allows for steroid-free remission within months of starting therapy.[@bib272]

Natalizumab (Tysabri) is a humanized Mab (IgG2κ) with selectivity to CD62L (L selectin α4 subunit of α4β1 and α4β7 integrins of leukocytes, not neutrophils, VLA-4). This Mab is FDA approved for Crohn\'s disease and multiple sclerosis. This medications is effective in induction of clinical remission in moderate-to-severe Crohn\'s disease. This medication does have the risk of PML.[@bib273], [@bib274]

Other Mab being studied for Crohn\'s disease but not yet approved by the FDA include Ustekinumab, brazikumab, etrolizumab, risankizumab, and ontamalimab. In contrast, Mabs studied but not beneficial for Crohn\'s disease include andecaliximab, eldelumab, and fontolizumab. Refer to [Table 16.1](#t0010){ref-type="table"} .Table 16.1Summary of Monoclonal Antibody Therapies.Generic Drug NameBrand NameType of AntibodyAHFS ClassificationDosage Form(s)Target8H9Iodine 124 monoclonal antibody\
(Murine)Antineoplastic\
Neuroblastoma, sarcoma, metastatic brain cancers\
Another study Sloan Kettering using I[@bib331] version phase I good resultsIntravenousB7--H3AbagovomabMonoclonal antibody\
(Murine)\
An antiidiotypic mAb that mimics ovarian cancer CA125 proteinAntineoplastic\
Phase II study for ovarian cancer\
Phase III good immune response but no increase RFS or OS no benefitSubcutaneousCA-125AbataceptOrencia\
FDA 2005\
EU 2010Recombinant soluble fusion protein of the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) linked to the modified Fc portion of human immunoglobulin G1 (IgG1).Disease modifying\
Rheumatoid arthritis\
Juvenile and adult psoriatic arthritis (phase III)Subcutaneous or intravenousSelective costimulation modulator, inhibits T cell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking interaction with CD28. This interaction provides a costimulatory signal necessary for full activation of T lymphocytes.Abciximab\
c7Ec FabReoPro\
FDA 1994\
EU 1995 (country-specific approval)Human-murine chimera\
Recombinant monoclonal IgG1 FabProcedure modification\
High-risk coronary intervention\
Platelet aggregation inhibitorIntravenousPlatelet glycoprotein IIb/IIIa receptor (CD41 7E3)/Intergrin α-IIbAbituzumab\
DI17E6\
EMD525797Humanized monoclonal antibody IgG2κAntineoplastic\
Colorectal cancer phase I 2013, phase II 2015 primary endpoint PFS not met\
Sclerosing interstitial lung disease phase II terminated 2018 slow enrollment\
Prostate phase IIno significant increase PFSIntravenousCD51 (?integrin alpha V)Abrilumab\
AMG 181Phase II study discontinued development (2016)Integrin α-4 β-7ActoxumabHuman monoclonal antibodyDisease modifying\
*Clostridium difficile*\
Phase I and II anti-CDTB1 much better*Clostridium difficile* toxin AAdalimumabHumira\
FDA 2002\
EU 2003\
Amjevita\
FDA 2016\
EU 2017Recombinant human IgG1 monoclonal antibodyDisease modifying\
Humira\
**Rheumatoidarthritis; juvenile idiopathic arthritis; psoriatic arthritis; ankylosing spondylitis; Crohn\'s disease, plaque psoriasis**\
Amjevita\
Arthritis; juvenile rheumatoid arthritis; psoriatic arthritis; rheumatoid colitis; ulcerative Crohn\'s disease; psoriasis; spondylitis; ankylosing\
Possibly hemolytic disease of newbornInjection subcutaneousTNF-αAdecatumumab\
MT-201Recombinant human monoclonal antibody IgG1κAntineoplastic\
Breast phase Ib+, colorectal and prostate\
Phase II completed\
Phase III soon?IntravenousEpCAM (CD326) epithelial cell adhesion moleculeAducanumabHuman monoclonal antibody IgG1Disease modifying\
Alzheimer\'s disease\
Phase III x 2 ongoing started 2015IntravenousBeta-amyloid (N-terminus 3--6) soluble oligomers and insoluble fibrilsAfasevikumabHuman monoclonal antibody IgG1κDisease modifying\
Multiple sclerosis\
Phase I completed\
Nothing in pubmedSubcutaneousIL17A and IL17FAfelimomabMurine F(ab\')\
Antibody Fab' fragment IgG3κDisease modifying\
Sepsis\
Phase III trial marginal benefit abandonedTNF-αAlacizumab pegolHumanized monoclonal antibody F(ab\')~2~Limited information on development;\
CancerVEGFR2Alemtuzumab\
LDP-03\
Campath-1HLemtrada\
FDA 2014\
EU 2013\
MS\
Campath\
FDA 2001\
EU 2001\
CLLHumanized rat monoclonal antibody IgG1κAntineoplastic\
**B-Cell CLL**, CTCL, T cell lymphoma\
Disease modifying\
**Multiple sclerosis** (phase III)\
Not effective for kidney transplant conditioning or rejection preventionIntravenousCD52AlirocumabPraluent\
FDA 2015\
EU 2015Human monoclonal antibody IgG1Disease modifying\
Decrease cholesterol\
Phase IIISubcutaneousProprotein convertase subtilisin kexin type 9 (PCSK9)Altumomab pentetate In[@bib98]Hybri-ceakerMurine monoclonal antibody IgG1Diagnostic purpose radiology colorectal cancer (diagnosis)CEAALX-0171Trimeric nanobodyAntiinfectious\
RSV phase II 2020InhalationRSVFAmatuximab\
MORAb-009Chimeric murine-human monoclonal antibody IgG1κAntineoplastic\
Ovarian cancer\
Phase II\
Now research on using to treat mesotheliomas\
Phase I/II\
Pancreatic cancerIntravenousMesothelin\
Prohibits binding of MSLN with antigen CA125/MUC16AMG330Bispecific T-cell engager (BiTE)Antineoplastic\
AML phase I AML 2020IntravenousCD33 and CD3Anatumomab mafenatoxMurine monoclonal fragment FabAntineoplastic\
Nonsmall cell lung carcinomaTumor-associated glycoprotein 72 (TAG-72)Andecaliximab\
GS 5745Chimeric monoclonal antibody IgG4κAntineoplastic gastric cancer phase I, II, III ongoing or gastroesophageal junction adenocarcinoma phase III ongoing\
Crohn phase II no response, UCIntravenousGelatinase B is a matrix metalloproteinase-9 (MMP-9)Anetumab ravtansine\
In[@bib98]Human monoclonal antibody IgG1λAntineoplastic ovarian phase II, lung, pancreatic phase I, breast now research on using to treat mesotheliomas\
Phase II\
Cervical cancer ?preclinicalMesothelin\
Prohibits binding of MSLN with antigen CA125/MUC16AnifrolumabHuman monoclonal antibody IgG1κDisease modifying\
Systemic lupus erythematosus phase I and IIb 2018IntravenousInterferon α/β receptorAnrukinzumab (=IMA-638)Humanized monoclonal antibody IgG1κDisease modifying\
Asthma phase II ?results\
UC phase II no benefitIL-13ApolizumabHumanized monoclonal antibodyAntineoplastic non-Hodgkin\'s lymphoma abandoned 2009 toxic effects\
2009 CLL phase I/IIHLA-DRβArcitumomabCEA-Scan\
FDA 1996\
EU 1996\
Withdrawn EU market 2005Murine monoclonal antibody IgG1 Fab\'Diagnostic imaging\
Gastrointestinal cancers\
Colorectal cancersCEAAscrinvacumabHuman monoclonal antibodyAntineoplastic mesothelioma\
Nothing in pub med or web searchActivin receptor-like kinase 1AselizumabHumanized monoclonal antibodyDisease modifying\
Severe injured patients phase II 2004, no benefitL-selectin (CD62L)Atezolizumab\
MPDL3280ATecentriq\
FDA 2016Fc engineered, humanized monoclonal antibody IgG1κAntineoplastic agent, treat metastatic **urothelial carcinoma**, **non-small cell lung cancer**\
Phase III\
Bladder/urothelial cancer phase I\
Breast cancer phase Ib **triple marker neg breast cancer**IntravenousBinds to PD-L1 and blocks interactions with the PD-1 and B7.1 receptors FDA-approved atezolizumab (TECENTRIQ, Genentech, Inc.), in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic nonsquamous, nonsmall cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrationsAtidortoxumabHuman monoclonal antibody IgG1κLimited information on use and developmentNegative search PubMed-internet*Staph aureus* alpha toxinAtinumabHuman monoclonal antibody IgG4κDisease modifying\
Acute spinal cord injuryRTN4AtorolimumabDeveloped??Human monoclonal antibody IgG3Disease modifying hemolytic disease of the newbornRhesus factorAvelumabBavencio\
FDA 2017Human monoclonal antibody IgG1λAntineoplastic\
Cancers, ovarian, gastric, nonsmall cell lung (NSCLC), metastatic, solid tumors\
phase II\
Studies completed metastatic **Merkel cell carcinoma**IntravenousPD-L1Azintuxizumab vedotinChimeric/humanized monoclonal antibody IgG1Antineoplastic\
Nothing in PubMedCD319BAN-2401Humanized monoclonal antibody IgG1Disease modifying Alzheimer A phase IIb study ongoing started 2013IntravenousSoluble Aβ amyloid protofibrilsBapineuzumabHumanized IgG1 monoclonal antibodyDisease modifying\
Alzheimer\'s disease\
Phase III no more studies discontinued research 2012 ARIA-E, amyloid-related imaging abnormalities--edemaIntravenousBeta amyloid\
Fibrillary and soluble β amyloidBasiliximabSimulect\
FDA 1998\
EU 1998Chimeric monoclonal antibody IgG1κImmunosuppressive agents\
**Prophylaxisof acute rejection in allogeneic renal transplantation**IntravenousCD25 (α chain of IL-2 receptor)BavituximabChimeric monoclonal antibody IgG1κ\
IgG3 (SUNRISE trial)Cancer, viral infections (Hep C) phase III NSCLC failed to improve survival Sunrise trial stopped Feb 2016, phase II/III breast cancer, phase II pancreatic cancer, phase I/II trial hepatocellular carcinoma, phase I malignant melanoma + rectal cancer good response rectal; not for prostate cancer, phase II hepatitis C not resulted?PhosphatidylserineBAY-103356\
CDP 571Humicade\
SenlizumabHumanized monoclonal antibody IgG4κFor research only\
Phase II 1995TNF α*BCD-100*Human monoclonal antibodyAntineoplastic\
Phase II/III melanoma\
NCT03269565 (complete Dec 2019)IntravenousProgrammed cell death-1 (PD1)BectumomabLymphoScanFab'-IgG2κAntineoplastic\
Non-Hodgkin\'s lymphoma (detection)CD22BegelomabBegedinaMurine IgG2bDisease modifying GvHD phase II/IIIDPP4 binds CD26 on T lymphocytesBelantamab mafodotinHumanized monoclonal antibodymabAntineoplasticNo studies or info on clinical trial, PubMed, FDA substanceBCMABelataceptNulojix\
FDA 2011Soluble fusion\
Protein consisting of the modified extracellular domain of CTLA-4 fused to Fc domain of a recombinant human monoclonal antibody IgG1Immunosuppressive agents\
**Prophylaxisrenal transplant rejection in adults**\
Phase III\
FDA approvedIntravenousSelectively inhibits T-cell activation through costimulation blockade binds to both CD80 and CD86 blocking CD28BelimumabBenlysta\
FDA 2011\
EU 2011 LymphoStat-BHuman monoclonal antibody IgG1λDisease modifying\
Kidney transplant phase II\
Treat **SLE** (testing phase III for renal involvement)\
Phase II Rheum arthritis failure\
Phase II Srogren ±\
GVHD ongoingIntravenous\
SubcutaneousB-cell activating factor (BAFF), B-lymphocyte stimulatorBemarituzumabHumanized monoclonal antibodyAntineoplasticFGFR2BenralizumabFasenra\
FDA 2017\
EU 2017Humanized monoclonal antibody IgG1κDisease-Modifying\
Asthma phase III completed\
**Severe asthma eosinophilic subtype**SubcutaneousInterleukin-5 (IL-5α) receptor alpha subunit-directed cytolytic (CD125)BerlimatoxumabHuman monoclonal antibodyStaph aureus bicomponent leukocidinNo studies clinical, no find creative, zero pub medBermekimab\
MABp1\
T2-18C3\
CA-18C3XilonixHuman monoclonal antibody IgG1κDisease modifying psoriasis phase III *x*2 2020\
Ank spond II 2022\
Psor arth II 2020 III 2020Subcutaneous\
IntravenousIL17ABersanlimabHuman monoclonal antibodyICAM-1BertilimumabCAT-214Human monoclonal antibody IgG4κDisease modifying\
Severe allergic disorders phase II atopic dermititis\
Ongoing studies bullous pemphigoid and ulcerative colitis phase IIIntravenousCCL11 (eotaxin-1)BesilesomabScintimun\
EU 2010\
Not FDA approvedMurine monoclonal antibody IgG1κDiagnostic use\
Inflammatory lesions and metastases (detection)CEA-CAM8-related antigenBevacizumabAvastin\
FDA 2004\
EU 2005Humanized monoclonal antibody IgG1κ\
BiTEAntineoplastic agent\
Antiangiogenesis inhibitor\
**Colorectalcancer** 2004, **NSCLC** 2006, **RCC** 2009, GBM phase III, **ovarian cancer, metastatic cervical cancer, fallopian** 2014\
Breast cancer (FDA removed approval for breast cancer 2010)\
**Recurrentglioblastoma multiform**\
**Nonsquamous nonsmall cell lung cancer**Intravenous solution or ophthalmic injection\
May not be so good for GBM or ovarianVEGF-A anti-angiogenesis inhibitorBezlotoxumabZinplava\
FDA 2016\
EU 2017Human monoclonal antibody IgG1Disease modifying phase III studies done MODIFY I and II\
Modify III ongoing\
Pseudomembranous colitisIntravenous*Clostridium difficile* colitis anti-B toxinBiciromabFibriScintMurine monoclonal fragment Fab' IgG1κDetect cardiovascular thromboembolism (diagnosis)Fibrin II, beta chainBimagrumab\
BYM338Human monoclonal antibody IgG1λDisease modifying\
Myostatin inhibitor\
DM II decrease BMI phase II\
Sporadic inclusion body myositis phase III not meet endpoint\
Treat sarcopenia in older adults phase IIIntravenousActivin A receptor type IIB (ACVR2B)BimekizumabHumanized monoclonal antibody IgG1κDisease modifying\
Ankylosing spondylitis (2018 II, 2022 II, +), plaque psoriasis (2021 III, 2020 III, 2019 III, +), psoriatic arthritis (2020), RA (2017 II), UC phase IISubcutaneousIL 17A and IL 17FBivatuzumab mertansineHumanized monoclonal antibody IgG1Antineoplastic squamous cell carcinoma, breast phase I fail *x*2, head/neck or esophagus phase I fail, toxicityCD44 v6BleselumabHuman monoclonal antibody IgG4κDisease modifying organ transplant rejection phase II 2020 to prevent FSGS in kidney transplant patients\
Phase II psoriasis- medication tolerated with minimal reaction, no benefit to disease processIntravenousCD40BlinatumomabBlincyto\
FDA 2014\
EU 2015Murine(scFv - kappa - heavy) - (scFv - heavy - kappa) BiTEAntineoplastic\
Ph chrom neg pre-B ALL (CD19+) phase II\
**B-cellprecursor acute lymphoblastic leukemia (ALL) initial or relapsed/refractory**IntravenousBispecific T-cell engager monoclonal antibody construct that directs CD-3 positive effector memory T cells to CD19-positive target cellsBlontuvetmabBlontressCanine monoclonal antibody IgG2 κ/λVeterinary treat canine B-cell lymphomaCD20BlosozumabHumanized IgG4κDisease modifying\
Osteoporosis 3 phase I and one phase 2 injection site reaction and antibodies to antibodyIntravenous\
SubcutaneousSOST\
AntisclerostinBococizumab\
RN316\
PF-04950615Humanized IgG2κDisease modifying\
Dyslipidemia\
Phase III 2019\
Discontinued secondary to antidrug antibodies, no primary endpoint achievedSubcutaneous intravenousNeural apoptosis-regulated proteinase 1\
PCSK9 (proprotein convertase subtilisin/kexin type 9, neural apoptosis-regulated convertase 1, NARC1, NARC-1, proproteine convertase 9, PC9)BrazikumabHuman monoclonal antibody IgG2λDisease modifying\
Ulcerative colitis phase II 2021\
Phase I/II completed Crohn. Phase III ongoingSubcutaneousIL23Brentuximab vedotinAdcetris\
FDA 2013\
Breakthrough therapy status by FDA 2018Chimeric humanized monoclonal antibody IgG1κAntineoplastic\
**Hodgkinlymphoma**\
**Anaplasticlarge-cell lymphoma**IntravenousCD30 (TNFRSF8) an antibody-drug conjugate (ADC) 3 parts: anti-CD30 (cAC10, a cell membrane protein of the tumor necrosis factor receptor), a microtubule disrupting agent monomethyl auristatin E (MMAE) and a protease-cleavable linker that attaches MMAE covalently to cAC10. The combination disrupts the intracellular microtubule network causing cell-cycle arrest and apoptotic cellular deathBriakinumabHuman monoclonal antibodyDisease modifying psoriasis,\
Drug development stopped for psoriasis, phase IIb study in Crohn\'sIntravenousIL-12, IL-23Brodalumab\
AMG827Siliz\
FDA 2016Human monoclonal antibody IgG2κDisease modifying\
**Plaque psoriasis**\
Completed phase IIISubcutaneousReceptor IL-17RABrolucizumab\
RTH258\
ESBA1008FDA review 2018Humanized single chain antibody fragment (scFv κ)Disease modifying\
Wet or age-related macular degeneration phase III to be completed Sept 2018, 2020 HAWK (NCT02307682) and HARRIER (NCT02434328) phase III trials good resultsIntravitreal\
<https://www.novartis.com/news/media-releases/new-novartis-phase-iii-data-brolucizumab-demonstrate-reliability-12-week-treatment-interval>VEGFABrontictuzumabHumanized IgG2λAntineoplastic\
Phase I\
Colorectal\
Lymphoid\
Adenoid cystic\
Solid tumorsIntravenousNotch 1Burosumab\
KRN23Crysvita\
FDA 2018Human monoclonal antibody IgG1κDisease modifying\
X-linked hypophosphatemia\
Phase III completedSubcutaneous\
<https://www.creativebiolabs.net/burosumab-overview.htm>FGF 23 phosphaturic hormone fibroblast growth factor 23CabiralizumabHumanized monoclonal antibody IgG4κAntineoplastic metastatic pancreatic cancer phase II 2020\
Many other cancers phase IIntravenousCSF1RCamidanlumab tesirine\
ADCT-21Human monoclonal antibodyAntineoplastic\
B-cell Hodgkin\'s lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia [2018](mi:2018){#interref3} phase I\
Advanced solid tumors with literature evidence of CD25(+) treg content\
Head and neck\
Nonsmall cell lung\
Gastric, esophageal,\
Pancreas, bladder,\
Renal cell, melanoma,\
Triple-negative breast, ovarian phase I [2021](mi:2021){#interref4}IntravenousCD25Sinilimab\
Camrelizumab\
IBI308China pending approvalHumanized monoclonal antibody IgG4κAntineoplastic\
Phase III nasopharyngeal cancer 2021\
Phase III esophageal cancer 2021Programmed cell death 1 (PDCD1)Canakinumab\
ACZ885Ilaris\
FDA 2009\
EU 2009Human monoclonal antibody IgG1κDisease modifying\
**Cryopyrin-associatedperiodic syndromes**\
**Includingfamilial cold auto-inflammatory syndrome andMuckle--Wells syndrome**; **tumor necrosis factor receptor-associated periodic syndrome (TRAPS); hyperimmunoglobulin Dsyndrome(HIDS)/mevalonate kinase deficiency (MKD) and familial Mediterranean fever (FMF)**\
**SystemicJuvenile idiopathic arthritis**\
Treat Juvenile idiopathic arthritis phase III\
NSCLC 2025 phase III\
CVD rejected by FDA\
BehcetSubcutaneousIL-1βCantuzumab mertansineHumanized monoclonal antibody IgG1κAntineoplastic\
Colorectal cancer phase I 2007IntravenousMucin CanAgCantuzumab ravtansineHumanized monoclonal antibody IgG1κAntineoplastic\
CancersMUC1Caplacizumab-yhdpCablivi\
(Nanobody program)\
FDA 2019\
EU 2018Humanized single variable domain antibody (bivalent nanobody)Disease modifying\
Inhibits interaction vWF and platelets\
Treat acquired TTP\
Phase III Hercules study completedIntravenous\
SubcutaneousVWFCapromab pendetideProstascint\
FDA 1996Murine monoclonal antibodyDiagnostic imaging\
Prostatic carcinoma cells detectionIntravenousTumor surface antigen PSMACarlumabHuman monoclonal antibody IgG1κAntineoplastic\
Prostate phase II no long term benefit\
Pulm fibrosis phase II no benefitIntravenoushMCAF/MCP-1 (human macrophage/monocyte chemotactic protein-1)Carotuximab\
TRC105Chimeric monoclonal antibody IgG1κAntineoplastic angiosarcoma\
Hepatocellular car phase I/II 2020\
Glioblastoma multi-phase II 2014 terminated poor accrual ?results\
Angiosarcoma phase III 2019 TAPPAS trial\
Prostate ca phase II 2021\
NSCLC phase I 2019IntravenousEndoglin (CD105)CatumaxomabRemovab\
FDA approved pend 2017)\
EU approved 2009Removab: A trifunctional rat/murine hybrid antibody IgG2a/IgG2bAntineoplastic\
Removab\
Ovarian cancer phase II, **malignant ascites** phase II, gastric cancer phase II (ovarian, gastric, colon, pancreatic, breast, endometrial)\
Proxinium\
Head and neck cancerIntraperitonealEpCAM, CD3\
Catumaxomab consists of one "half" (one heavy chain and one light chain) of an anti-EpCAM antibody and one half of an anti-CD3 antibody, so that each molecule of catumaxomab can bind both EpCAM and CD3. In addition, the Fc-region can bind to an Fc receptor on accessory cells like other antibodies, which has led to calling the drug a trifunctional antibody.cBR96-doxorubicin immunoconjugate\
aka SGN-15Humanized monoclonal antibody IgG1κAntineoplastic\
Cancer\
Sponsorship ceased 2005CedelizumabCIMZIAHumanized monoclonal antibody IgG4κPrevent organ transplant rejectionCD4CemiplimabLibtayo\
FDA 2018Human monoclonal antibody IgG4Antineoplastic\
Nonsmall cell lung cancer (NSCLC) phase I 2021, phase III 2022 × 3\
Oropharynx phase II 2022\
Multiple myeloma phase II 2022\
Ovarian ca phase II 2022\
Head neck squamous cell carcinoma phase II 2020\
**Cutaneoussquamous cell**\
Glioblastoma multiforme phase II 2021\
Lung ca phase II 2022\
Cervical cancer phase III 2023IntravenousProgrammed cell death receptor PCDC1Cergutuzumab amunaleukin\
Aka RO6895882, CEA-IL2vHumanized monoclonal antibodyAntineoplastic phase I Dec 2018IntravenousIL2Certolizumab pegol\
CDP870Cimzia\
FDA 2008\
EU 2009Recombinant, humanized antibody Fab' fragmentDisease-Modifying\
**Crohns**\
**Rheumatoidarthritis** (phase IIIs completed)\
Psoriatic arthritis phase III\
Ankylosing spondylitisSubcutaneousTumor necrosis factor α blockerCetrelimabRelatimabHuman monoclonal antibody IgG4κAntineoplasticNothing on PubMed or creative lab\
Substance is registered with FDAProgrammed cell death 1Cetuximab\
IMC-225Leukeran\
Erbitux\
FDA 2004\
EU 2004Recombinant chimeric monoclonal antibody IgG1κAntineoplastic agent\
**Metastaticcolorectal cancer** and head and neck cancer\
NSCLCIntravenous solutionEGFRCitatuzumab bogatoxHumanized Fab IgG1κAntineoplastic ovarian cancer and other solid tumorsStudy phase I terminated 2008EpCAMCixutumumabHuman monoclonal antibody IgG1κAntineoplastic\
Solid tumors\
Sarcoma phase II\
Esophageal cancer phase II\
Rhabdomyosarcoma phase II no benefit\
Liver cancer phase I\
Low antitumor effect\
Pancreas no benefit 2012IntravenousIGF-1 receptor (CD221)Clazakizumab\
ALD−518Humanized monoclonal antibodyDisease modifying rheumatoid arthritis phase II 2015 × 3\
Crohn disease phase II 2013\
Highly sensitized renal transplant candidates phase II 2020\
Treat post-tx rejection kidney phase II 2020\
Antibody-mediated rejection phase III 2027SubcutaneousIL6ClenoliximabChimeric monoclonal antibodyDisease modifying Rheum Arth\
No study since 2003CD4Clivatuzumab tetraxetan\
(90)Y-clivatuzumab tetraxetanhPAM4-CideHumanized monoclonal antibody IgG1κAntineoplastic\
Pancreatic cancer\
Phase III 2017 PANCRIT-1 study. Study terminated no increase improvement of overall survivalMUC1CodrituzumabHumanized monoclonal antibody IgG1κAntineoplastic\
HCC\
Phase Ib no response\
Phase II no responseGlypican 3Cofetuzumab pelidotinHumanized monoclonal antibody IgG1κAntineoplasticNothing on PubMed or creative lab\
Substance is not registered with FDAProtein tyrosine kinase 7 (PTK7)Coltuximab ravtansine\
SAR3419Chimeric monoclonal antibody IgG1 conjugated to DM4 (N2′-(4-((3-carboxypropyl)dithio)-4-methyl-1-oxopentyl)-N2′-deacetylmaytansine)Antineoplastic\
Relapse/refractory ALL phase II 2015 low clinical response\
Phase II moderate responseCD19Conatumumab\
AMG655Human monoclonal antibody IgG1κAntineoplastic\
Phase II 2019: Advanced solid tumors\
Carcinoid\
Colorectal cancer\
Locally advanced\
Lymphoma\
Metastatic cancer\
Nonsmall cell lung cancer\
Sarcoma\
Solid tumors\
Colon cancer phase Ib/II no benefitIntravenousTRAIL-R2ConcizumabHumanized IgG4κDisease modifying\
Hemophilia A and B phase II 2020SubcutaneousKunitz-type protease inhibitor 2 domain of tissue factor pathway inhibitor (TFPI)CosfroviximabZMappChimeric monoclonal antibody IgG1κ\
Triple monoclonal antibody cocktailDisease modifying Ebola virus\
Ongoing studies show benefit but not enough enrolled to power studyEbola virus glycoproteinCrenezumab\
RG7412\
MABT5102AHumanized monoclonal antibody IgG4Disease modifying\
Alzheimer\'s disease phase III study ongoing prodromal/mild AD 2021\
Phase III 2022Intravenous1-40-β-amyloidCrizanlizumab\
SelG1FDA review possible 2019Humanized monoclonal antibody IgG2κDisease modifying\
Sickle cell disease phase II 2022 children\
Phase II adults decrease pain crisisIntravenousP SelectinCrotedumabHuman monoclonal antibody IgG4κDisease modifying DM type IINo resultsGCGRCusatuzumab\
ARGX-110Humanized monoclonal antibody IgG1Antineoplastic\
Phase I completed safe\
Phase I/II CTCL dec 2018\
Nasopharyngeal carcinoma 2018IntravenousCD70Dacetuzumab\
HU-S2C6\
ASKP1240\
SGN-40Humanized monoclonal antibody IgG1Antineoplastic\
Hematologic cancers\
Multiple myeloma phase I 2007\
Large B-cell lymphoma phase II 2009 enrollment stopped no benefit\
CLL phase II 2006\
NHL phase I\
Renal transplant (CIRRUS I) phase II 2022\
SLE nephritis phase II 2020IntravenousCD40DaclizumabZenapax\
Zinbryta\
FDA 1997\
EU 1999\
Zenapax withdrawn from market Apr 2009 for commercial reasons\
Zinbryta withdrawal 2018 secondary to risk/benefit profileHumanized monoclonal antibody IgG1κDisease modifying\
Prevention of organ transplant rejections\
Phase IV kidney transplants, multiple sclerosis phase III 2018 pulled from market secondary inflammatory brain disorders Biogen\
Heart transplant phase IV 108 studies Zanapax discontinued from market by Roche (basiliximab replace)CD25 (α chain of IL-2 receptor)DalotuzumabHumanized monoclonal antibody IgG1κAntineoplastic\
Phase I multiple\
Phase II breast no improvement × 2\
Phase III colon no improvement\
Ped solid phase IIntravenousIGF-1 receptor (CD221)Dapirolizumab pegolHumanized monoclonal antibody IgG1κSLE phase II Nov 2018\
Phase I safeIntravenousCD154 (CD40L)DaratumumabDarzalex\
FDA 2015\
EU 2016Human IgG1κAntineoplastic agent\
**Multiple myeloma relapse/refractory**\
Phase III completedIntravenous solutionCD38\
Induces CDC, ADCC, ADCP, and apoptosisDectrekumab\
QAX576Human monoclonal antibody IgG1κCancers, asthma phase II, idiopathic pulmonary fibrosis, eosinophilic Esophagitis phase II some benefit but primary endpoint not achieved, Keloids, Crohn\'s disease phase II trials 2013Nothing on PubMed\
Substance is registered with FDA, creative labIL-13DemcizumabHumanized monoclonal antibody IgG2κAntineoplastic\
NSCLC phase II 2018\
Phase I safety established with 50% tumor regression responseIntravenousDelta-like ligand 4DLL4\
DLL4 and Notch1, signaling stimulated by DLL4 plays a role in development of blood vessels throughout lifeDenintuzumab mafodotin\
HBU-12\
SGN-CD19AHumanized monoclonal antibody IgG1κ\
Antibody-drug conjugate (ADC) composed of a humanized anti-CD19 monoclonal antibody conjugated to the microtubule-disrupting agent monomethyl auristatin F (MMAF)Antineoplastic\
LBCL phase II terminated study by company\
Acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma\
Phase I 2017\
Phase II 2018 terminated by sponsorIntravenousCD19Denosumab\
AMG162Prolia\
FDA 2010\
EU 2010\
Xgeva\
FDA 2011\
EU 2011Human monoclonal antibody IgG2Disease modifying\
Osteoporosis FREEDOM trial, bone metastases, etc. 186 studies\
Phase III completed\
Melanoma phase II 2022\
Bone giant cell tumor phase II 2025SubcutaneousReceptor activator of nuclear factor kappa-B ligand (RANKL)\
Xgeva: Prevention of skeletal-related events (SREs) in adults with bone metastases from breast and castration-resistant prostate cancer.\
Prolia: Osteoporosis*Depatuxizumab* mafodotin\
ABT 414Chimeric humanized monoclonal antibody IgG1κ CONJUGATED TO AURISTATIN FGlioblastoma\
Phase III Nov 2019\
Children phase III 2020IntravenousEGFRDerlotuximab biotin\
Iodine (131 I) derlotuximab biotinChimeric monoclonal antibody IgG1κImmunoassays\
Potential for glioblastoma multiformeHistone complexDetumomabMurine monoclonal antibody IgG1Antineoplastic\
B-lymphoma cellNothing on PubMed or clinical trials\
Substance is not registered with FDA, is on creative labCD3EDezamizumab\
GSK-2398852Humanized monoclonal antibody IgG1κDisease modifying\
Treat amyloidosis\
Transthyretin cardiomyopathy amyloidosis (ATTR-CM), suspended pending data review Aug 2018 phase I x 4IntravenousSerum amyloid P componentDinutuximab\
APN311Unituxin\
FDA 2015\
EU 2015 then withdrawn EUChimeric monoclonal antibody IgG1κAntineoplastic\
Neuroblastoma phase I 2022\
SCLC phase III Nov 2019\
Osteosarcoma phase II Dec 2018\
**Neuroblastoma** phase II 2020IntravenousGD2 gangliosideDiridavumab\
CR6261Human monoclonal antibody IgG1λDisease modifying\
Infectious disease/influenza A\
Very good response in animal study mice\
Phase II 2019IntravenousInfluenza A hemagglutininDomagrozumab\
PF-06252616Humanized monoclonal antibody IgG1κDisease modifying\
Duchenne muscular dystrophy phase II 2018\
Phase I completedGDF-8Dorlimomab aritoxF(ab\')~2~MurineNothing on PubMed or clinical trials\
Substance is not registered with FDA, or creative labDostarlimab\
TSR042\
WBP285FDA review pending 2019Humanized monoclonal antibody IgG4κAntineoplastic\
Solid tumor\
Phase I, II, III studies ongoing\
Ovarian CA (first study) phase III 2023Programmed cell death protein-1 (CD279) PCDP1Drozitumab\
PRO95780\
rhuMAB DR5Human monoclonal antibody IgG1λAntineoplastic\
Colorectal cancer Ib 2012\
Preclinical rhabdomyosarcoma 2018\
Chondrosarcoma not efficacious\
NHL results?IntravenousDeath receptor 5 (DR5)Duligotuzumab\
MEHD7945AHuman monoclonal antibody IgG1κAntineoplastic squamous head and neck phase II no benefit\
Colon ca phase II no benefitAnti-EGFR × Anti-HER3 bispecific antibodyDupilumabDupixent\
FDA 2017Human monoclonal antibody IgG4Disease modifying asthma, **atopic dermatitis**\
Ongoing studiesSubcutaneousIL4DurvalumabImfinzi\
FDA 2017Human monoclonal antibody IgG1κAntineoplastic agent\
Treat NSCLC stage III phase I, urothelial carcinomaIntravenousPD-L1 (CD274) and CD80---inhibit binding of programmed death ligand 1 to PD-1 and CD80 allowing T cell to recognize and kill tumor cellsDusigitumab\
MEDI 573Human monoclonal antibody IgG2λAntineoplastic\
Breast cancer phase II results?\
HCC phase II results?IntravenousILGF2Duvortuxizumab\
MGD011Chimeric/humanized monoclonal antibodyAntineoplastic\
B-cell malignancy\
Phase I/II Jul 2018/2020IntravenousCD19, CD3EEcromeximab\
KW2871Chimeric monoclonal antibody IgG1κAntineoplastic\
Metastatic melanoma\
Phase I/II clinical activity limitedIntravenousGD3 gangliosideEculizumabSoliris\
PNH\
FDA 2007\
EU 2007\
aHUS, and myasthenia gravis\
FDA 2018\
EU 2018\
Japan 2018Humanized monoclonal antibody IgG1/4Immuno-regulation\
**Paroxysmalnocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (HUS**)\
**Generalizedmyasthenia gravis (MG)**\
Phase II CADIntravenousC5Edobacomab\
E5Murine monoclonal antibodyNo improved survivalEndotoxinEdrecolomabPanorexMurine monoclonal antibody IgG2κAntineoplastic\
Colorectal carcinoma phase III 2003 no improvementIntravenousGlycoprotein EpCAM/17-1AEfalizumabRaptiva\
FDA 2003\
EU 2004\
Withdrawn both markets 2009Recombinant humanized monoclonal antibody IgG1κDisease modifying\
(2003 approved) psoriasisSubcutaneous\
Voluntary withdrawal 2009Human CD11a\
Increase risk progressive multifocal leukoencephalopathy (PML)Efungumab\
MYC123Mycograb\
Mycograb C28YHuman scFvAntiinfectious agent\
Invasive Candida infectionIntravenousHeat shock protein 90 (Hsp90)Eldelumab\
Mdx 1100Human monoclonal antibody IgG1κCrohn\'s disease phase IIa no significant response, ulcerative colitis phase IIb prim endpoint not achieved\
Rheum arthritis phase IIIntravenousInterferon γ-induced protein\
CXCL 10Elezanumab\
PR-1432051\
ABT-555Human monoclonal antibody IgG1λSpinal cord injury and multiple sclerosis phase II 2021IntravenousREPULSIVE GUIDANCE MOLECULE FAMILY MEMBER A (RGMA)Elgemtumab\
LJM716Human IgG1κAntineoplastic\
Breast gastric phase IIntravenousERBB3 (HER3)Elotuzumab\
PDL063Empliciti\
FDA 2015\
EU 2016Human IgG1κAntineoplastic\
Multiple myeloma\
Phase III completed and ongoingIntravenousSLAMF7Elsilimomab\
B-E8Humanized monoclonal antibody IgG1Antineoplastic multiple myeloma\
Not effective in miceIL-6Emactuzumab\
RG7155Humanized monoclonal antibody IgG1ANTINEOPLASTIC\
Phase I 2019 solid tumors\
Phase II 2025 REDIRECT study ovarian, fallopian tube cancer\
Pancreatic phase II 2020HUMAN MACROPHAGE COLONY-STIMULATING FACTOR RECEPTOR (CSF1R, CD115)Emapalumab\
NI-0501Gamifant\
FDA 2018\
EU pendingHuman monoclonal antibody IgG1λHemophagocytic lymphohistiocytosis\
Phase III 2021IntravenousInterferon γEmibetuzumab\
LA480\
LY2875358Humanized monoclonal antibody IgG4κ\
Bivalent antibodyAntineoplastic\
NSCLC phase II 2020\
Advanced cancer\
Gastric safe ?effective adenocarcinoma\
Gastroesophageal junction adenocarcinoma\
Hepatocellular cancer\
Renal cell carcinoma\
Nonsmall cell lung cancer phase II Jan 2018\
Phase I safe with tumor responseIntravenousHepatocyte growth factor receptor (HHGFR) and MET signalingEmicizumab\
ACE910Hemlibra\
FDA 2018Humanized monoclonal antibody IgG4κ\
BispecificDisease modifying\
Hemophilia A phase III 2020\
With or without inhibitorsSubcutaneousActivated F9, F10Enapotamab vedotinHuman monoclonal antibody IgG1κAntineoplasticNothing on PubMed or clinical trials\
Substance is not registered with FDA, or creative labHuman growth factor receptor AXLEnavatuzumab\
PDL192Humanized monoclonal antibody IgG1κAntineoplastic\
Phase I 2011\
No responses and liver pancreatic toxicityIntravenousTWEAK receptorEnfortumab vedotinFDA review pending 2019Human monoclonal antibodyAntineoplastic bladder cancer phase I\
Phase II ongoingNectin-4\
Anti-Nectin-4\
Monoclonal antibody attached to a microtubule-disrupting agent, monomethyl auristatin E (MMAE)Enlimomab pegolMurine monoclonal antibodyIgG2aDisease modifying\
StrokeNothing on PubMed or clinical trials\
Substance is not registered with FDAICAM-1 (CD54)Enoblituzumab\
MGA 271Humanized monoclonal antibody IgG1κAntineoplastic\
Phase I 2022 children Neuroblastoma\
Rhabdomyosarcoma\
Osteosarcoma\
Ewing sarcoma\
Wilms tumor\
Desmoplastic small round cell tumor\
Phase I melanoma, NSCLC 2018\
Phase II prostate 2021CD276 (B7--H3)Enokizumab\
MEDI528Humanized monoclonal antibody IgG1κAsthma phase II\
No improvementIntravenousIL9Enoticumab\
REGN421Human monoclonal antibody IgG1κAntineoplastic\
Phase 1 2014 ovarian cancer +Delta-like canonical notch ligand 4 (DLL4)Ensituximab\
NEO-201\
NPC-1CChimeric monoclonal antibody IgG1κAntineoplastic\
Phase II pancreatic and colorectal cancer 2017Intravenous5ACEnterecept\
RHU-TNFR:FCEnbril\
FDA 20031-235-Tumor necrosis factor receptor fusion protein attached to recombinant human IgG1 Fc fragmentDisease modifying\
Antirheumatic drug\
Not effective for inflammatory bowel diseaseSubcutaneousTNFαEpitumomab cituxetan\
AS-1402\
HuHMFG-1SontuzumabHumanized monoclonal antibody IgG1Antineoplastic\
Breast cancer phase II 2012 no benefitEpisialin\
MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20 (HMFG-1)Epratuzumab\
HLL2\
AMG412Humanized monoclonal antibody IgG1κ\
ADCC/CDCAntineoplastic\
B-ALL phase III ongoing 2018\
Disease modifying\
SLE phase III no improvementIntravenousCD22Eptinezumab\
ALD403FDA review possible 2019Monoclonal antibody IgG1κDisease modifying\
Migraine phase IIICalcitonin gene-related peptideErenumabAimovig\
FDA May 2018Human monoclonal antibody IgG2λDisease modifying\
Migraine phase IIICalcitonin gene-related peptide (CGRP)Erlizumab\
Rhumab CD18Humanized IgG1 F(ab\')~2~ fragmentAntineoplastic\
(lab tests)\
Immunosuppressive drug phase I study cough up blood and phase II did not meet goals\
Heart attack, stroke, traumatic shock ??no successful CD18 drug to dateLGL type leukemiaITGB2 (CD18) and LFA-1 block growth factor of blood vessels stop lymphocytes from moving into inflamed tissueErtumaxomabRexomunRat/murine hybrid triomab, murine IgG2a HET2 target, RAT IgG2bλ CD3 targetAntineoplastic\
Breast\
Gastric, esophageal\
Phase II studies terminated company to focus on other plans not safety concerns concentrate on catumaxomab\
Phase I found safe 2016IntravenousHER2/neu, CD3Etaracizumab or etaratuzumab\
MEDI-522Abegrin\
VitaxinHumanized monoclonal antibody IgG2κAntineoplastic\
Melanoma phase II 2010 not beneficial, prostate cancer, ovarian cancer small and large bowel cancer phase I and II completed results unreported 2017IntravenousIntegrin αvβ3EtigilimabHumanized monoclonal antibody IgG1κNothing on pubmed or clinical trials\
Substance is registered with FDA, or is not in creative labTIGIT T-cell immunoreceptor with Ig and ITIM domainsEtrolizumab\
PRO145223\
RHUMAB BETA7Humanized monoclonal antibody IgG1κDisease modifying\
Inflammatory bowel disease UC phase III 2020 × 4/2023/2024/2025\
Crohn phase III 2021SubcutaneousIntegrin β7\
Inhibits binding of\
αEβ7 to E-cadherinEvinacumab\
REGN1500Human monoclonal antibody IgG4κDisease modifying\
Dyslipidemia\
Phase II 2020\
Phase III 2020/2022Angiopoietin 3EvolocumabRepatha\
FDA 2015\
EU 2015Human monoclonal antibody IgG2λDisease modifying hypercholesterolemia\
Completed phase III\
Heterozygous familial hypercholesterolemia, CVDSubcutaneousProprotein convertase subtilisin kexin type 9 (PCSK9)ExbivirumabHumanized monoclonal antibody IgG1λDisease modifying prevent disease Hep BOral therapy\
Abstract of randomized study of 50 patientsHepatitis B surface antigenFanolesomab\
RB5-IGMNeutroSpecMurine monoclonal antibodyDiagnostic imaging\
Appendicitis (diagnosis only)CD15FaralimomabMurine monoclonal antibody IgG1Nothing on PubMed or clinical trials\
Substance is not registered with FDA, or is not in creative labInterferon receptorFaricimab\
RG7716\
RO6867461Humanized monoclonal antibody IgG1mabDisease modifying angiogenesis, ocular vascular diseases\
STAIRWAY, BOULEVARD, RHINE, Yosemite phase II and III studies phase III 2022 for diabetes maculae edema\
AMD LUCERNE phase III 2022 TENAYA phase III 2022IntravitreousANTIVASCULAR ENDOTHELIAL GROWTH FACTOR/ANTIANGIOPOIETIN 2 BISPECIFIC ANTIBODY (VEGF-A and Ang-2)Farletuzumab\
MORAB-003Humanized monoclonal antibody IgG1κAntineoplastic\
Ovarian cancer phase III subgroup may benefitIntravenousFolate receptor 1Fasinumab\
REGN475\
SAR164877\
MT5547Human monoclonal antibody IgG4κDisease modifying acute sciatic pain phase III\
Knee arthritis pain phase III 2021Subcutaneous (auto injector)Human nerve growth factor (HNGF)FBTA05\
Bi20LymphomunRat IgG2b (CD3)/murine IgG2a (CD20) hybrid trifunctAntineoplastic\
Chronic lymphocytic leukemia trial terminated recruitment too slowIntravenous?CD20/CD3FelvizumabHumanized monoclonal antibody IgG1κAntiinfectious agent\
Respiratory syncytial virus infectionNothing on PubMed or clinical trials\
Substance is not registered with FDA, but is in creative labRespiratory syncytial virusFezakinumabHuman monoclonal antibody IgG1λDisease modifying\
Rheumatoid arthritis, psoriasis (not good for)\
Atopic dermatitis phase IIb good resultsIntravenousIL-22Fibatuzumab\
IfabotuzumabHumanized monoclonal antibody IgG1κDisease modifying\
Myelodysplastic syndrome\
Research in Australia for GBM phase IEphrin receptor A3Ficlatuzumab\
SCH 900105\
AV 299Humanized monoclonal antibody IgG1κAntineoplastic\
Head and neck cancer phase I 2020\
Pancreatic phase I 2023\
NSCLC phase I/II 2013\
AML phase I 2020IntravenousHepatocyte growth factor (HGF) hepapoietin AFigitumumab\
CP751871Human monoclonal antibody IgG2κ\
Ceased development in 2011 by pfizerAntineoplastic\
Adrenocortical carcinoma, nonsmall cell lung carcinoma etc. ?additional benefit in phase IInsulin-like growth factor receptor IGF-1 receptor (CD221)FirivumabHuman monoclonal antibody IgG1κDisease modifying\
Influenza A virus hemagglutininNothing on PubMed or clinical trials\
Substance is registered with FDA, and is in creative labINFLUENZA A VIRUS HEMAGGLUTININ HAFlanvotumab\
IMC20D7SHuman monoclonal antibody IgG1κAntineoplastic\
Melanoma phase I 2012Intravenous\
No published dataTYRP1 (glycoprotein 75)FletikumabHuman monoclonal antibody IgG4Disease modifying\
Rheumatoid arthritis\
phase IIa good, phase IIb no resultsIL 20Flotetuzumab\
MGD006\
S80880Humanized di-scFv\
dual affinity retargeting (DART) to CD123 and CD3Antineoplastic\
Hematologic malignancies (ALL, NHL)\
Phase II not yet recruiting 2018Intravenous?IL 3 receptorFontolizumabHuZAFHumanized monoclonal antibody IgGDisease modifying\
Treat Crohn\'s clinical development stopped despite some benefit phase II ustekinumab is betterIFN-γFOR46Antibody drug conjugateAntineoplastic\
Phase I for multiple myeloma failed remission or relapse\
Phase I prostate cancerIntravenousCD46ForalumabHuman monoclonal antibody IgG1κDisease modifying NASH phase II 2019OralCD3 epsilonForavirumabHuman monoclonal antibody IgG1κDisease modifying rabies (prophylaxis)Nothing in pub med or clinical trialsRabies virus glycoproteinFremanezumab\
LBR-101\
RN307Ajovy\
FDA 2018Humanized monoclonal antibody IgG2κDisease modifying migraine and cluster headache phase III 2019Subcutaneousα-Calcitonin gene-related peptideFresolimumabHumanized monoclonal antibody IgG4Disease modifying\
Idiopathic pulmonary fibrosis (IPF), scleroderma, focal segmental glomerulosclerosis (phase 2), cancer (kidney cancer and melanoma)Need larger study for FSGS\
Good response scleroderma\
<https://newdrugapprovals.org/2016/01/30/fresolimumab/>TGF β 1Frovocimab\
LY3015014Humanized monoclonal antibody IgG4κDisease modifying hypercholesterolemia\
Completed phase II trials 2014 good response and safeSubcutaneousPROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9)Frunevetmab [https://en.wikipedia.org/wiki/List_of_therapeutic_monoclonal_antibodies - cite_note-WHOList 116-17](https://en.wikipedia.org/wiki/List_of_therapeutic_monoclonal_antibodies%20-%20cite_note-WHOList%20116-17){#interref6}\
NV-02Veterinary monoclonal antibody IgG1κVeterinaryFeline muscle nerve growth factorFulranumab\
AMG403Human monoclonal antibody IgG2κDisease modifying\
Pain osteoarthritis pain phase III 2017SubcutaneousNerve growth factorGalcanezumab\
LY2951742Emgality\
FDA 2018Humanized monoclonal antibody IgG4κDisease modifying\
Migraine\
Phase III completed\
Cluster HA phase III 2020SubcutaneousCalcitonin gene-related polypeptides (CGRPs) α and βGaliximab\
IDEC-114Chimeric monoclonal antibody IgG1λ\
ADCC/CDCAntineoplastic lymphoma phase II 2015 minimal response ORR 10.3%IntravenousCD80Gancotamab\
MM-302Human cFv\
Single chain fragmentAntineoplastic\
Breast cancer phase I--IIIIntravenousHER2/neuGanitumab\
AMG479Human monoclonal antibody IgG1κAntineoplastic\
Pancreatic phase III---no increase benefit\
Phase III for rhabdomyosarcoma and Ewings 2021\
Not beneficial in NSCLCIntravenousIGF-1 receptor (CD221)Gantenerumab\
R04909832\
R1450Human monoclonal antibody IgG1κDisease modifying\
Alzheimers\
Phase III stopped for potential futility additional studies at higher dosing (DIAN in a phase II/III trial in individuals at risk\
For and with early-stage autosomal-dominant AD phase III 2021SubcutaneousBeta amyloidGatipotuzumabPankoMab-GEXHumanized monoclonal antibody IgG1κAntineoplastic\
Ovarian, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), breast cancer (BC), gynecological cancers (GYN) phase I used for diag/prog nowIntravenousMusculus, antimucin (MUC1)Gavilimomab\
ABX-CBLMurine monoclonal antibody IgMDisease modifying\
Graft versus host disease phase III completed 2005 less effective than antithymocyte antibodyCD147 (basigin)Gedivumab\
RG7745\
RO6876802Human monoclonal antibody IgG1κDisease modifying\
Influenza virus ANo studies\
PubMed/clinical trialsInfluenza virus hemagglutinin HAGemtuzumab ozogamicinMylotarg\
AML FDA 2000\
Voluntary withdrawal 2010 VOD now black box warning\
Returned to market with FDA approval 2017Humanized monoclonal antibody IgG4/toxin conjugateAntineoplastic\
Acute myelogenous leukemia\
Many ongoing and completed studiesIntravenousCD33Gevokizumab\
XOMA 052Humanized monoclonal antibody IgG2κDisease modifying DM phase II (late stage) no results\
Other dz too 24 studies behcet uveitis failed primary end point phase III (Eyeguard \_B) 2015SubcutaneousIL-1βGilvetmab\
PD1Veterinary monoclonal antibody IgG2κAntineoplasticNo studies clinical trial, pub med*CANIS FAMILIARIS* PROGRAMMED CELL DEATH PROTEIN 1 (PCDC1)Gimsilumab\
MORAb-022Human monoclonal antibody IgG1Disease modifying\
Rheumatoid arthritis\
Asthma\
Phase I poster presentation of safety results good 2016IntravenousHUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (CSF2)Girentuximab\
WX-G250\
CG250Rencarex\
ReductaneChimeric monoclonal antibodyIgG1κ\
Radioactive labeled abAntineoplastic\
Clear cell renal cell carcinoma for treatment and imagingIntravenousCarbonic anhydrase 9 (CA-IX)Glembatumumab vedotin\
CR011Human monoclonal antibody IgG2κ\
Antibody drug complexAntineoplastic\
Melanoma phase II, breast cancerIntravenous**Human glycoprotein NMB extracellular domain** (GPNMB)Golimumab\
CNTO 148Simponi\
FDA 2009\
EU 2009Human monoclonal antibody IgG1κDisease modifying\
**Rheumatoidarthritis, psoriatic arthritis**, juvenile rheum arth, **ankylosing spondylitis** many studies, UC, DM1 phase I (2020, 2021)Subcutaneous, intravenousTNF-αGomiliximab\
IDEC-152\
Lumiliximab\
ST-152Chimeric monoclonal antibody IgG1κ\
ADCC/CDCAllergic asthma ?\
Antineoplastic CLL\
Phase I, phase 2/3 2014\
Failed efficacyCD23 (IgE receptor)Gosuranemab\
BIIB092\
IPN-007FDA orphan drug statusHumanized monoclonal antibody IgG4κProgressive supranuclear palsy\
Phase I 2020\
Alzheimer 2021Intravenousτ proteinGuselkumab\
CNTO 1959Tremfya\
FDA ?Human monoclonal antibody IgG1λDisease modifying\
Psoriasis\
Adenomatous polyposisSubcutaneousIL23AHu3F8Humanized monoclonal antibody IgG3Antineoplastic\
Phase I\
For neuroblastoma mod tox and substantial effect on tumor\
Phase II ongoingIntravenousGD2 gangliosideIanalumabHuman monoclonal antibody IgG1κImmunomodulation\
Autoimmune hepatitisHuman cytokine receptor BAFF-RIbalizumabTrogarzo\
FDA/EU approvedHumanized monoclonal antibody IgG4Disease modifying anti-HIV\
Phase IIICD4Ibritumomab tiuxetan\
IDEC-129\
IDEC-IN2B8\
IDEC-Y2B8Zevalin\
FDA 2002\
EU 2004Murine monoclonal antibody IgG1κ YT[@bib77] or In[@bib98] boundAntineoplastic\
**Follicularnon-Hodgkin\'s lymphoma**, **B-cell NHL**, multiple myeloma conditioning for BMT, B-cell DLCL, mantle cell\
Many studiesCD20 (human B-lymphocyte-restricted differentiation antigen, Bp35)Icrucumab\
IMC 18F1Human monoclonal antibody IgG1κAntineoplastic\
No benefit breast phase II\
No benefit colon phase II\
No benefit urothelial phase IIIntravenousVascular endothelial growth factor receptor (VEGFR-1)IdarucizumabPraxbind\
FDA 2015\
EU 2015Humanized monoclonal antibody Fab fragmentAntidotes\
Drug reversal agent\
Reversal of anticoagulant effects of dabigatran\
Phase III trial RE-VERSE ADIntravenousDabigatran etexilateIgovomabIndimacis-125Murine F(ab\')~2~Diagnostic imaging\
Ovarian cancer (diagnosis)Iladatuzumab vedotin\
RG7986Humanized monoclonal antibody IgG1κAntineoplasticNothing in PubMed or clinical trialsHuman gene B29 protein (CD97B)Imalumab\
BAX69Human monoclonal antibody IgG1κAntineoplasticIntraperitoneal infusion, intravenousMacrophage migration inhibitory factor (MIF)ImaprelimabHumanized IgG1κAntineoplasticNothing in PubMed or clinical trialsMelanoma cell adhesion molecule (MCAM)Imciromab pentetateMyoscint\
FDA approved 1996\
Withdrawn from marketMurine monoclonal antibody fragment Fab IgG2aκDiagnostic\
Cardiac imagingCardiac myosinImgatuzumab\
RG7160\
RO5083945\
GA201\
HUMA-BHumanized monoclonal antibody IgG1κAntineoplastic\
Colorectal 2013\
Head and neck 2017\
NSCLC 2017Epidermal growth factor receptor (EGFR, HER1)IMGN632Monoclonal antibody with antibody drug conjugateAntineoplastic\
AML, ALL phase I 2021\
NCT03386513IntravenousCD123Inclacumab\
RG1512\
RO4905417Human monoclonal antibody IgG4κDisease modifying\
Cardiovascular disease phase IIIntravenousSelectin PIndatuiximab ravtansineChimeric monoclonal antibody IgG4κAntineoplastic\
Preclinical breast cancerCD138 (syndecan-1) SDC1Indusatumab vedotin\
TAK-264\
MLN0264Human monoclonal antibody IgG1κ conjuagated via a mc-val-cit-PABC linker to monomethyl auristatin E {MMAE (5F9-mc-val-cit-PABC-MMAE)}Antineoplastic\
Gastrointestinal, pancreatic, gastroesophageal\
Safe phase I, phase II pancreatic min response, three studies terminated by company businessIntravenousGuanylate cyclase C (GUCY2C)Inebilizumab\
MEDI-551Humanized monoclonal antibody IgG2κ ADCCAntineoplastic\
Refractory DLBCL phase II 2016\
Disease modifying systemic sclerosis, multiple sclerosis\
Neuromyelitis opticaIntravenousCD19InfliximabRemicade\
FDA 1998\
EU 1999\
Inflectra\
FDA 2016\
EU 2013\
Remsima\
EU 2013Human-murine chimera IgG1κ\
Human constant, murine variable regionDisease modifying\
Remicade\
Crohn\'s disease; ulcerative colitis; rheumatoid arthritis; ankylosing spondylitis; psoriatic arthrits; plaque psoriasis Inflectra\
Spondylitis; ankylosing; arthritis; rheumatoid colitis; ulcerative arthritis; psoriatic Crohn\'s disease; psoriasis\
Remsima\
Spondylitis; ankylosing arthritis; rheumatoid colitis; ulcerative Crohn\'s disease; arthritis; psoriatic psoriasisIntravenous solutionTNF-αInolimomabMurine monoclonal antibodyDisease modifying GVHD phase III\
No better than ATG in 3 studies\
Abandoned not in 2017 Cochrane reviewCD25 (α chain of IL-2 receptor)Inotuzumab ozogamicin\
G544Besponsa\
FDA 2017Humanized monoclonal antibody IgG4κ ADCC/CDCAntineoplastic\
ALL phase II 2023\
Multiple other studiesIntravenousCD22Intetumumab\
CNTO095Human monoclonal antibody IgG1κAntineoplastic\
Solid tumors (prostate cancer, melanoma)\
Melanoma phase II possible benefit 2011\
Prostate cancer no additional benefit 2013 phase IIIntravenousCD51IpilimumabYervoy\
FDA 2011\
EU 2011Human monoclonal antibody IgG1κAntineoplastic agent\
Bladder carcinoma (trials ongoing)\
MelanomaIpilimumab\
MDX010\
MDX101\
BMS-734016Yervoy\
FDA 2011 melanoma\
Metastatic renal cancer/colorectal cancer 2018Human monoclonal antibody IgG1κAntineoplastic\
**Melanoma(checkmate 067)**\
**Renalcell carcinoma (checkmate 214)**\
**Colorectalcancer**\
Pancreatic?IntravenousCD152 cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and blocks interaction with its ligands CD80/CD86Iratumumab\
MDX060Human monoclonal antibody IgG1κAntineoplastic Hodgkin\'s lymphoma phase II completed\
Clinical research discontinued 2009IntravenousCD30 (tumor necrosis factor receptor superfamily,\
Member 8; TNFRSF8) aka Ki-1 AgIsatuximab\
SAR650984FDA review possible 2019Chimeric monoclonal antibody IgG1κAntineoplastic multiple myeloma\
Phase I 2019\
Phase II 2022\
Phase III 2025IntravenousCD 38Iscalimab\
CFZ533Human monoclonal antibody IgG1κDisease modifying\
Potential treat autoimmune disease\
Lupus nephritis phase II 2020\
Myasthenia gravis\
GVHD\
Kidney transplant 2022 phase II\
PreclinicalsIntravenousCD40Istiratumab\
MM-005\
MM-141Human monoclonal antibody IgG1Antineoplastic\
Advanced solid tumors\
Pancreatic cancer phase II 2018Insulin-like growth factor I receptor/neuregulin receptor HER3 (IGF1R, CD221)ItolizumabAlzumab\
FDAHumanized monoclonal antibody IgG1κDisease modifying\
Psoriasis\
GVHS phase II 2022CD6IxekizumabTaltzHumanized monoclonal antibodyDisease modifying\
Phase III radiographic axial spondyloarthritis\
Psoriatic arthritisSubcutaneousIL 17AKeliximab\
Became clenoliximab IgG4Chimeric monoclonal antibody IgG1λDisease modifying\
Chronic asthma\
Rheumatoid arthritisCD4Labetuzumab\
hMN14CEA-CideHumanized monoclonal antibody IgG1Antineoplastic\
Colorectal cancer\
Gastrointestinal phase II 2021imagin\
Phase II completed therapy 2003IntravenousCEALacnotuzumab\
MCS110Humanized monoclonal antibody IgG1κAntineoplastic\
Breast, pigmented villonodular synovitis (PVNS)\
Squam ESOP phase II 2024\
Gastric 2019CSF1, MCSFLadiratuzumab vedotinHumanized monoclonal antibody IgG1κ\
Antibody drug conjugateAntineoplastic\
Phase I triple-negative breast cancer 2017 ongoing studyLIV-1Lampalizumab\
RG7417Humanized monoclonal fragment IgG1κDisease modifying\
Geographic atrophy secondary to age-related macular degeneration phase III Jan 2018 ineffectiveIntravitreousComplement factor D (CFD)Lanadelumab\
SHP643\
DX-2930Takhzyro\
FDA 2018Human monoclonal antibody IgG1κDisease modifying\
Angioedema phase III 2019SubcutaneousKallikrein (KLKB1)Landogrozumab\
LY2495655Humanized monoclonal antibody IgG4κDisease modifying\
Muscle wasting disorders, i.e., after hip surgery phase II\
Pancreatic cancer phase II no benefit cancer, some muscle improvement but primary objective not metIntravenous\
SubcutaneousHuman growth differentiating factor 8 (GDF-8) aka myostatin (MSTN)Laprituximab emtansine\
IMGN289Chimeric monoclonal antibodyNo trials or PubMed or creative lab only in FDA registry ?newEGFRLarcaviximabZMAPPChimeric monoclonal antibody IgG1κDisease modifying\
Ebola virusNo studies clinical trial or PubMedEbolavirus glycoproteinLebrikizumab\
MILR1444A\
TNX-650\
RG-3637\
PRO301444Humanized monoclonal antibody IgG4κDisease modifying\
Asthma phase III\
Atopic dermatitis HL phase II 2007Subcutaneous injectionInterleukin-13 (IL-13)LemalesomabMurine monoclonal antibody IgG1κDiagnostic agentNCA-90 (granulocyte antigen)Lendalizumab\
Olendalizumab\
ALXN-1007Humanized monoclonal antibody IgGκDisease modifying\
Antiphospholipid syndrome\
GI GVHDIntravenousAnticomplement 5ALenvervimabHumanized IgG1κDisease modifying\
Hepatitis BNo studies in clinical trials or PubMedHepatitis B surface antigenLenzilumab\
KB-003Human monoclonal antibodyAntineoplastic chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia phase IIntravenousGRANULOCYTEMACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF)Lerdelimumab\
CAT-152TrabioHuman monoclonal antibody IgG4Disease modifying\
Phase I studies\
?Cancer and fibrosis\
Trials stopped for fibrosis after glaucoma surgeryTransforming growth factor β 2Leronlimab\
PRO-140FDA review 2018Humanized IgG4κDisease modifying\
HIV phase III ongoing no results published good results phase IISubcutaneousChemokine receptor 5 (CCR5)Lesofavumab\
RG70026Human monoclonal antibody IgG1κDisease modifying\
Influenza ANo studies clinical trials or PubMedHemagglutinin HALetolizumabHumanized synthetic light chain variable region (scFv)Disease modifying inflammatory diseasesNo studies clinical trials or PubMed or creative labsTRAPLexatumumab\
HGS1018\
HGS-ETR2Human monoclonal antibody IgG1λAntineoplastic\
Breast\
PancreaticIntravenousTumor necrosis factor receptor superfamily member 10B/death receptor 5 (TRAIL-R2)LibivirumabHumanized monoclonal antibody IgG1κAntiinfectious\
Prevent disease Hep BOral therapy\
Abstract of randomized study of 50 patientsHepatitis B surface antigenLifastuzumab vedotin\
DBNIB0600AHumanized monoclonal antibodyAntineoplastic\
Ovarian cancer\
Phase 2IntravenousPhosphate-sodium cotransporterLigelizumab\
QGE031Humanized monoclonal antibody IgG1κDisease modifying\
SSevere asthma and chronic spontaneous urticaria phase II and III ongoing trial 2021SubcutaneousImmunoglobulin E (IGHE)Lilotomab satetraxetanBetalutinMurine monoclonal antibody IgG1Antineoplastic\
NHL 2020/phase II 2025\
Diffuse lg B-cell lymphoma 2019CD37Lintuzumab\
SGN33Humanized monoclonal antibody IgG1κAntineoplastic\
AMLphase I/II 2022\
Mult myeloma phase I 2020\
Myelodysplastic phae II 2011IntravenousCD33Lirilumab\
IPH2102Human monoclonal antibody IgG4Antineoplastic\
Solid and hematological cancers\
No good aml, squam cell head neck no good, bladder cancer ongoing?\
May benefit MDSIntravenousKiller cell immunoglobulin like (KIR2D)\
Block the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligandsLodelcizumab\
LFU720Humanized monoclonal antibody IgG1κDisease modifying\
HypercholesterolemiaUnknown studies in clinical trials and PubMedProprotein convertase subtilisin/kexin type 9 (PCSK9)LokivetmabCytopoint\
FDA approved for dogs onlyCanis monoclonal antibody IgG2κDisease modifying\
Veterinary\
Clinical signs of atopic dermatitis in dogs*Canis lupus* familiaris IL31Loncastuximab tesirine\
ADCT-402Chimeric monoclonal antibody IgG1κAntineoplastic\
Diffuse large B-cell lymphoma phase II 2020IntravenousCD19Lorvotuzumab mertansine\
BB-10901\
IMGN901Humanized monoclonal antibody IgG1κAntineoplastic\
SCLC\
Ovarian\
AML phase II\
Wilm, rhabdomyosarcoma, Neuroblast, MPNST, Synovial sarcoma 2018 phase IIIntravenousCD56Losatuxizumab vedotin\
ABBV-221Chimeric/humanized monoclonal antibody IgG1AntineoplasticEpidermal growth factor (EGRF, ERBB1 HER1)Lucatumumab\
HCD122Discontinued development by Novartis 2013Human monoclonal antibody IgG1κAntineoplastic\
Multiple myeloma, non-Hodgkin\'s lymphoma, Hodgkin\'s lymphomaIntravenousCD40Lulizumab pegolHumanized monoclonal antibodyDisease modifying\
SLE\
Phase I safe\
Phase II no responseIntravenous\
SubcutaneousCD28Lumretuzumab\
RG7116\
RO5479599Humanized monoclonal antibody IgG1κAntineoplasticIntravenousCD28; receptor for tyrosine-protein kinase(erbB-3, HER3)Lupartumab amadotin\
BAY-1129980Human monoclonal antibody IgGAntineoplastic\
Phase I terminated Why?IntravenousGPI- anchored cell surface-associated protein C4.4A (LYPD3)Lutikizumab\
ABT981Humanized monoclonal antibodyDisease modifying\
Osteoarthritis\
Phase IIa no effectSubcutaneousInterleukin 1 alpha/interleukin 1 betaMapatumumab\
HGS1012Human monoclonal antibody IgG4λAntineoplastic\
Hepatocellular no benefit\
Multiple myeloma\
Cervical cancer\
NSCLC no benefit\
NHL\
Bladder cancer may be beneficialTumor necrosis factor receptor superfamily member 10A; cytokine receptor DR4 (death receptor 4 tumor necrosis receptor apoptosis-induced ligand (TRAIL-R1)Margetuximab\
MGAH22Chimeric/Humanized monoclonal antibody IgG1κAntineoplastic\
Breast cancer\
Gastric cancer/GEC phase Ib/II trialIntravenouserbB2/HER2Marstacimab\
PF-06741086Human monoclonal antibody IgG1λDisease modifying\
Bleeding with hemophilia phase II 2020SubcutaneousTissue pathway factor inhibitor (TFPI)MaslimomabMurine monoclonal antibodyImmunosuppressive\
Unknown no studies and not listed in creative lab or FDAT-cell receptorMatuzumab\
EMD 72000Humanized monoclonal antibody IgG1κAntineoplastic\
Colorectal, lung and stomach cancer weakly beneficialIntravenousEpidermal growth factor receptor (EGFR)Mavrilimumab\
CAM3001Human monoclonal antibody IgG4λDisease modifying rheumatoid arthritis phase IIb goodSubcutaneousGMCSF receptor α-chainMEDI565\
MT111\
AMG211Fab IgG1 BiTEAntineoplastic\
Gastrointestinal adenocarcinoma phase I 2018IntravenousCD3 and CEAMepolizumab\
SB-240563Bosatria\
Nucala\
FDA 2015\
EU 2015Human monoclonal IgG1κDisease modifying\
No benefit in eosinophilic esophagitis\
Beneficial allergic **severe asthma**SubcutaneousInterleukin-5 (IL-5) antagonistMetelimumab\
CAT 192Humanized monoclonal antibody IgG4Disease modifying\
SclerodermaDropped from further developmentTGF β 1Milatuzumab\
HLL1\
IMMU-115Humanized monoclonal antibody IgG1κAntineoplastic\
Multiple myeloma\
Lupus\
LeukemiaIntravenousCD74Minretumomab\
MOAB CC49Murine monoclonal antibody IgG1Diagnostic\
Tumor detection/diagnostic/prognostic\
Failed phase I clinical trialsTumor-associated glycoprotein 72 (TAG-72)Mirikizumab\
LY3074828Humanized monoclonal antibodyDisease modifying\
Psoriasis phase III 2020\
UC phase III 2023\
LUCENT 1 2021 phase III\
LUCENT 2 2022IntravenousIL23A*Mirvetuximab* soravtansine\
M9346A\
IMGN853Chimeric monoclonal antibody IgG1Antineoplastic\
Ovarian phase III 2019\
Breast ca phase II 2020IntravenousFolate receptor alphaMitumomab\
BEC-2Murine monoclonal antibodyAntineoplastic\
SCLC phase III no benefit 2005GD3 gangliosideModotuximab\
1024 DS\
Zatuximab\
Futuximab\
SYM004Chimeric monoclonal antibody IgG1κAntineoplastic\
Antineoplastic\
Colorectal\
Phase 2019\
Phase III 2025SubcutaneousEGFR extracellular domain III/HER1Mogamulizumab\
AMG761\
KM8761Poteligeo\
FDA 2018Humanized monoclonal antibody IgG1κAntineoplastic\
Adult T-cell leukemia/lymphoma\
Solid tumors\
Many studies ongoingIntravenousCC chemokine receptor CCR4MOR202\
MOR03087Human monoclonal antibody IgG1Antineoplastic multiple myeloma phase I 2018IntravenousCD38Monalizumab\
NN8765\
IPH2201Humanized monoclonal antibody IgG4κDisease modifying\
Rheumatoid arthritis, antineoplastic gynecologic malignancies, and other cancers phase II 2021\
NSCLC phase II 2022\
s/p stem cell transplant phase I 2020\
CLL phase II 2019IntravenousKiller cell lectin-like receptor subfamily C member1 (NKG2A, CD159A, CD94) that recognize nonclassical HLA (i.e., HLA-E)MorolimumabHuman monoclonal antibody IgG1?DiagnosticNo studies in pub med, creative lab or FDA substanceRhesus factorMosunetuzumab\
RG7828\
BTCT4465AHumanized monoclonal antibody IgG1κ bispecificAntineoplastic\
NHL phase II 2023\
DLBCL phase II 2023Intravenous\
SubcutaneousCD3E, MS4A1, CD20Motavizumab\
MEDI-524Numax\
FDA not approved 2010\
Older drug just as effective with less side effectsHumanized monoclonal antibody IgG1κDisease modifying\
Respiratory syncytial virus phase III completed\
Safety concerns hives and allergic reactionsIntramuscularRespiratory syncytial virus glycoprotein FMoxetumomab pasudotoxLumoxiti\
FDA 2018Recombinant immunotoxin comprised of a variable fragment (Fv) of a Murine IgG4 anti-CD22 monoclonal antibody genetically\
Fused to a truncated fragment of Pseudomonas exotoxin AAntineoplastic\
Hairy cell leukemia\
Phase I ALL pedsIntravenousCD22Muromonab-CD3\
Muromab\
Aka teplizimab/MGA031Orthoclone OKT3\
FDA 1986\
EU 1986 (country specific approval)Humanized monoclonal antibody IgG2aκDisease modifying\
Prevention of kidney transplant rejection\
Many trials GVHD, NASH and T2DM, giant cell myocarditis AbATEIntravenous\
OralCD3Nacolomab tafenatoxMurine monoclonal fragment FabAntineoplastic\
?Colorectal cancerNo studies in clinical trial or PubMedC242 antigenNamilumab\
MT203Human monoclonal antibody IgG1κDisease modifying\
Ank spond psoriasis, RA phase IISubcutaneousColony-stimulating factor 2 (CSF2)Naptumomab estafenatox\
TTS-CD3\
ANYARA\
ABR-217620Murine monoclanl antibody fragment FabAntineoplastic\
Nonsmall cell lung carcinoma, renal cell carcinoma phase III completed primary endpoint not achievedIntravenousTumor-associated antigen 5T4Naratuximab emtansine\
IMGN529Chimeric monoclonal antibody IgG1κAntineoplastic\
B-Cell lymphoma\
NHLIntravenousTetraspanin-26 (CD37)Narnatumab\
IMC-RON-8\
Ron8Human monoclonal antibody IgG1κAntineoplastic\
Solid tumors phase IIntravenousHuman cell surface receptor RON (CD 135) macrophage-stimulating 1 receptorNatalizumab\
Antegran\
AntegrenTysabri\
FDA 2004\
EU 2006Humanized monoclonal antibody IgG4κDisease modifying\
**Relapsingmultiple sclerosis, Crohn\'s disease**IntravenousL selectin (CD62L)\
α4-subunit of α4β1 and α4β7 integrins of leukocytes (except neutrophils) (VLA-4)Navicixizumab\
OMP 305B83Humanized/chimeric monoclonal antibody IgG2κAntineoplastic\
Phase I study colorectal\
gyn tumorsIntravenousDelta-like 4 (DLL4)\
Vascular endothelial growth factor A (VEGF-A)Navivumab\
CT-P27Human monoclonal antibody IgG1κDisease modifying\
Influenza ANo studies PubMedInfluenza A virus hemagglutinin HANaxitamab\
HU3F8Humanized monoclonal antibody IgG3Antineoplastic\
High-risk neuroblastoma and refractory osteomedullary disease study 2023?Intravenousc-Met\
Ganglioside anti-GD2NebacumabHumanized monoclonal antibody IgMWithdrawn for safety,\
Efficacy and commercial reasonsEndotoxinNecitumumab\
IMC-11F8Portrazza\
FDA 2015\
EU 2016Human monoclonal antibody IgG1κAntineoplastic\
Nonsmall cell lung carcinomaIntravenousEGFRNemolizumab\
CIM331\
CD14152Humanized monoclonal antibody IgG2κDisease modifying\
Eczema phase I and IISubcutaneousInterleukin-31 receptor A (IL31RA)NEOD001\
Birtamimab\
ELT1-01\
HU2A4Humanized monoclonal antibody IgG1κDisease modifying\
Primary systemic amyloidosis lack clinical benefitIntravenousAmyloid A protein/amyloid light chainNesvacumab\
REGN910\
SAR307746Human monoclonal antibody IgG1κAntineoplastic\
Solid tumors not as beneficial as other agents in breast cancer\
Disease modifying\
Macular degenerationIntravenousAngiopoietin 2NetakimabChimeric monoclonal antibodyDisease modifying\
Psoriasis\
PLANETA study (Russia, future EU and China)Interleukin 17ANimotuzumabTheracim\
TheralocHumanized monoclonal antibodyIgG1κAntineoplastic\
Squamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, gliomaIntravenousEGFRNirsevimab\
MEDI8897Human monoclonal antibody IgG1κDisease modifying\
Respiratory syncytial virus phase II 2018IntramuscularRespiratory syncytial virus fusion protein (RSVFR)NivolumabOpdivo\
FDA 2015\
EU 2015Human monoclonal antibody IgG4κ immunoglobulinAntineoplastic agent\
Programmed death receptor-1 (PD-1) blocking antibody\
**NSCLC,** bladder cancer, **renal cell cancer** phase III 2021\
**Hodgkinlymphoma**\
**Melanoma**\
**Smallcell lung cancer**\
**Squamouscarcinoma head and neck**\
**Colorectalcancer**\
GBM no added benefit 2017IntravenousBlocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2Nofetumomab merpentanVerluma\
FDA 1996\
No longer marketed in USAMurine monoclonal fragment IgG2bκ FabCancer diagnostic imaging\
SCLCAntitumor\
Membrane-spanning 4-domains, subfamily A, member 1Obiltoxaximab\
ETI-204Anthim\
FDA 2016Chimeric monoclonal antibody IgG1κDisease modifying\
Bacillus anthracis anthrax phase IV 2021Intravenous\
Intramuscular*Bacillus anthracis* spores\
PA component of *B. anthracis* toxinObinutuzumab\
GA101HUMAB\
RG7159\
RO5072759\
AfutuzumabGazyvaro\
FDA 2013Humanized monoclonal antibody IgG1κAntineoplastic lymphoma phase II (MCL, DLBCL)\
**Chroniclymphocytic leukemia**\
Phase II 2021IntravenousCD20\
Induces B-cell apoptosisOcaratuzumab\
LY2469298\
AME-133VHumanized monoclonal antibody IgG1κAntineoplastic\
NHL\
Pemphigus phase IIIIntravenousCD20OcrelizumabOcrevus\
FDA 2017Humanized monoclonal antibody IgG1κDisease modifying\
Multiple sclerosisIntravenousCD20OdulimomabMurine monoclonal antibodyDisease modifying\
Transplant rejection\
Only studied in miceLymphocyte function-associated antigen-1 (LFA-1 (CD11a))OfatumumabArzerra\
FDA 2009\
EU 2010Human monoclonal antibody IgG1κ\
Complement-dependent cytotoxicity (CDC)Antineoplastic **CLL**\
Phase III 10% ORR after ritux\
Phase II as first line 86% ORR\
With CHOP 100% ORR with 62% CRIntravenousCD20Olaratumab\
IMC3G3Lartruvo\
FDA 2016\
EU 2016Human monoclonal antibody IgG1κAntineoplastic\
**Sarcoma** phase II 2023\
Ovarian not beneficialIntravenousPlatelet derived growth factor receptor alpha (PDGF-R α)Oleclumab\
MEDI9447Human monoclonal antibody IgG1λAntineoplastic pancreatic phase II 2021\
Colorectal cancer\
Bladder cancer phase I 2020\
Breast cancer phase II 2022\
NSCLC phase II 2022Intravenous?5′-nucleotidase\
CD73OlokizumabHumanized monoclonal antibody IgG4κDisease modifying rheumatoid arthritis\
Phase I 2014 phase IIb mod resultsIL6Omalizumab\
IGE25\
RG3648XolairHumanized monoclonal antibody IgG1κDisease modifying allergic asthma\
UrticariaSubcutaneousIgE Fc region*Omburtamab*Murine monoclonal antibody IgG1κAntineoplastic\
Neuroblastoma\
Phase III 2022Intracerebroventricular treatmentCD276OMS721Human monoclonal antibodyDisease modifying\
Atypical hemolytic uremic syndrome phase III 2020\
Lupus nephritis phase II 2018IntravenousMannan-binding lectin-associated serine protease-2 (MASP-2)Onartuzumab\
PRO143966\
RO5490258\
METMABHumanized monoclonal antibody IgGAntineoplasticIntravenousHuman scatter factor receptor kinaseOntuxizumab\
MORAB-004Chimeric/humanized monoclonal antibodyAntineoplastic\
No clinical responseIntravenousEndosialin tumor endothelial marker-1 (TEM1)OnvatilimabHuman monoclonal antibody IgG1κNothing in PubMedVista (V-domain immunoglobulin suppression of T activation (VSIR)Opicinumab\
BIIB033Human monoclonal antibody IgG1Disease modifying multiple sclerosis\
Phase II 2020Leucine-rich repeat and immunoglobulin domain containing neurite outgrowth inhibitor receptor interacting protein-1 (LINGO-1) LINGO-1Oportuzumab monatox\
VB4-845Vicinium\
Proxinium\
FDA 2005\
EU 2005\
Additional approval pending 2019Humanized monoclonal antibody fragment\
scFvAntineoplastic\
Bladder phase III\
**Headand neck cancer**IntravescicalEpithelial cell adhesion molecule (EPCAM) and tumor-associated calcium signal transducer 1 (TACSTD1) and pseudomonas exotoxin A immunotoxin fusion protein (anti-EPCAM antibody fragment-Pseudomonas exotoxin fusion protein)Oregovomab\
MAB-B43.13OvaRexMurine monoclonal antibody IgG1κ\
Antiidiopathic antibody to ovarian antigen CA-125Antineoplastic\
Ovarian cancer\
Not effective in achieving increase RFS or OS\
Ovarian phase I 2021\
Phase II 2019Subcutaneous\
IntravenousCA-125Orticumab\
RG7418Human monoclonal antibody fragment FabDisease modifying\
AntiinflammatoryOxidized low-density lipoprotein oxLDLOtelixizumabChimeric humanized monoclonal antibody IgG1Disease modifying\
Diabetes mellitus type 1\
TTEDD phase II\
DEFEND-1 phase III failed\
DEFEND-2 phase III- no real benefitSubcutaneousCD3Otilimab\
MOR103\
GSK3196165Human monoclonal antibody IgG1λDisease modifying\
Osteoarthritis, rheumatoid arthritis phase II 2012\
Multiple sclerosis phase II 2014IntravenousGranulocyte-macrophage colony-stimulating factor (GMCSF)Otlertuzumab\
TRU-016Humanized monoclonal antibody IgG fragmentAntineoplastic\
CLL phase I and II 2014 and 2019IntravenousCD37Oxelumab\
OX40L\
R4930\
HUMAB OX40LHuman monoclonal antibody IgG1κDisease modifying\
Asthma mainly preclinical mice\
Many clinical studies ongoing leukemia and asthmaIntravenousOX-40 (CD252)Ozanezumab\
GSK1223249Humanized IgG1Disease modifying\
ALS phase II 2015 ALS no goodIntravenousNeurite outgrowth inhibitor (NOGO-A)Ozoralizumab\
ATN 103Humanized monoclonal antibodyDisease modifying\
Rheumatoid arthritis phase II 2012SubcutaneousTNF-αPagibaximabChimeric monoclonal antibodyDisease modifying\
Staph sepsis low birth weight infants\
Phase II/III studies 2010IntravenousLipoteichoic acidPalivizumabSynagis, Abbosynagis\
FDA 1998\
EU 1999Humanized monoclonal antibody IgG1κDisease modifying\
RSV many phase III studiesIntramuscularF protein of respiratory syncytial virusPamrevlumab\
FG-3019Human monoclonal antibody IgG1κDisease modifying\
Idiopathic pulmonary fibrosis (IPF),\
Antineoplastic\
Pancreatic cancer\
Muscular dystrophy phase II 2021\
Diabetes nephropathyConnective tissue growth factor (CTGF)\
Insulin-like growth factor binding protein 8 (IGFBP-8)Panitumumab\
ABENIX\
ABX-EGF[https://en.wikipedia.org/wiki/List_of_therapeutic_monoclonal_antibodies - cite_note-WHOList91-38](https://en.wikipedia.org/wiki/List_of_therapeutic_monoclonal_antibodies){#interref7}Vectibix\
FDA 2006\
EU 2007Human monoclonal antibody IgG2κAntineoplastic\
**Metastaticcolorectal cancer**IntravenousEGFR/erbB-1/HER1PankoMab-GEX\
GatipotuzumabHumanized monoclonal antibody IgG1κAntineoplastic\
Phase IIb 2017\
Phase I solid tumors 2019IntravenousTumor-specific glycosylation of MUC1Panobacumab\
Aerumab 11\
AR-101\
KBPA-101Human monoclonal antibodyAntimicrobial\
*Pseudomonas aeruginosa* infectionIntravenous*Pseudomonas aeruginosa* serotype O11Parsatuzumab\
MEGF0444A\
RG-7414Human monoclonal antibody IgG1κAntineoplastic\
Colorectal cancer phase II 2014 no benefitEpidermal growth factor-like domain 7 (EGFL7)PascolizumabHumanized monoclonal antibodyDisease modifying\
Not effective trails abortedIL-4PasotuxizumabChimeric/humanized monoclonal antibody fragmentAntineoplasticNo studiesFolate hydrolase/prostate-specific membrane antigen (PSMA)Pateclizumab\
RG7415\
PRO283698\
MLTA3698AHumanized monoclonal antibody IgG1κDisease modifying rheumatoid arthritis\
Phase II not as efficacious as adalimumab but had responseSubcutaneousLymphotoxin-αPatritumab\
AMG888\
U3-1287Human monoclonal antibody IgG1κAntineoplastic\
May not be beneficial head/neck NSCLC CT siteErbB3 (HER3)*Spartalizumab*\
*PDR001*FDA review possible 2019Humanized monoclonal antibodyAntineoplastic\
Breast cancer phase II 2021\
NSCLC 2021\
Melanoma phase II 2022\
Phase III 2020IntravenousPD1, PDCD1, CD279Pembrolizumab\
MK-3475Keytruda\
FDA 2014\
EU 2015\
FDA 2018 for metastatic Merkel cell carcinoma, HCC, NSCLCHumanized monoclonal antibody IgG4κAntineoplastic\
Squamous carcinoma trachea, **NSCLC**, urothelial (HCC phase II)\
Melanoma\
cHL, LgB cell lymph\
Gastric cancer\
**Cervicalcancer**\
Hepatocellular **carcinoma**Intravenous\
Trials for multiple myeloma discontinued by FDAPD-1Pemtumomab\
HMFG1 antibody labeled with 90YttriumTheragynMurine monoclonal antibodyAntineoplastic\
Phase III Europe 2009/US 2013 no benefit after 3.5 years follow-upMUC1/human milk fat globule antigen 1 (HMFG1)PerakizumabHumanized monoclonal antibody IgG1κDisease modifying psoriatic arthritis\
Phase I discontinuedIL 17APertuzumabPerjeta\
FDA2012\
EU 2013\
OmnitargHumanized monoclonal antibody IgG1Antineoplastic agent\
HER2-positive metastatic **breast cancer**\
Gastric/breast cancer\
Phase III gastricIntravenousExtracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2/neu)PexelizumabHumanized scFvDisease modifying acute myocardial infarctionsAPEX-AMI trial negative results\
PRIMO-CABG I and II trials no significant benefitC5Pidilizumab\
CT-011Humanized monoclonal antibody IgG1κAntineoplastic\
Mult myeloma\
DLBCL\
Pontine glioma\
Pancreas\
Melenaoma\
HCC\
AntiinfectionIntravenousPD-1Pinatuzumab vedotinHumanized monoclonal antibody\
ADC consisting of the microtubule-disrupting agent, monomethyl auristatin E (MMAE), conjugated to an anti-CD22 mAbvia the protease-cleavable peptide linker maleimidocaproylvaline-citrulline(vc)-p-aminobenzoyloxycarbonylAntineoplastic B-cell NHL phase I study good response\
Phase II completion 2019IntravenousCD22PintumomabMurine monoclonal antibodyNot therapeutic\
Diagnostic imaging adenocarcinoma antigenAdenocarcinoma (imaging)PlaculumabHuman monoclonal antibody V-kappa)2 FCDisease modifying pain and inflammatory diseases\
Development discontinued 2012Human TNFPlozalizumab\
MLN1202\
HU1D9Withdrawn by companyHumanized monoclonal antibody IgG1κDisease modifying\
Diabetic nephropathy and arteriovenous graft patency\
RA no benefitIntravenousCC chemokine receptor 2 (CCR2)Pogalizumab\
MOXR0916\
R07021608\
VonlerolizumabHumanized monoclonal antibody IgG1κAntineoplastic\
Solid tumors phase I 2019 may be safe but may not be effective\
No formal manuscripts yetIntravenousTumor necrosis factor receptor superfamily member 4 (ACT35, OX40, CD134)Polatuzumab vedotin\
FCU2711\
RO5541077-000FDA review 2018Humanized monoclonal antibody IgG1κAntineoplastic\
NHL phase II 2019\
DLBCL phase III 2023IntravenousCD79BPonezumab\
RN1219\
PF-04360365Humanized monoclonal antibody IgG2Disease modifying Alzheimer\'s disease\
Safe but no clinical efficacy 2013IntravenousHuman beta-40-amyloid Aβ40Porgaviximab\
C2G4Chimeric monoclonal IgG1κAntiinfectious\
Ebola virus diseaseNo known ongoing studiesZaire ebolavirus glycoproteinPrasinezumab\
PRX002\
RG7935\
RO7046015Humanized monoclonal antibody IgG1κDisease modifying\
Parkinson\'s disease\
Phase II 2021IntravenousAnti-alpha-synuclein (NACP)Prezalizumab\
AMG-557\
MEDI5872Humanized monoclonal antibody IgG2Disease modifying\
SLE phase II 2018\
Sjogren\'sSubcutaneousB7-related protein inducible T-cell costimulator ligand (ICOSL)Priliximab\
cMT 412\
CEN 000029Chimeric monoclonal antibodyDisease modifying\
Crohn\'s disease, multiple sclerosisIN FDA no known studiesCD4PritoxaximabChimeric monoclonal antibody IgG1κAntiinfectious*E. coli* shiga toxin type-1PritumumabHuman monoclonal antibody IgG1κAntineoplastic\
Brain cancer\
Phase II studies in Japan, could not find literature reportedly increase survivability 10 foldVimentinQuilizumab\
MEMP1972A\
RG-7449\
Anti-M1Humanized monoclonal antibody IgG1κDisease modifying\
Asthma phase II 2014 no great benefit\
Urticaria phase II 2014 no great benefit\
Allergic rhinitisSubcutaneous\
IntravenousM1 prime segment of membrane bound IgE (IGHE)RacotumomabVaxiraMurine monoclonal antibody IgG1κAntineoplastic\
Nonsmall cell lung cancer phase III 2016 cimavax better (recombinant EGF injection) 2 more months survival over placebo\
Neuroblastoma phase II 2020Intradermal\
SubcutaneousN-glycolylneuraminic acid gangliosides (NGNA ganglioside)Radretumab\
F16SIP\
L19SIP radiolabeled with I[@bib331]Human monoclonal antibody\
Imaging study PETAntineoplastic\
Lymphoma brain mets 2012 phae I\
Stage III NSclCFibronectin extra domain-BRafivirumab\
CR57Human monoclonal antibody IgG1λ\
Used in cocktail and with vaccinationAntiinfectious\
Rabies (prophylaxis)No known studiesRabies virus glycoproteinRalpancizumab\
RN317\
PF-05335810Humanized monoclonal antibody IgG2κDisease modifying\
Dyslipidemia phase I 2017PCSK9 (proprotein convertase subtilisin/kexin type 9, neural apoptosis-regulated convertase 1, NARC1, NARC-1, proprotein convertase 9, PC9)Ramucirumab\
LY3009806\
IMC-1121BCyramza\
FDA 2014\
EU 2014Human monoclonal antibody IgG1κAntineoplastic\
Urothelial phase III done\
**Adenocarcinomastomach** and GE junction phase II 2023\
Colorectal cancer\
NSCLC\
HCC phase III 2017 no additional benefitIntravenousVEGFR2Ranevetmab\
NV-01Veterinary monoclonal antibody IgG1κ canineDisease modifying\
Osteoarthritis in dogsNerve growth factor-β (NGF-β)Ranibizumab\
RBZ\
RG-3645\
RHuFAbLucentis\
FDA 2006\
EU 2007Humanized monoclonal fragment IgG1κ FabDisease modifying\
**Maculardegeneration** (wet form) post market studies phase IIIntravitrealVascular endothelial growth factor A (VEGF-A)Ravagalimab\
PR-1629977\
ABBV-323Humanized monoclonal antibody IgG1κDisease modifying UC phase II 2023Intravenous\
SubcutaneousCD40Ravulizumab\
ALXN1210Ultomiris\
FDA 2019\
EU pendingHumanized monoclonal antibody IgG2/IgG4κDisease modifying\
Paroxysmal nocturnal hemoglobinuria (PNH)\
Phase III 2021 similar to eculizumab, atypical hemolytic uremic syndrome phase III 2021IntravenousComplement C5 (C5)RaxibacumabABthrax\
FDA 2012Human monoclonal antibody IgG1λAntiinfectious\
Treat inhalation anthraxIntravenous*Bacillus anthracis* protective antigenRefanezumab\
GSK249320Humanized monoclonal antibody IgG1κDisease modifying recovery of motor function after stroke\
Phase II completed 2011 no benefitIntravenousMyelin-associated glycoproteinRegavirumab\
MCA C23\
TI-23Human monoclonal antibodyAntiinfectious\
Cytomegalovirus glycoprotein B\
ONLY STUDIES IN RATS 1994Cytomegalovirus infectionRelatlimab\
BMS-986016Human monoclonal antibody IgG4κAntineoplastic\
Melanoma phase II 2022\
Colon cancer phase II 2022\
Chordoma phase II 2020\
Cannot find manuscripts but company website phase II good results\
Glioblastoma phase I 2020IntravenousLymphocyte activation gene 3 (LAG3) CD223Remtolumab\
ABT-122Human monoclonal antibodyDisease modifying\
RA\
Phase II 2016 no increased benefit over adalimumabSubcutaneousInterleukin 17 alpha, TNF-αReslizumab\
DCP 835\
Scheme 55700\
CEP-38072Cinqair\
FDA 2016\
EU 2016Humanized monoclonal antibody IgG4κDisease modifying\
Inflammations of the airways asthma completed and ongoing, skin and gastrointestinal tract, polyarteritis stage II 2018\
Rhino sinusitis 2020Intravenous\
SubcutaneousIL-5Rilotumumab\
AMG-102Human monoclonal antibody IgG2κAntineoplastic\
Gastric completed phase III 2015 not effective\
NSCLC phase II 2014 no benefit\
Glioma phase II no responseIntravenousHepatocyte growth factor (HGF)Rinucumab\
REGN2176Human monoclonal antibody IgG4κDisease modifying neovascular age-related macular degeneration phase II 2014IntravitrealPlatelet-derived growth factor receptor betaRisankizumab\
ABBV-066\
BI-655066FDA/EU pending approvalHumanized monoclonal antibody IgG1κDisease modifying Crohn\'s disease phase II good, phase III ongoing\
psoriasis phase II response better than ustekinumab, psoriatic arthritis, and asthmaSubcutaneousIL23ARituximab\
GP2013\
IDEC-102\
RG-105MabThera, Rituxan\
FDA 1997\
EU 1998Chimeric monoclonal antibody IgG1κAntineoplastic\
Non-Hodgkin lymphomas, chronic lymphocytic leukemias, some autoimmune disorders, i.e., rheumatoid arthritis, \>2K studies ongoingSubcutaneousCD20Rivabazumab pegolHumanized monoclonal antibody fragment Fab' IgG1κAntiinfectiousNo studies found*Pseudomonas aeruginosa* type III secretion systemRmabRabishield\
Made in IndiaHuman monoclonal antibodyAntiinfectious\
Postexposure prophylaxis of rabiesRabies virus G glycoproteinRobatumumab\
19D12\
SCH 717454\
MK-7454\
P04722Human monoclonal antibody IgG1κAntineoplastic\
Colorectal phase II 2009 little benefit\
Ewings no response 2016IntravenousInsulin-like growth factor I (IGF-1 receptor) (CD221)RoledumabHuman monoclonal antibody IgG1κImmunomodulation\
Rh disease\
Phase III 2017IntravenousRHDRomilkimab\
SAR156597\
HUBTI3_2\_1Humanized chimeric monoclonal antibody IgG4 bispecificDisease modifying\
Systemic sclerosis phase II 2019\
Pulm fibrosis phase II 2017 no benefitSubcutaneousInterleukin 13 and IL4RomosozumabEvenity\
FDA pending\
EU pending\
Japan 2018Humanized monoclonal antibody IgG2κDisease modifying\
Postmenopausal osteoporosis phase III study FRAME\
Men phase III\
BRIDGE phase IIIIntravenousSclerostin/scleroscin SOSTRontalizumab\
rhuMAb IFNalphaHumanized monoclonal antibodyDisease modifying\
Systemic lupus erythematosus phase II 2013 end points not metSubcutaneousIFN-αRosmantuzumab\
OMP-131R10Humanized monoclonal antibody IgG1κAntineoplastic\
Colorectal cancer phase I 2018IntravenousRoot plate-specific spondin r-spondin-3\
WNT? (wingless/integrated)Rovalpituzumab tesirine\
SC0002\
SC16LD6.5\
ABBV-181Humanized monoclonal antibody IgG1κAntineoplastic\
Small cell lung cancer phase I 2018\
Phase II 2024IntravenousDelta-like ligand-3 (DLL3)Rovelizumab\
Hu23F2GLeukArrestHumanized monoclonal antibody IgG1κDisease modifying\
Hemorrhagic shock, MI stroke phase III goals not met 2000CD11, CD18Rozanolixizumab\
UCB7665Chimeric/humanized monoclonal antibody IgG4κThrombocytopenia ITP phase II 2019\
Myasthenia gravis phase II 2018Subcutaneous\
IntravenousNeonatal Fc receptor (FCGRT)RuplizumabAntovaHumanized monoclonal antibodyDisease modifying lupus and lupus nephritis not effective\
Life-threatening thromboembolismBioDrugs. 2004; 18(2):95--102.\
Costimulation blockade in the treatment of rheumatic diseasesCD154 (CD40L)Sacituzumab govitecan\
IMMU-132FDA/EU pending approvalHumanized monoclonal antibody IgG1κAntineoplastic agent\
Prostate cancer phase II 2021\
Urothelial phase II 2020\
Trip neg breast ca phase III 2020 NSCLC SCLC UCIntravenousTumor-associated calcium signal transducer 2 (TROP-2) inhibits topoisomerase ISamalizumab\
ALXN6000\
BAML-16-001-S1Humanized monoclonal antibody IgG2/G4κAntineoplastic\
CLL MM phase I 2010 (terminated by sponsor)\
AML phase II 2021IntravenousOX-2 membrane glycoprotein (CD200)Samrotamab vedotinChimeric/humanized monoclonal antibody IgG1κAntineoplasticNo studies foundLeucine-rich repeat-containing protein 15 (LRRC15)Sarilumab\
REGN88\
SAR153191Kevzara\
FDA?EU/Japan under review approved in CanadaHuman monoclonal antibody IgG1κDisease modifying rheumatoid arthritis phase III 2015/2020/2027(preg exposure), ankylosing spondylitis\
Juvenile idiopathic arthritis phase II 2022SubcutaneousIL6Satralizumab\
SA237\
SapelizumabFDA review possible 2019Humanized monoclonal antibody IgG2κDisease modifying\
Neuromyelitis optica phase III 2019/2020Subcutaneous?IL6 receptorSatumomab pendetideOncoScint CR103\
FDA 1992Murine monoclonal antibody IgGκ fragment Fab'Diagnostic imaging\
Detection colorectal and ovarian cancerIntravenousTumor-associated glycoprotein (TAG-72)Secukinumab\
AIN457Cosentyx\
FDA 2015\
EU 2015Human monoclonal antibody IgG1κDisease modifying\
Uveitis, rheumatoid arthritis psoriasis phase II 2019 over 100 other studies **arthritis; psoriatic psoriasis; spondylitis; ankylosing**SubcutaneousIL 17ASelicrelumab\
CP 870.893\
RG7876\
RO-7009789Human monoclonal antibody IgG2κAntineoplastic\
Solid tumors phase I 2020\
Pancreatic cancer phase II 2020\
Colon cancer phase II 2021\
Mesothelioma phase ib 2015Subcutaneous\
IntravenousTumor necrosis factor receptor superfamily member 5 (CD40)Seribantumab\
MM121\
SAR256212Human monoclonal antibody IgG2λAntineoplastic\
Breast phase II 2020\
Ovarian phase I 2014IntravenousReceptor tyrosine-protein kinase erbB-3 (HER3)SetoxaximabChimeric monoclonal antibody IgG1κAntiinfection\
*E. coli*No known studies or clinical use*E. coli* shiga toxin type-2Setrusumab\
BPS804\
MOR05813Human monoclonal antibody IgG2Disease modifying\
Osteogenesis imperfecta phase II 2020IntravenousSclerostin (SOST)Sevirumab\
MSL-109Antiinfectious\
CMV retinitis early termination trial secondary to safety\
Phase II 2003Cytomegalovirus infectionSHP647\
Ontamalimab\
PF-00547659Human monoclonalantibodyIgG2κDisease modifying\
Crohn\'s/UC phase III 2020--2025 × 7\
Phase II study 2007 better response in UC than in Crohn (?more time needed to evaluate clinical significanceSubcutaneousMucosal addressin cell adhesion molecule (MADCAM)Sibrotuzumab\
BIBH1\
F19Humanized monoclonal antibody IgG1κAntineoplastic\
Colorectal cancer phase II 2003 failed\
Lung cancer2001IntravenousFAPSifalimumab\
MDX-1103\
MEDI-545\
CP145Humanized monoclonal antibody IgG1κDisease modifying\
SLE phase II 2015 dermatomyositis, polymyositisIntravenous\
SubcutaneousIFN-αSiltuximab\
CLLB8\
CNTO-328Sylvant\
FDA 2014\
EU 2014Chimeric monoclonal antibody IgG1κAntineoplastic\
Multiple myeloma phase II 2019\
DM type I phase I 2017\
Schizophrenia adjunct 2020 phase II\
**MulticentricCastleman\'s disease (MCD) with HIV negative and HHV-8 negative**IntravenousIL-6Simtuzumab\
AB0024\
GS-6624Humanized monoclonal antibody IgG4κDisease modifying\
Hepatic fibrosis\
Phase II 2016 no benefit\
Pulm fibroses phase II 2017 no benefit\
Myelo fibr 2017 phase IISubcutaneous\
IntravenousLysyl oxidase homolog 2 (LOXL2)Siplizumab\
MEDI-507Humanized monoclonal antibody IgG1κAntineoplasticCD2\
T Or NK cellsSirtratumab vedotinHuman monoclonal antibodyAntineoplasticNothing in PubMed or clinical trialsSLITRK6SirukumabHuman monoclonal antibody IgG1κDisease modifying\
Rheumatoid arthritis\
Phase III done good resultsSubcutaneousIL-6Sofituzumab vedotinHumanized monoclonal antibodyAntineoplastic\
Ovarian pancreatic\
Phase I (2014)CA-125Solanezumab\
LY2062430Humanized monoclonal antibody IgG1Disease modifying Alzheimer\'s\
Phase III study discontinued no effect\
In preclinical trial for secondary prevention 2022\
Hereditary AD phase III 2021IntravenousBeta amyloidSolitomab\
MT110-011\
AMG110Murine monoclonal antibody bispecific T-cell engager (BiTE)Antineoplastic\
Gastrointestinal, lung, and other cancers\
Phase I 2015IntravenousEpithelial cell adhesion molecule (EpCAM) CD3Sonepcizumab\
LT1009iSONEPHumanized monoclonal antibodyDisease modifying\
Choroidal and retinal neovascularization phase II 2015 not so good\
Antineoplastic phase II renal cancer 2017 potentialIntravenous\
IntravitreousSphingosine-1-phosphate (S1P)StamulumabHumanized monoclonal antibodyDisease modifying muscular dystrophy\
Animal studies, minimal efficacy\
Phase I/II studies ongoing (no improvement)IntravenousMyostatinSulesomab\
IMMU-MN3LeukoScan\
EU 1997Murine monoclonal IgG1 fragment Fab′Diagnostic\
Osteomyelitis (imaging)NCA-90 (granulocyte antigen)Suptavumab\
REGN2222\
SAR438584Human monoclonal antibody IgG1κAntiinfectious\
Medically attended lower respiratory disease phase III 2017 not meet primary endpoint\
Another study no data yet at 30 mg/kg doseIntramuscularResp sync virus fusion protein (RSVFR)Sutimlimab\
BIVV009Chimeric/humanized monoclonal antibody IgG4κDisease modifying cold agglutinin disease phase III 2020IntravenousComplement C1s (C1s)Suvizumab\
KD-247Humanized monoclonal antibody IgG1κAntiinfectious\
HIV\
Phase I KD-247\
2007IntravenousHuman immunodeficiency virus glycoprotein 120 third variable loopSuvratoxumab\
MEDI4893Human monoclonal antibody IgG1κDisease modifying\
Nosocomial pneumonia phase II 2018Intravenous*Staphylococcus aureus* alpha toxinTabalumab\
LY2127399Human monoclonal lantibodyIgG4κAntineoplastic\
Rheum arthr phase III 2013 no signif response\
SLE phase III 2015 endpoints not met\
Mult myelo phase I 2014 may not treat but be prognosticSubcutaneousCytokine B-cell activating factor (BAFF)Tacatuzumab tetraxetan\
HAFP-31AFP-CideHumanized monoclonal antibody yttrium[@bib77]AntineoplasticNo studies in clinical trial or PubMedAlpha-fetoproteinTadocizumab\
C4G1\
YM337Humanized monoclonal antibody fragment IgG1κ Fab'Disease modifying\
Percutaneous coronary intervention phase I 1999\
?not further developedIntegrin αIIbβ3Talacotuzumab\
CSL362\
JNJ-56022473Humanized monoclonal antibody IgG1-2κAntineoplastic\
AML phase III 2018\
MDS phase II 2019\
SLE 2019 phase IIntravenousInterleukin 3 receptor subunit-α (IL3Rα, CD123)Talizumab\
C21/AL-90\
TNX-901Humanized monoclonal antibody IgG1κDisease modifying\
Peanut allergy\
Allergic reaction\
Phase II 2003 good results legal issues shelved the drugSubcutaneousIgETamtuvetmab\
AT-005TactressCanine monoclonal antibody IgG2λCD52Tanezumab\
RN624\
PF-4383119FDA review possible 2019Humanized monoclonal antibody IgG2Disease modifying\
Pain\
Osteoarthritis\
Back pain\
Metastatic cancer pain\
Phase II ∼2008Nerve growth factor (NGF)Tanibirumab\
Olinvacimab\
TTAC-0001Human monoclonal antibody IgG1Disease modifying\
Antineoplastic\
Phase I glioblastoma 2020\
Breast cancer phase I 2020\
AMD murine no human studies foundIntravenousVEFR-2Taplitumomab paptoxMurine monoclonal antibody IgG1κAntineoplasticNo studies pub med or clinical trialsCD19Tarextumab\
OMP-59R5Human monoclonal antibody IgG2Antineoplastic\
Phase II trial NSCLC no benefit 2017\
Pancreatic phase II 2017IntravenousNotch2/3, Notch receptorTavolimab\
MEDI0562Chimeric/humanized monoclonal antibody IgG1κAntineoplastic\
Head and neck phase I 2024\
Ovarian cancer phase II 2023Tumor necrosis factor receptor superfamily member 4 (TNFRS4) OX40L receptor (CD134)Technetium (99 mTc) acritumomabRabbit monoclonal IgGNot for use in humans- research purpose onlyCEATechnicium (99 mTc) FanolesomabNeutroSpec\
FDA2004Murine monoclonal IgM radiolabeledDisease modifying osteomyelitis\
Sales and marketing suspended (2005)\
**Diagnosticscans for acute appendicitis**IntravenousCD15Tefibazumab\
INH--H2002AurexisHumanized monoclonal antibody IgG1κAntiinfectious\
*Staphylococcus aureus* infection\
Phase II 2006IntravenousClumping factor ATelimomab aritox\
(TAB-885)Recombinant murine monoclonal antibody Fab with ricinAntineoplastic\
T Cell lymphoma/leukemiaNo studies in pub med or clinical trialsCD5Telisotuzumab vedotin\
ABT-700Humanized monoclonal antibody IgG1κAntineoplastic\
Phase I 2017\
SCLC phase II 2022\
NSCLC phase II 2021IntravenousHepatocyte growth factor receptor HGFRTenatumomabMurine monoclonal antibody IgG2bAntineoplastic\
Phase I 2017\
Phase II brain tumors 2010IntravenousP24821, tenascin CTeneliximabChimeric monoclonal antibody IgG1Not in clinical trials 2009CD40 (TNF receptor superfamily member 5)Teplizumab\
MGA031\
PRV-031\
hOKT3g1(Ala-Ala)Humanized monoclonal antibody IgG1κDisease modifying type I DM phase II completion AbATE trial 2019\
Psoriasis phase I and II completed 2010 study stopped secondary to injection reaction severe allergyIntravenous\
SubcutaneousCD3TepoditamabHuman monoclonal antibody IgG1κ bispecificAntineoplasticNo studies on PubMed or clinical trialsc-type dendritic cell-associated lectin 2 (CLEC-2A, MCLA-117) and CD3Teprotumumab\
RV001\
R-1507\
RO4858696\
HZN-001FDA review possible 2019Human monoclonal antibodyDisease modifying\
Thyroid eye disease phase II 2017\
Graves phase III 2020IntravenousInsulin-like growth factor receptor type I (IGF-1 receptor) (CD221)Tesidolumab\
LFG316\
NOV-4Human monoclonal antibodyPhase I 2017\
PNH phase II 2020\
AMD phase II 2015 not beneficialIntravenous\
IntravitreousC5Tetulomab tetraxetan LU-177BetalutinHumanized monoclonal antibodyAntineoplastic\
Animal studies 2013CD37Tezepelumab\
MEDI9929\
AMG-157Human monoclonal antibody IgG2λDisease modifying\
Asthma, atopic dermatitis\
Phase II 2017SubcutaneousThymic stromal lymphopoietin (TSLP)Theralizumab\
TGN1412\
TAB08Humanized monoclonal antibodyAntineoplastic\
Solid tumors phase I 2020\
Disease modifying\
Rheum arth, SLE phase IIIntravenousCD28\
History of cytokine storm at higher doses 2006Tibulizumab\
LY3090106Humanized monoclonal antibody bispecific tetravalentDisease modifying\
Autoimmune disorder\
Phase I 2020Subcutaneous\
Intravenous\
No manuscripts found specific to this antibodyHuman B-cell activating factor of the tumor necrosis factor family interleukin 17 (BAFF)Tigatuzumab\
CS-1008\
TRA-8Humanized monoclonal antibody IgG1κAntineoplastic\
Colon phase II 2011no added benefit\
Colon phase I 2013\
NSCLC phase II 2011 no benefit\
Pancreatic phase II 2008 benefit\
TN breast canc 2015 phase II no added benefitCytokine receptor DR5 (death receptor 5) TRAIL-R2Tildrakizumab\
MK-3222\
SCH-900222Ilumya\
Ilumetri\
FDA 2018Humanized monoclonal antibody IgG1κImmunologically mediated inflammatory disorders\
Mod/severe psoriasis phase III 2018-20SubcutaneousIL23TimigutuzumabHumanized monoclonal antibody IgG1κAntineoplasticNo studies in clinical trial or PubMederbB2/HER2Timolumab\
BTT-1023Human monoclonal antibodyDisease modifying\
Scler cholang phase II 2019IntravenousAOC3Tiragotumab\
MTIG-7192A\
RG6058\
RO7092284Human monoclonal antibody IgG1κAntineoplastic\
Phase I 2020\
NSCLC phase II 2021\
HL phase II 2019Intravenous\
Nothing published yetT-cell IG and immune-receptor tyrosine-based inhibitory motif (TIGIT)TislelizumabChina pending approvalHumanized monoclonal antibodyAntineoplastic\
NSCLC phase III 2020\
Gastric phase III 2022\
Esophageal cancer phase III 2021\
NHL phase II 2020Intravenous\
Nothing published yet 2019PCDC1, CD279Tisotumab vedotinHuman monoclonal antibody IgG1κAntineoplastic\
Ovary cancer\
Cervix cancer\
Endometrium cancer\
Bladder cancer\
Prostate cancer\
Esophagus cancer\
Lung cancer, NSCLC\
Squamous cell carcinoma of the head and neck\
Pancreatic phase II 2022/3IntravenousCoagulation factor IIITocilizumab\
MRA\
R-1569\
RG-1569\
RHPM-1\
RO-4877533\
AtlizumabActemra, RoActemra\
FDA 2010\
EU 2009Humanized monoclonal antibody IgG1κDisease modifying **rheumatoid arthritis**\
\>100 studies\
Behcet syndromeIntravenous\
SubcutaneousIL-6 receptorTomuzotuximabfibriHumanized monoclonal antibody IgG1κAntineoplastic\
Phase I 2019EGFR, HER1Toralizumab\
E−6040\
IDEC-131Humanized monoclonal antibody IgG1κDisease modifying rheumatoid arthritis, lupus nephritis etc.\
Phase II trials failed with TECD154 (CD40L)TosatoxumabHuman monoclonal antibody IgG1λAntiinfectiousNo studies PubMed or Clin trials*Staphylococcus aureus* α-hemolysinTositumomab\
and iodine 131 TositumomabBexxar\
FDA 2003Murine monoclonal antibody IgG2aλAntineoplastic\
Follicular lymphoma (**NHL**)\
\>100 studiesIntravenousCD20Tovetumab\
MEDI-575Human monoclonal antibody IgG2κAntineoplastic\
Phase I/II 2012\
Glioblastoma limited clin activityIntravenousPlatelet-derived growth factor receptor α (CD140a)Tralokinumab\
CAT-354Human monoclonal antibody IgG4Disease modifying asthma phase IIb +/−, atopic dermatitis phase II 2016Intravenous\
SubcutaneousIL-13Trastuzumab\
4D5v8\
R-597\
SYD977Herceptin\
FDA 1998\
EU 2000\
Herceptin Hylecta FDA 2019 --trastuzumab/hyaluronidase\
Herzuma 2018Humanized monoclonal antibody IgG1κAntineoplastic\
**Breastcancer**\
**Gastricand gastro-esophageal junction cancer** HER2-positive phase IIISubcutaneous\
IntravenousHER2/neu*Trastuzumab* Deruxtecan DS-8201Hercion\
FDA breakthrough therapyAntibody drug conjugate humanized antibody IgG1κ with topoisomerase I inhibitor (DXd)Antineoplastic breast cancer phase I study breast, gastric, colorectal, salivary, and nonsmall cell lung cancer participated in part 2 2020\
phase II DESTINY-Breast01HER2Trastuzumab emtansine\
RG-3502\
PRO132365Kadcyla\
FDA2013\
EU 2013Humanized monoclonal antibody IgG1κ as ADCAntineoplastic\
**Breastcancer**IntravenousHER2/neuTRBS07Ektomab3functAntineoplastic\
MelanomaGD2 gangliosideTribbles-related protein (TRB) family members are the mammalian orthologs of Drosophila tribbles. Tribbles was originally identified as a cell cycle regulator during Drosophila development. Tribbles genes are evolutionary conserved, and three TRB genes (TRB1, TRB2 and TRB3) have been identified in mammals. TRBs are considered pseudokinases because they lack an ATP binding site or one of the conserved catalytic motifs essential for kinase activity. Instead, TRBs play important roles in various cellular processes as scaffolds or adaptors to promote the degradation of target proteins and to regulate several key signaling pathways. Recent research has focused on the role of TRBs in tumorigenesis and neoplastic progression. In this review, we focus on the physiological roles of TRB family members in tumorigenesis through the regulation of the ubiquitin-proteasome system and discuss TRBs as biomarkers or potential therapeutic targets in cancerTregalizumab\
BT-061Humanized monoclonal antibody IgG1κDisease modifying\
Rheumatoid arthritis\
Phase IIb no benefitSubcutaneousCD4*Tremelimumab*\
*(aka ticilimumab)*∗CP-675,206Human monoclonal antibody IgG2Antineoplastic agent\
NSCLC, small cell lung cancer, urethelial cancer phase II 2020, head and neck cancer and colon phase I 2021\
Mesothelial phase IIb DETERMINE not beneficial\
\>100 studiesCTLA4 (cytotoxic T lymphocyte-associated antigen 4, CD152Trevogrumab\
REGN1033\
SAR391786Human monoclonal antibody IgG4κDisease modifying\
Muscle atrophy due to orthopedic disuse and sarcopenia phase II 2020Myostatin, growth differentiation factor 8 (GDF8)TRL3d3\
3D3IgGStudies only in mice to this pointAti-G protein antibody (RSVGV)Tucotuzumab celmoleukin\
EMD-273066\
HUKS-IL2Humanized monoclonal antibody IgG1Antineoplastic\
Ovarian phase II 2008\
Lung, kidney, bladder phase I 2000 no benefitIntravenousInterleukin2 (EpCAM)TuvirumabHumanized monoclonal antibodyAntiinfectious\
Not effective in achieving primary efficacy as assessed by neutralization of circulating HBsAgIntravenousHepatitis B virus surface antigenUblituximab\
TG-1101FDA review pending 2019Chimeric monoclonal antibodyIgG1κAntineoplastic\
Chronic lymphocytic leukemia, follicular cell lymphoma phase II 2020\
Disease modifying\
Multiple sclerosis phase II 2019, phase III 2021\
Awaiting result looks good prelimIntravenousCD20 MS4A1UlocuplumabHuman monoclonal antibody IgG4Antineoplastic CLL phase I 2014\
Phase I/II Waldenstrom macroglobulinemia 2025\
Phase I/II AML 2021IntravenousCXCR4 (CD184)Urelumab\
BMS-663513Human monoclonal antibody IgG4κAntineoplastic\
CLL phase II 2020\
Solid tumors phase II 2023IntravenousHuman receptor 4-1BB (CD137)Urtoxazumab\
TMA-15Humanized monoclonal antibody IgG1κDisease modifying EHEC animal studies*Escherichia coli* (EHEC) shiga toxin 2UstekinumabStelara\
FDA 2009\
EU 2009Human monoclonal antibody IgG1κDisease modifying\
Crohn disease\
**Plaque psoriasis**\
Psoriatic arthritisSubcutaneous\
Intravenousp40 subunit of interleukin 12 (IL-12p40), IL-23Utomilumab\
PF-05082566Human monoclonal antibody IgG2Antineoplastic\
Diffuse large B-cell lymphoma\
Phase I 2021 phase II 2020\
Breast phase II 2025Intravenous4-1BB (CD137)Vadastuximab talirine\
H2H12ECChimeric monoclonal antibody IgG1κAntineoplastic\
Acute myeloid leukemia phase II 2017 phase III 2017\
MDS phase II 2017IntravenousCD33Vanalimab\
MitazalimabHumanized monoclonal antibody IgG1λAntineoplastic?No studies clinical trial or PubMedImmune checkpoint receptor, tumor necrosis receptor family CD40, (TNFRSF5)Vandortuzumab vedotinHumanized monoclonal antibodyAntineoplastic\
Prostate cancerSTEAP1Vantictumab\
OMP-18R5Human monoclonal antibody IgG2mabAntineoplastic\
NSCLC, breast phase I 2017IntravenousFrizzled receptorVanucizumab\
RG-7221\
RO5520985Humanized monoclonal antibody IgG1κ bispecific ANG-2/VEGF-AmabAntineoplastic\
Phase I 2018IntravenousAngiopoietin 2/vascular endothelial growth factor AVapaliximab\
BTT-1002\
HUVAPChimeric monoclonal antibody IgG2κNo studies in PubMed or clinical trialsVascular adhesion protein AOC3 (VAP-1)Varisacumab\
GNR-011\
R-84Human monoclonal antibody IgG1κNo studies in PubMed or clinical trialsVEGF-AVarlilumab\
CDX-1127Human monoclonal antibody IgG1κAntineoplastic\
Solid tumors and hematologic malignancies\
Phase I 2017, phase II 2019/20\
Melanoma phase II 2018/21IntravenousCD27Vatelizumab\
GBR500\
SAR339658Humanized monoclonal antibody IgG4Disease modifying\
UC phase II 2016\
MS phase II 2016 withdrawn lack of efficacyΑ2β1 integrin I domain ITGA2 (CD49b)Vedolizumab\
LDP02\
MLN02Entyvio\
FDA 2014\
EU 2014Humanized monoclonal antibody IgG1κDisease modifying\
**Crohndisease**\
**Ulcerativecolitis**\
In CD resolution extraintestinal manifestationsIntravenousIntegrin α4β7\
Selectively blocks trafficking of\
Memory T cells to inflamed gut tissue by inhibiting a4b7-mucosal addressin cell adhesion molecule-1 (MAd-CAM-1) interactionVeltuzumab\
IMMU-106\
HA20Humanized monoclonal antibody IgG1κAntineoplastic\
Non-Hodgkin\'s lymphoma phase II 2013\
ITP phase II 2016SubcutaneousCD20VepalimomabMurine monoclonal antibodyAOC3 (vascular adhesion protein-1)Vesencumab\
MNRP1685AHuman monoclonal antibody IgG1mabAntineoplastic\
Solid malignancies\
Phase I 2011 proteinuriaNeuropilin1 (NRP1)VisilizumabNuvionHumanized monoclonal antibody IgG2Disease modifying\
Prevent GVHD\
Not effective in UCCD3VobarilizumabHumanize monoclonal scFvDisease modifying inflammatory autoimmune diseasesNothing in PubMedIL6RVolociximab\
M200Chimeric monoclonal antibody IgG4κAntineoplastic\
Solid tumors\
NSCLC phase I/II 2010\
Disease modifying phase I AMD terminated no resultsIntegrin α5β1Vopratelimab\
JTX-2011Humanized monoclonal antibody IgG1κAntineoplastic\
Solid tumors phase II 2022IntravenousInducible T-cell costimulator (ICOS)Vorsetuzumab mafodotin\
H1F6\
SGN-70Humanized monoclonal antibodyAntineoplastic\
Phase I 2017IntravenousCD70VotumumabHumaSPECT\
Diagnostic\
EU 1998\
Withdrawn from market 2003Human monoclonal antibodyDiagnostic\
Human colon cancer imagingTumor antigen Cytokeratin tumor-associated antigen (CTAA16.88)Vunakizumab\
SHR-1314Humanized monoclonal antibody IgG1Disease modifying\
Psoriasis phase II 2019Subcutaneous\
Nothing publishedInterleukin 17 alphaXentuzumab\
BI-836845Humanized monoclonal antibodyAntineoplastic\
Breast, prostate, solid phase I 2019Intravenous\
No clinical studies publishedInsulin-like growth factor (IGF1, IGF2)XMAB-5574\
Tafasitamab\
MOR00208FDA review possible 2019Humanized monoclonal immunoglobulin fragment κ FcAntineoplastic\
Diffuse large B-cell lymphoma phase II 2015/18/19/22\
phase III 2022IntravenousCD19Zalutumumab\
2F8\
HUMAX-EGFRHuMax-EGFr\
Suspended for commercializationHuman monoclonal antibodyAntineoplastic\
Squamous cell carcinoma of the head and neck phase II 2011\
phase III 2016IntravenousEGFRZanolimumabHuMax-CD4 (trade name)Humanized monoclonal antibody IgG1κAntineoplastic CTCL\
Phase II good results\
Phase III suspended by company?IntravenousCD4ZenocutuzumabHumanized monoclonal antibodyIgG1 bispecific epidermal growth factor receptors her2,her3AntineoplasticERBB3, HER3ZiralimumabHuman monoclonal antibody IgMDisease modifying\
immunosuppressiveNo studies clinical trials or PubMedCD147 (basigin)Zolbetuximab\
IMAB362\
ClaudiximabChimeric monoclonal antibody IgG1κ ADCC enhance antibodyAntineoplastic gastric cancer phase I, IIb\
Phase III 2023\
Gastrointestinal adenocarcinomas and pancreatic tumorIntravenousClaudin protein (CLDN18.2)Zolimomab aritox\
H65-RTA\
ZX-CD5Orthozyme CD 5 plusHuman monoclonal antibody IgG1Disease modifyingNot effective in preventing GVHD 1994CD5[^1]

*Ulcerative Colitis* {#s0525}
--------------------

Mabs being studied for UC but not yet approved by the FDA include bimekizumab, etrolizumab, golimumab, mirikizumab, ravagalimab, sacituzumab govitecan, ontamalimab, and vatelizumab. Refer to [Table 16.1](#t0010){ref-type="table"}.

Autoimmune Diseases {#s0530}
-------------------

Autoimmune diseases affect many organs and tissues including liver, gall bladder, pancreas (β islet cells in diabetes mellitus), nerve junctions (myasthenia gravis), thyroid, bone and joints, blood vessels, and multiorgan systems, systemic lupus erythematosus (SLE). Autoimmune arthritis is of multiple types including psoriatic, sclerosis, rheumatoid arthritis (RA), and SLE. Many of these diseases are mediated by antibody or cellular autoimmunity but ultimately appear to be secondary to an underlying abnormality in T-cell immune-regulatory control. These disease processes are historically controlled with antiinflammatory agents, immunosuppressive/immunomodulatory agents, or low-dose chemotherapy. Those with resultant hormone deficiencies are supplemented with hormones depleted by the disease process. It is hoped that passive antibody therapy will mitigate the sequelae of these inflammatory processes.

### Plaque psoriasis/psoriatic arthritis {#s0535}

Psoriasis affects 2%--3% of the world population and is an inflammatory skin disease. Brodalumab (Siliz) is a human Mab (IgG2κ) with specificity to IL-17 receptor A (IL-17RA). It is FDA approved for treatment of plaque psoriasis, and its mechanism of action is by inhibiting IL-17A, IL-17F, IL-17C, IL-25, and IL-17A/F heterodimer cytokine-induced responses including release of proinflammatory cytokines. When compared to ustekinumab, response rates nearly doubled with brodalumab in phase II and phase III trials during induction and maintenance therapies.[@bib275], [@bib276]

Other therapies currently also approved or being studied for treatment of this disease include bermekimab (MABp1,T2-18C3, CA-18C3, Xilonix), bimekizumab, briakinumab, certolizumab pegol (Cimzia), etanercept (Enbrel), infliximab (Remicade, Inflectra, Remsima), itolizumab (Alzumab), adalimumab (Humira, Amjevita), ustekinumab (Stelara), secukinumab (AIN457, Cosentyx), guselkumab (Tremfya), tildrakizumab (MK-3222, SCH-900,222, Ilumya, Ilumetri), risankizumab (ABBV-066, BI-655,066), mirikizumab (LY3074828), namilumab (MT203), netakimab, and vunakizumab. Refer to [Table 16.1](#t0010){ref-type="table"}.

Withdrawn from market or ineffective for treating psoriasis include efalizumab (Raptiva), fezakinumab, bleselumab, and teplizumab (MGA031, PRV-031, hOKT3g1(Ala-Ala)) Refer to [Table 16.1](#t0010){ref-type="table"}.

### Systemic juvenile idiopathic arthritis {#s0540}

Abatacept (Orencia) is a recombinant soluble fusion protein of the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) linked to the modified Fc portion of human IgG1. Its mechanism of action is as selective costimulation modulator as it inhibits T lymphocyte activation by binding to CD80 and CD86, thereby blocking interaction with CD28. This interaction provides a costimulatory signal necessary for full activation of T lymphocytes. This medication is FDA approved for both juvenile idiopathic arthritis (JIA) and adult RA.[@bib277], [@bib278], [@bib279]

*Rheumatoid Arthritis* {#s0545}
----------------------

Certolizumab pegol alone or with methotrexate improves quality of life in RA and may cause disease remission and reduce joint damage.[@bib280]

*Ankylosing Spondylitis* {#s0550}
------------------------

Certolizumab pegolis is also approved for use with ankylosing spondylitis.

*Systemic Lupus Erythematosus* {#s0555}
------------------------------

Belimumab (Benlysta) is a human Mab (IgG1λ) that binds to B-cell activating factor and acts as a B-lymphocyte stimulator-specific inhibitor. It was approved by the FDA in 2011 for treatment of adult patients with active, autoantibody-positive SLE receiving standard therapy. This medication also decreases episodic frequency of lupus nephritis.[@bib281], [@bib282], [@bib283]

Cardiovascular Disease {#s0560}
----------------------

Despite marked improvement in survival from cardiovascular disease, this illness remains the number one cause of mortality in the US. This process causes injury to the endothelium of blood vessels of the heart secondary to toxins, accumulation of cholesterol, or chronic low-grade inflammation. Treatment has been preventive, primarily during actual injury or following injury. Therapies involve changes in behavior (diet, exercise, and cessation of tobacco use), pharmacologic to control contributing underlying illness (hypercholesterolemia, hypertension, diabetes type I and II), to diminish injury through thrombolytics, stents, vasodilators, supplemental oxygen, or to control sequelae of infarctions (cardiac dysfunction/failure). Passive antibody therapies are being tried to decrease the effects of some of the contributing factors of atherosclerotic plaque formation.

Abciximab (ReoPro) is a chimeric recombinant monoclonal fragment (IgG1 Fab') with specificity to platelet glycoprotein IIb/IIIa receptor (CD41 7E3)/Intergrin α-IIb that prevents platelets from binding to fibrinogen. This Mab also prevents coagulation factor XIII from binding to platelets allowing stabilization of clots and are more easily lysed. The Fc portion of the antibody is removed to decrease thrombocytopenias. This antibody is used during high-risk coronary intervention to prevent clot formation and cardiac ischemia.[@bib284]

Alirocumab (Praluent) is a human Mab (IgG1) with specificity to proprotein convertase subtilisin/kexin type 9. This medication is used to control cholesterol levels in patients at high risk for cardiovascular events and in patients with familial hypercholesterolemia who are not controlled by other agents.[@bib285], [@bib286], [@bib287]

Evolocumab (Repatha) is a human Mab (IgG2λ) FDA approved for the treatment of hypercholesterolemia in patients with familial hypercholesterolemia or history of cardiovascular disease. This Mab has specificity to PCSK9. This medication reduced low-density lipoprotein (LDL) and cholesterol levels by 60% even after statin therapy. Hazard ratios for primary and secondary endpoints were less than one (∼0.80--0.85) with fewer cardiovascular-related death or infarction and stroke.[@bib288], [@bib289]

Under future watch is frovocimab (LY3015014) a humanized Mab (IgG4κ) with specificity to PCSK9 that completed phase I and II trials. There was up to 50% reduction in LDL cholesterol levels. Phase III studies have yet to be performed.[@bib290]

An additional antibody is lodelcizumab a humanized Mab (IgG1κ); however, no studies were found in [clinicaltrials.gov](http://clinicaltrials.gov){#interref15} or in Pubmed searches.

Bococizumab is a humanized Mab (IgG2κ) that was in phase III trial, which was discontinued secondary to primary endpoints not being achieved.[@bib291]

Neurologic Diseases {#s0565}
===================

Besides autoimmune and malignant diseases of the neurologic system, there are also diseases of the central nervous system classified as degenerative. Such diseases include supranuclear palsy (SNP), Alzheimer\'s, and Parkinson\'s. Alzheimer\'s is likely the most common cause of dementia first described in 1907. This disease may be depicted as presenile or senile dementia and progresses at a similar rate no matter age of onset. This disease has a genetic predisposition causing it to occur in younger age groups. Histological changes include diffuse plaques (containing amyloid), neurofibrillary plaques, and neuronal loss especially in the hippocampus and temporal regions. Medical management may reverse some of the symptoms but does not prevent disease progression. Parkinson\'s is a mainly sporadic degenerative disease with a gradual progressive course mainly affecting motor function more than memory. It was first described in 1817. This is a disease of the substantia nigra characterized by loss of melanin containing nerve cells and eosinophilic intracytoplasmic inclusions. Aside from emotional support and physical therapy, medical therapy is used to decrease tremors including anticholinergic drugs for tremors at onset, beta blockers for intention tremors, and levodopa for postural imbalance and akinesia. Deep brain stimulation is also used to treat symptoms later on as disease progresses. SNP starts in the same age range as Parkinson\'s (middle to later in life) that was first described in 1963 with disturbances in gait and balance secondary to rigidity of trunk muscles. Loss of neurons and gliosis is seen in the midbrain. Medical treatment is relatively unsuccessful. Multiple sclerosis is a demyelinating disease most often seen in young adults. The clinical manifestations are diverse and the progression can be chronic, acute, or remitting and relapsing. Medications and therapeutic plasma exchange have been used to treat this debilitating disease with limited efficacy. Clinical trials are ongoing looking at Mab therapies for treatment of these four neurologic degenerative diseases.

*Multiple Sclerosis* {#s0570}
--------------------

Alemtuzumab (Lemtrada) is a humanized Mab (IgG1κ) targeting CD52 that depletes lymphocytes (B and T cell) as reported earlier and is FDA approved for treatment of acute relapsing and remitting multiple sclerosis.[@bib292]

Ocrelizumab (Ocrevus) is a humanized Mab (IgG1κ) with specificity to CD20 (a B-cell membrane protein). In phase II trials, there were decreases in brain lesions on imaging, and decrease rate of disability decline in primary progressive multiple sclerosis.[@bib293]

Natalizumab (Tysabri) is a monoclonal IgG4κ humanized antibody with specificity to cell adhesion molecule (CD62L) that is FDA approved for relapsing multiple sclerosis.[@bib294], [@bib295]

The mabs to watch out for in the future and are in clinical trials include anifrolumab a human monoclonal antibody in phase I trials; elezanumab is a human Mab (IgG1λ) with specificity to repulsive guidance molecule family member-A that is in phase II trials to be completed 2021; and finally inebilizumab (MEDI-551) is a humanized monoclonal antibody (IgG2κ) with specificity to CD19 (a B-cell lymphocyte protein). This Mab mechanism of action is via ADCC and has completed phase I trials with good safety profile and response in decreasing lesions seen on contrast enhanced magnetic resonance imaging. Otilimabis (MOR103) is a human Mab (IgG1λ) completing phase I studies with good safety profile that targets granulocyte-macrophage colony-stimulating factor. Ublituximab is in phase II clinical studies to be completed in 2019, and phase III studies are scheduled to be completed in 2021. This Mab is a chimeric Mab (IgG1κ) with specificity to CD20 MS2A1.[@bib296], [@bib297], [@bib298], [@bib299], [@bib300]

Additional Mab have serious adverse effects such as daclizumab a humanized monoclonal (IgG1κ) with specificity to (CD25 {IL-2Rα}); or are ineffective as is opicinumab a human Mab IgG1 with specificity to Leucine-rich repeat and immunoglobulin domain containing neurite outgrowth inhibitor receptor interacting protein-1 which in a phase II trial was no more beneficial than placebo in treating optic neuritis in multiple sclerosis patients.[@bib301], [@bib302]

*Alzheimer\'s Disease* {#s0575}
----------------------

Aducanumab is a human Mab IgG1 with specificity to β-amyloid (N-terminus 3--6) soluble oligomers and insoluble fibers. Phase III clinical trials are ongoing since 2015.

BAN-2401 is a humanized Mab IgG1 with specificity to β-amyloid fibrillary and soluble β amyloid and is in phase IIb clinical studies since 2013.

Gosuranemab (BIIB092, IPN-007) is a humanized Mab IgG4κ with specificity to the tau protein and is in clinical trials to treat Alzheimer\'s disease scheduled to be completed in 2021. Gosuranemab is also in phase I studies to treat progressive suranuclear palsy and will be completed in 2020.

Crenezumab (RG7412, MABT5102A) is a humanized Mab IgG4 with specificity to 1--40 β-amyloid and is on phase III studies scheduled to be completed in 2021 and 2022.

Gantenerumab (R04909832, R1450) is a human Mab IgG1κ with targets β-amyloid. This Mab on initial phase III studies was found to be ineffective. Ongoing phase II/III trials are currently in place at higher dosing in a clinical population of people with autosomal dominant form of Alzheimer\'s disease.

Solanezumab (LY2062430) is a humanized Mab IgG1 with specificity to beta amyloid. Initial phase III trials discontinued for lack of efficacy in preventing Alzheimer\'s disease. Ongoing phase III trials are now in place for secondary prevention of this disease and will be completed in 2021 and 2022.

Mab antibodies studied and were ineffective include bapineuzumab, gantenerumab (R04909832, R1450), and ponezumab (RN1219, PF-04,360,365).

*Parkinson\'s Disease* {#s0580}
----------------------

Prasinezumab (PRX002, RG7935, RO7046015) is a humanized Mab IgG1κ with specificity to α-synuclein. This Mab is in phase II clinical trials to treat Parkinson\'s and will be completed in 2021.

Allergic Diseases {#s0585}
=================

Allergic reactions develop because of immunologic stimulation of IgE antibodies followed by their interaction with allergens and mast cells. Effects can be local (dermatitis) or systemic (respiratory, cardiovascular, and gastrointestinal). Treatment is either avoidance of the allergens or supportive therapy in acute allergic reactions including pharmacologic treatment with type 1 and 2 histamine blockers, glucocorticosteroids, and if life-threatening epinephrine. Passive antibody therapies are being studied and approved to curtail severe reactions.

*Asthma* {#s0590}
--------

Asthma affects 24 million individuals in the US, and up to 10% of asthma patients have severe disease that may be uncontrolled despite high doses of standard-of-care asthma medications requiring additional use of chronic oral corticosteroids. Benralizumab (Fensenra) is a humanized Mab (IgG1κ) with specificity to CD125 (IL-5Rα). This Mab is approved to treat severe asthma of the eosinophilic subtype in ages 12 and older. Its mechanism of action is to decrease the number of eosinophils via ADCC. Basophils are also depleted.[@bib303]

*Atopic Dermatitis* {#s0595}
-------------------

Dupilumab (Dupixent) is a human monoclonal gG4 antibody with specificity to interleukin-4 receptor subunit-alpha (IL-4Rα) that is approved to treat severe atopic dermatitis in adults.[@bib304]

Coagulopathy and Other Benign Hematologic Diseases {#s0600}
==================================================

Coagulopathies are usually either autoimmune or genetic. In factor VIII deficiency, recombinant factor VIII is used to replace lack of this protein. However, patients may develop antibodies to factor VIII leading to high titers of inhibitors. Furthermore, patients without deficiency may also develop autoantibodies to factor VIII de novo leading to coagulopathies. Other factor combinations as well as recombinant active factors have been created to overcome these inhibitory antibodies. Mabs with bispecific binding are also being researched as another avenue for treatment.

ITP can lead to critical low platelet levels increasing risk for severe bleeding. ITP can occur in both adult and pediatric settings as it is considered an autoimmune disease. Typically, this is treated with steroids and IVIG. In addition, as mentioned earlier, RhD^+^ patients have benefitted from polyclonal medications directed against the D antigen. Recently, Mab to treat this disease have been developed and will be discussed next.

Thrombotic thrombocytopenic purpura (TTP) is a blood disorder that does not lead to bleeding but to development of diffuse thrombi in small blood vessels. More often, this disorder is secondary to an autoimmune inhibitory antibody to the disintegrin and metalloproteinase with thrombospondin type 1 motif member-13 (ADAMTS-13), known as acquired TTP. Inhibiting this zinc containing metalloprotease leads to lack of cleavage of large multimers of von Willebrand Factor (vWF). The large vWF multimers then more easily bind to platelets resulting in platelet clots in small blood vessels. More rarely, this disorder is secondary to an inherited deficiency of ADAMTS-13. This patient population with congenital deficiency is managed with transfusion of FFP to replace the deficient enzyme. Acquired TTP is typically treated with therapeutic plasma exchange (TPE). This treatment modality removes the inhibitory antibody and ultralarge vWF multimers. Similarly, TPE will replete the missing enzyme. Immunosuppressive agents may be added if only TPE is not effective. A Mab preventing interaction of vWF and platelets was recently approved for use in treating this disorder.[@bib305], [@bib306] Caplacizumab-yhdp (Cablivi) is a humanized single-variable-domain immunoglobulin (Nanobody) that inhibits the interaction between ultralarge vWF multimers and platelets and is directed against vWF. It induces a faster response to therapy with TPE and decreases relapse with continued use during TPE. This medication is then used post-TPE treatment until immunological evidence of disease is controlled to prevent relapse.[@bib305], [@bib307], [@bib308] This medication was FDA approved for use in TTP in 2019.

Atypical hemolytic uremic syndrome (aHUS) is a disorder of the complement system due to uncontrolled activation. This disorder presents with thrombocytopenia, thrombi, and renal dysfunction. Historically, this illness was treated with TPE; however, end-stage renal failure occurred in 30% of patients and about 65% mortality in subsequent relapses with increasing incidence of renal failure. There are now two monoclonal antibodies approved for the treatment of aHUS. Refer to [Table 16.1](#t0010){ref-type="table"}.

*Sickle Pain Crisis* {#s0605}
--------------------

In sickle cell disease, one of the frequent complications is pain crises. This is usually treated with analgesics, oxygen, hydration, and transfusions (simple or exchange). Monoclonal antibodies are being developed to treat pain crises in sickle cell patients in both adult and pediatric populations. Crizanlizumab is a humanized Mab (IgG2κ) with specificity to selectin P. One phase II trial was completed in 2016 and three additional phase II studies will be completed between 2021 and 27 to treat vasoocclusive pain crisis. This medication may be under FDA review as early as 2019.[@bib309], [@bib310]

**Infections** {#s0610}
==============

Antimicrobials have historically been developed against a variety of viral, bacterial, fungal, and parasitic infections. These pharmaceuticals target differences from human cells of these particular organisms such as cell wall or membrane structure, genetic make-up, transcription/translation of genetic material, or metabolic pathways. Often organisms develop resistance to entire categories of these medications. Earlier in the chapter, passive polyclonal antibodies were discussed in the treatment of some of these infectious agents and we will now discuss research in monoclonal therapies to pathogenic microorganisms.

*Clostridium difficile* {#s0615}
-----------------------

Enterocolitis from *Clostridium difficile* is a community or hospital acquired infection increasing morbidity and mortality in those that acquire it. Treatment is supportive or with fecal transplants or antibiotics. Bezlotoxumab (Zinplava) is a human Mab (IgG1) with specificity to *Clostridium difficile*\'s B toxin. It is used to treat pseudomembranous colitis and prevent *C. difficile* reinfection.[@bib311], [@bib312]

Actoxumab, a monoclonal antibody against *C. difficile* toxin A, has shown not to be clinically significant.

*Respiratory Syncytial Virus* {#s0620}
-----------------------------

Respiratory syncytial virus (RSV) infects almost all children by 2 years old and poses extra risk in preterm infants. Supportive therapy, RSV-IG or IVIG, and antiviral therapy have been used to mitigate the sequela of this infection with optimal response yet to be seen. No vaccines have yet to be developed for this infection. Recently, monoclonal antibodies have been FDA approved or are undergoing pre/clinical trials to treat this infectious process and include palivizumab, Nirsevimab (MEDI8897), TRL3d3 (3D3), and ALX-0171.[@bib313], [@bib314]

Not beneficial or safe in use for RSV: motavizumab, Suptavumab (REGN2222, SAR438584).

### Influenza virus {#s0625}

Influenza is a worldwide respiratory infectious problem with cyclic epidemics yearly. Supportive therapy, yearly vaccinations, and antivirals are used to decrease the morbidity and mortality caused by this sometimes virulent pathogen. Both polyclonal and monoclonal therapies are being evaluated to better treat these infections. Mabs in pre/clinical trials include diridavumab (CR6262), firivumab, gedivumab (RG7745, RO6876802), lesofavumab (RG70026), and Navivumab (CT-P27).

### Rabies {#s0630}

Rabies is a devastating viral infection with swift mortality if not treated quickly after initial exposure. Vaccines usually react too slowly and have to be combined with polyclonal IVIG infusions. Monoclonal therapy was previously studied but usually the virus mutates quickly and the infection is not controlled. More recently, in clinical trials, cocktails of Mabs are being tried to more closely mimic the benefits of polyclonal therapies. These Mabs include foravirumab, rafivirumab (CR57), and Rmab.

### Hepatitis B virus {#s0635}

HBV is one of if not the most common infections in the world. Even though antivirals are available and effective, only recently they have they been widely used in the infant population and not just "high"-risk individuals. Mabs to treat this infection that are being investigated include libivirumab. Mab that is not found to be effective is tuvirumab.

### Ebola {#s0640}

Ebola is a relatively rare but devastating hemorrhagic infection. Most care is supportive with various studies being performed to prevent/mitigate this disease. Vaccines are under development as well as passive polyclonal therapies. Mab therapies being developed or studied include porgaviximab (C2G4), cosfroviximab, and larcaviximab.

For these and other bacterial, fungal, and viral antiinfectious agents, information may be found in [Table 16.1](#t0010){ref-type="table"}.

Immunomodulation {#s0645}
================

In solid organ transplants, cellular or humoral immunity can develop against the transplant leading to acute or chronic rejection. An additional complication with these and stem cell transplants is severe GVHD. In the past, these transplant complications were treated with high-dose glucocorticosteroids, immunosuppressive medication, chemotherapeutic agents, IVIG, or T-cell lymphocytic specific immunoglobulins. Recently, Mabs have been added to this armamentarium to better control these adverse reactions to transplantations.

Basiliximab (Simulect) is a chimeric Mab (IgG1κ) with specificity to CD25 IL-2α. The only FDA-approved indication for this medication is prophylaxis of acute rejection in renal transplant patients. There are multiple ongoing studies of this biological for other organ transplants including liver, lung, and heart as well as for inflammatory/immunologic diseases such as GVHD following stem cell transplantation, ulcerative colitis, and uveitis.[@bib315], [@bib316], [@bib317], [@bib318], [@bib319]

Belatacept (Nulojix) is a soluble fusion protein consisting of the modified extracellular domain of CTLA-4 fused to the Fc domain of a recombinant human Mab IgG1. This Mab selectively inhibits T-cell activation through costimulation blockade binding to both CD80 and CD86 while blocking CD28 via tighter binding than its parent antibody abatacept. Refer to [Table 16.1](#t0010){ref-type="table"}.

Metabolic Syndromes {#s0650}
===================

Hypercholesterolemia is associated with increased risk for cardiovascular disease/atherosclerosis secondary to inherited or dietary etiologies. Diet and exercise are used to treat mild forms of these disorders. Medications such as nicotinic acid, fibrates, bile acid binding resins, and 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors are used for more severe forms of these disorders. Phase III studies have been completed with monoclonal antibodies for patients\' refractory to the previously mentioned forms of therapy.

*Hypophosphatemia* {#s0655}
------------------

Burosumab (KRN23, Crysvita) is a human Mab IgG1κ with specificity to phosphaturic hormone fibroblast growth factor 23 (FGF 23). This hormone is a regulator of phosphate and vitamin D homeostasis. FGF23 inhibits the enzyme CYP27B1 and stimulates CYP24A1, thereby reducing circulating levels of 1,25-dihydroxyvitamin D (1,25(OH)2D), the active metabolite of vitamin D. This medication is FDA approved for the treatment of X-linked hypophosphatemic rickets.[@bib320], [@bib321]

*Osteoporosis* {#s0660}
--------------

Denosumab (Prolia) is an FDA-approved human Mab (IgG2) that is a receptor activator of nuclear factor κB ligand that inhibits development and activity of osteoclasts. As Prolia, this medication is used to prevent or treat osteoporosis in women.[@bib322], [@bib323], [@bib324] This medication under the trade name Xgeva is also used to prevent skeletal-related events in adults with bone metastasis from breast, prostate cancers, and multiple myeloma.[@bib325], [@bib326]

Endocrine Disorders {#s0665}
===================

Diabetes may be classified as primary or secondary. In this chapter, we will be mainly interested in both insulin-dependent (Type I) and insulin-independent types (Type II). Type I diabetes mellitus is generally secondary to loss of β cells in the islets of Langerhans and subsequent loss of insulin production. Type II typically is secondary to decreased sensitivity to the effects of insulin. In type I, insulin is replaced exogenously depending on glucose levels. In type II, medications are given to stimulate islet cells to produce more insulin. Mabs are being developed to potentially mitigate the autoimmune process leading to Type I diabetes mellitus or the sequela of renal failure often seen with this disease. For type II, Mabs are being investigated to potentially decrease body mass index and thus decrease disease severity. Refer to [Table 16.1](#t0010){ref-type="table"}.

Other Clinical Disorders {#s0670}
========================

Age-related macular degeneration (AMD) is the leading irreversible cause of visual loss affecting the elderly. Two forms include a dry form with deposits in the macula or a wet form involving abnormal growth of blood vessels. The wet form, even though less frequent, is associated with more severe visual acuity loss. Antiangiogenesic drugs or laser treatments are used to slow the progression or even partially reverse visual loss. Some trials have been completed while others are ongoing using Mab to treat the wet form of AMD. Brolucizumab was found as good as if not better than aflibercept in a phase III clinical trial.[@bib327]

Cryopyrin-associated periodic syndromes (including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome); tumor necrosis factor receptor-associated periodic syndrome (TRAPS); hyperimmunoglobulin D Syndrome (HIDS)/mevalonate kinase deficiency and familial Mediterranean fever (FMF) may also respond to canakinumab.[@bib328]

Potential Future Uses of Monoclonal Antibodies and Their Targets {#s0675}
================================================================

Passive antibody therapy continues to be useful clinically whether polyclonal or monoclonal therapy is implemented. Increased utilization of the classic polyclonal antibody preparations continue especially in the realm of infections. In the past 3 years, monoclonal therapy has evolved and revolutionized treatment in many areas. As targets are identified to modify disease pathology no matter its genre we continue to get a better handle on morbidity and mortality. We are learning that not only is the target important put the portion of the target mediating the effect we intend to modify is also important. Importantly, modification of antibodies to be more compatible with the immune system while decreasing rapidity of clearance also allows for more consistent therapy. There are also many targets yet to be discovered or only now being developed as in the canonical wingless/integrated (WNT) signaling. This receptor family is important in a multitude of diseases not limited to: hereditary colorectal cancer, various types of sporadic cancers, intellectual disability syndrome, Alzheimer\'s disease, bipolar disorder, bone diseases, and vascular diseases. One monoclonal antibody rosmantuzumab (OMP-131R10), a humanized Mab (IgG1κ), is in phase I trials to treat colorectal cancer.[@bib329], [@bib330] Other disease processes have yet to find their optimal therapy (Alzheimer\'s) or are advancing to fuller therapeutic benefit. The future is wide open for this newer class of pharmaceuticals as they continue to develop to full fruition.Table 16.2Summary of Polyclonal Antibody Therapies.Generic Drug NameBrand NameAdditional Brand NamesAHFS ClassificationDosage Form(s)Restricted MedicationAntithymocyte globulin (equine)AtgamImmunosuppressive agentIntravenous solutionAntithymocyte globulin (rabbit)ThymoglobulinImmunosuppressive agentIntravenous solutionAntivenin *Latrodectus mactans*Black widow\
AntiveninSerumsIntravenous solutionAntivenin micrurusEastern and\
Texas coral\
Snake\
AntiveninSerumsIntravenous solutionBotulism immune globulinBabyBIGCrotalidae polyvalent immune FabCrofabSerumsIntravenous solutionCytomegalovirus immune globulinCytogamSerumsIntravenous solutionYesDigoxin immune FabDigibindSerumsIntravenous solutionHepatitis B immune globulinHepagam-BSerumsIntramuscular solution,\
Intravenous solutionHepatitis B immune globulinBayHepBHepaGam B, Hyper Hep B, Nabi-HBHigh antibody titer Ebola FFPHigh antibody titer influenza FFPImmunoglobulin (generic)GamunexVivaglobin, Cuvitru, Privigen, gammagard, octagam, gamunex, hizentra, Bivigam, Carimune, Flebogamma, Gamastan, Gamimune, Gammaplex, gammar, Panglobulin, Panzyga, SandoglobulinIntravenous,\
SubcutaneousTreat XLA, CVID, Hyper IgM syndromes, Wiskott Aldrich syndromeRabies immune globulinBayrabHyperRAB, Imogam rabies, KedRABRespiratory syncytial virus immune globulinRespiGamRho (D) immune globulinWhinRho\
RhoGamRhophylac, MicRhoGAM, BatRhoD, HyperRhoSerumsIntravenous, intramuscular solutionsRimabotulinumtoxin BMyoblocOther Miscellaneous\
Therapeutic agentsInjection solutionYesRozrolimupabAnti-RhD\
Prevent isoimmunization\
ITPTetanus immune globulinBaytetHypertetVaricella zoster immune globulinVariZIG[^2]

[^1]: Auristatins are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid-binding domain, and causes cell to accumulate in metaphase arrest.

[^2]: Searched sites for table information. Monoclonal. [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm](http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm){#interref8}. <https://fdasis.nlm.nih.gov/srs/>. <https://clinicaltrials.gov/ct2/>. <https://www.ncbi.nlm.nih.gov/pubmed/>. <https://chem.nlm.nih.gov/chemidplus/rn>. <https://druginfo.nlm.nih.gov/drugportal/>. <https://www.creativebiolabs.net/>.
